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ABSTRACT 
 Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the 
accumulation of amyloid-β peptide (Aβ) in the brain and intraneuronal 
hyperphosphorylated tau.  Microglia in the brain adopt M1 (pro-inflammatory) or M2 
(anti-inflammatory) phenotypes similar to peripheral monocytes.  M1 microglia 
negatively affect neurogenesis and have reduced phagocytic capabilities whereas M2 
microglia can enhance neurogenesis and support phagocytosis.  Cluster of 
Differentiation-200 (CD200) is an anti-inflammatory glycoprotein physiologically 
expressed on neurons and lymphocytes, and its receptors (CD200R1 and CD200R3) are 
expressed on glia.  Both AD patients and mouse models of AD show an age-related or 
Aβ-induced reduction in neural CD200 that may contribute to M1-skewing of microglia 
in AD. We hypothesize that CD200 skews microglia to an M2 phenotype, and that 
genetic over-expression of CD200 in transgenic mice expressing the Swedish familial 
AD mutation of human β-amyloid precursor protein (APP mice) can restore neurogenesis 
and enhance Aβ clearance in the hippocampus.  In this study, we constructed a 
tetracycline-controlled transactivator-inducible adeno-associated virus serotype 2/1 
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expressing full-length CD200 (AAV2/1-CD200) or green fluorescent protein (AAV2/1-
GFP).  These were bilaterally injected into the hippocampi at 6 months of age, and mice 
were sacrificed at 12 months of age. AAV2/1-GFP-injected APP mice showed a 
reduction in number of proliferating neural stem cells (NSCs) by 65.0% and 
differentiating NSCs by 70.5% in the dentate gyrus compared to wild-type controls.  
AAV2/1-CD200 restored these neurogenic deficits to those of wild-type mouse levels.  
AAV2/1-CD200 reduced diffuse Aβ plaques in the hippocampal region by 65.5% 
compared to AAV2/1-GFP-injected APP mice, but did not alter thioflavin-S-positive 
compact plaques as measured by protein and immunohistochemical assays.  In vitro 
studies demonstrated that CD200-stimulated microglia co-cultured in transwells 
increased differentiation and complexity of neural stem cells.  CD200 also directly 
enhanced Aβ phagocytosis by microglia. CD200 enhanced expression of the adaptor 
protein TYRO protein tyrosine kinase binding protein (TYROBP), suggesting this may 
be the mechanism by which CD200 enhances phagocytosis of Aβ.  Overall, the data 
presented here indicate that CD200 is a plausible therapeutic agent in patients with AD to 
enhance neural differentiation and microglial-mediated clearance of Aβ. 
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Chapter 1.  GENERAL INTRODUCTION 
 
I.  Alzheimer’s Disease 
1.1 Clinical Presentation and Neuropathology 
 Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease in the 
nation, affecting an estimated 5.2 million Americans, and it will cost the country over 
$200 billion in 2014 according to most recent estimates by the Alzheimer’s Association. 
AD clinically presents with a progressive decline in memory formation and cognitive 
function (Minati et al., 2009).  Pathologically, it presents with intraneuronal 
accumulations of hyperphosphorylated microtubule-associated protein tau, known as 
neurofibrillary tangles (NFTs) and extracellular depositions of amyloid β-peptide (Aβ) 
known as amyloid plaques (Dickson et al., 1988; Alzheimer et al., 1995).  Patients exhibit 
a particular loss of synapses and neurons in the temporal and frontal cortices and in the 
hippocampus (Davies et al., 1987; Scheff et al., 2006; Scheff et al., 2007).  Patients with 
the disease live for an average of only seven years after clinical diagnosis (Molsa et al., 
1986).  It is still not understood how and why a person develops AD, but it is known that 
the greatest risk factor for the disease is age.  AD primarily affects the elderly with the 
average age of patients around 65, however, there are cases of early-onset AD that can 
occur in people aged 40-50, and these are often associated with genetic pre-dispositions 
to the disease.  Most cases of AD are late-onset and seem to occur spontaneously. 
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1.2 Current State of Alzheimer’s Disease Therapeutics 
 There is currently no cure or sufficient therapeutic for the treatment of AD.  There 
are few pharmaceutical drugs used to treat the cognitive symptoms of AD, and they offer 
little benefit and do not slow the progression of the disease.  AD patients show a 
dysfunction in cholinergic signaling in the brain (Pascual et al., 1991).  
Acetylcholinesterase inhibitors are often used to compensate for this dysfunction, such as 
tacrine, donepezil, rivastigmine, and galantamine (Pohanka, 2011; Jindal et al., 2014). 
There is also evidence of glutamate-mediated excitotoxicity in the brains of AD patients, 
which has been implicated in neuronal damage from calcium overload (Lipton and 
Rosenberg, 1994).  Because glutamate stimulates the N-methyl-D-aspartate (NMDA) 
receptor, which is involved in the formation of memories in the hippocampus, the NMDA 
receptor antagonist, memantine, is also used to treat the symptoms of AD (Reisberg et al., 
2003).   Active vaccination against Aβ42 proved to be beneficial in AD mouse 
models by reducing brain Aβ levels and improving memory (Schenk et al., 1999), but 
these largely failed in clinical trials due to dangerous autoimmune and inflammatory 
patient responses to the vaccines (AN1792, CAD106) (Gilman et al., 2005; Winblad et 
al., 2012).  Some active vaccines have been designed to reduce activation of Aβ-specific 
inflammatory T cells (CAD106, ACC001, Affitope), and these are showing more promise 
and continuing in Phase 2 clinical trials (Lambracht-Washington and Rosenberg, 2013).  
Passive immunization using humanized anti-Aβ monoclonal antibodies caused less 
autoimmune and inflammatory reactions, but still failed clinical trials and are not very 
beneficial to late-onset AD patients.  These include solanezumab, gantenerumab, and 
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crenezumab (Lambracht-Washington and Rosenberg, 2013).  Most experts agree that AD 
therapy needs to be initiated prior to symptomatic onset.   
 
1.3 Amyloid Precursor Protein and the Formation of Aβ 
 The aggregation of Aβ has been the focus of most AD research ever since the 
formation of the “Amyloid Cascade Hypothesis” (Selkoe, 1996; Hardy and Selkoe, 2002) 
after increasing evidence showed that Aβ formation precedes the formation of NFTs and 
that aggregated Aβ fragments are neurotoxic and lead to synaptic and neural degradation 
(Selkoe, 1991; Mattson et al., 1998; Lue et al., 1999; Shankar and Walsh, 2009).  The 
Amyloid Cascade Hypothesis posits that genetic or spontaneous abnormal processing of 
the amyloid precursor protein (APP) results in an overproduction of aggregate-prone 
Aβ42 fragments that cannot be cleared by the immune system and gradually accumulate, 
creating a toxic environment for neurons and synapses (McGeer and McGeer, 2010).  
Neuronal damage results in innate immune activation of microglia and astrocytes that 
further exacerbate cell damage due to the production of reactive oxygen species and 
subsequent oxidative injury (Kish et al., 1992; Gutowicz, 2011).  Combined with the 
formation of NFTs due to changes in kinase and phosphatase activity (Iqbal et al., 1998), 
AD patients suffer from a consequent loss of neurons, synaptic dysfunction, and gradual 
neurodegeneration that manifests as a decline in memory formation then cognitive 
dysfunction.   
 Aβ is formed from the proteolytic cleavage of APP (see Fig. 1), which contains 
the Aβ-encoding region (Zhao et al., 2006).  APP undergoes two consecutive cleavages 
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by α- or β-secretase followed by γ-secretase as it is secreted from the cell (Esch et al., 
1990).  Non-amyloidogenic processing of APP occurs through consecutive cleavages by 
α- then γ- secretases (Esch et al., 1990).  α-secretase is composed of members of the a 
disintegrin and metalloproteinase (ADAM) family (Zhang et al., 2011b), and they cleave 
within the Aβ-encoding region between amino acid residues 16 and 17, thus creating a 
short 83-residue fragment known as p83 (Esch et al., 1990).  γ-secretase is a complex of 
the catalytic domains, presenilin 1 or 2 (PS1 or PS2), Nicastrin, APH-1, and presenilin 
enhancer-2 (PEN-2) (Kimberly et al., 2003; Takasugi et al., 2003).  The p83 fragment 
generated by α-secretase is then cleaved by γ-secretase within the transmembrane region, 
creating a p3 fragment (Aβ17-40) and an APP intracellular domain (AICD) which can 
translocate to the nucleus and act as a transcription factor (Baek et al., 2002; Leissring et 
al., 2002; Cao and Sudhof, 2004).   
 Amyloidogenic cleavage of APP occurs through consecutive cleavages by β- then 
γ-secretases (Seubert et al., 1993).  Both β-site APP converting enzymes (BACE) 1 and 2 
are β-secretases that are implicated in Aβ formation (Vassar et al., 1999).  They cleave at 
the N-terminus of the Aβ-encoding region, and this is subsequently followed by cleavage 
by γ-secretase to form the 40-42-residue Aβ fragment.  The majority of fragments formed 
from this cleavage are Aβ40 fragments, but the less common Aβ42 fragment is 
considered the more amyloidogenic species and has a greater tendency to aggregate into 
fibrils and accumulate with age (Jarrett et al., 1993; Iwatsubo et al., 1995; Lemere et al., 
1996).  Most cases of AD appear to occur spontaneously, but some are known to be of 
genetic origin resulting in abnormal accumulations of Aβ.  The most common cause of 
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early-onset familial dementia is due to missense mutations in γ-secretase, particularly in 
the PS1 or PS2 components of the enzyme (Levy-Lahad et al., 1995; Sherrington et al., 
1995). Mouse models expressing the mutant form of PS1 have been heavily utilized in 
AD research and are discussed below (Duff et al., 1996).  There are also genetic 
mutations in APP, however, that occur near the Aβ-encoding region, and these have also 
been identified in early-onset familial AD (Chartier-Harlin et al., 1991; Goate et al., 
1991; Murrell et al., 1991; Hendriks et al., 1992), and are represented with transgenic 
mouse models.  One of the most abundant APP isoforms that results from alternative 
splicing is APP695, a polypeptide expressed in neurons (Koo et al., 1990).  APP695 is an 
alternatively spliced variant with a double mutation in Lys670 and Met671 residues 
(K670N and M671L, respectively) that was identified in a Swedish family with high 
incidence of early-onset AD (Mullan et al., 1992).  The APP695 mutation lacks a Kunitz 
protease inhibitor domain that evidence suggests results in an increase in both Aβ40 and 
Aβ42 in neuronal cells (Ho et al., 1996; Belyaev et al., 2010).  This results in a build-up 
of amyloid and early presentation of AD.   
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Figure 1. Abnormal processing of APP leads to the production of Aβ42. Non-
amyloidogenic cleavage of APP occurs by consecutive processing by α- then γ-
secretases.  Amyloidogenic cleavage of APP produces both Aβ40 and Aβ42 after 
consecutive cleavages by β- then γ-secretases.  Mutations in APP (APP695, the Swedish 
mutation) and γ-secretase (PS1 and PS2) are associated with abnormal processing of APP 
and enhanced build-up of Aβ42. 
 
 
 Although the Amyloid Cascade Hypothesis is still the most widely accepted 
hypothesis, several pieces of evidence suggest that Aβ is not the sole cause of AD [see 
(Struble et al., 2010) for review].  Aβ can actually be found even in the healthy human 
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brain, and in fact, about 20-30% of people with normal cognition have significant levels 
of amyloid in the brain but never develop AD (Bennett et al., 2006; Aizenstein et al., 
2008).  More importantly, experimental therapeutics that were successful at removing Aβ 
from human patients did not halt the progression of AD and failed in clinical trials 
(Holmes et al., 2008; Salloway et al., 2009).  This evidence suggests that there are 
additional underlying factors in the AD brain that lead to the progressive 
neurodegeneration and cognitive decline.  
 
1.4 Mouse Models of Alzheimer’s Disease 
 In order to discover therapeutic targets and develop medicines that manipulate 
them for a particular disease or illness, it is necessary to characterize that target and its 
therapeutic potential in the context of the diseased state.  This would ideally mean 
utilizing human tissue and cells both in vivo and ex vivo.  In vitro modeling systems are 
useful to investigate responses and mechanisms in specific cell types, but these systems 
are limited in their scope and translation to their human counterparts.  In vitro systems 
can elucidate cell signaling mechanisms and even some cell-to-cell interactions, but it 
cannot take into account the complex network of organs, cell types, neurotransmitters, 
hormones, and other factors present in the living body that affect how a cell reacts to a 
stimulus.  To attempt to overcome these limitations, the scientific community develops 
what are referred to as “models” of human disease.  Models are artifically developed in a 
variety of ways from genetic manipulation to injection of an inducing agent that results in 
disease-like symptoms, or sometimes a combination of both.  These models then mimic 
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one or more of the phenotypes of the target disease by developing similar pathology, 
behavior, cognitive deficits, neuronal loss, or other disease characteristics.  This allows 
the researcher to measure specific outcomes and disease biomarkers after manipulation of 
their target of interest.  Because models are not human, however, they very rarely 
encompass all aspects of a disease, and it is often found that successful manipulation of a 
target in one model does not translate to an effective therapeutic in the clinic.  Despite 
this shortcoming, models of human disease are essential to the development of 
therapeutics, and they provide valuable insight into biological interactions in their own 
right.      
 Several mouse models were developed to study the contribution of Aβ to the 
development of AD. One such mouse has become one of the most widely used transgenic 
mouse models in all of AD research.  Transgenic mice on a C57Bl/6 background 
expressing the human APP695 with the double mutation (Hsiao et al., 1996), referred to 
as Tg2576 or APP mice in this report, were created using a hamster prion protein (PrP) 
cosmid vector (Scott et al., 1992) with the PrP open reading frame replaced with the APP 
open reading frame (Hsiao et al., 1995).  These mice show significant increases in Aβ40 
and Aβ42 in both the plasma and the brain by three to five months (Lanz et al., 2004) and 
Aβ plaques in the brain by eight months (Kawarabayashi et al., 2001).  These mice show 
deficits in learning and memory tasks by nine months of age, such as the Morris water 
maze (MWM) and the Y-maze, compared to age-matched controls (Hsiao et al., 1996; 
King et al., 1999).   
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 The mouse model used in most of my in vivo studies described below is an 
APP695 mouse model on a C57Bl/6 and B6129SF2/J background, which also shows 
deficits in cognitive behavior (Rustay et al., 2010).  Other mouse models of AD include 
the aforementioned PS1 mice (Duff et al., 1996), double-mutant APP+PS1 mice (Patel et 
al., 2005), and a triple transgenic AD mouse model (3xTg-AD) that contains mutations in 
APP, PS1, and a human tauP301L mutation.  3xTg-AD mice develop both amyloid 
plaques and tangles (Oddo et al., 2003a; Oddo et al., 2003b).  PS1 mice have been used in 
several studies, but it was recently shown that the PS1 mutation itself impairs neuronal 
proliferation, differentiation, and survival in vivo (Choi et al., 2008; Veeraraghavalu et 
al., 2013; Veeraraghavalu and Sisodia, 2013), and so using PS1 or APP+PS1 mice for the 
study of anti-inflammatory therapeutics in AD on neurogenesis is not appropriate.  APP 
mice were chosen for this study because they are one of the most highly utilized and 
well-characterized AD mouse models in this field.   
 
1.5 Conclusions 
 The prevalence of AD has made this disease a growing public health concern.  
Although we have a better understanding of its pathology and clinical presentation, we 
still do not completely understand how AD is initiated and how it progresses.  This 
greatly hinders therapeutic intervention, and it is therefore necessary to explore other 
components of the disease that contribute to disease progression, such as 
neuroinflammation. 
 
	  	  10	  
II.  Neuroinflammation 
2.1 The Innate and Adaptive Immune Response 
 In the central nervous system (CNS), mononuclear phagocytes, which include 
brain resident microglia and perivascular macrophages, are the principal mediators of the 
innate immune response.  These cells survey the surrounding neural environment and are 
ubiquitously localized so as to promptly respond to stimuli.  They express pathogen 
recognition receptors (PRRs) that serve to recognize signals known as pathogen-
associated molecular patterns (PAMPs, such as double-stranded deoxyribonucleic acid 
(DNA), lipopeptide, and single-stranded ribonucleic acid (RNA)) or damage-associated 
molecular patterns (DAMPs, such as heat-shock proteins, chromatin, and mitochondria) 
that are released or activated by dying and damaged cells.  Some commonly known PRRs 
include toll-like receptors (TLRs) and nucleotide oligomerization domain (NOD) -like 
receptors.  TLRs are ubiquitously expressed in the brain on the plasma membranes of 
macrophages, microglia, astrocytes, neurons, and other immune cells (Bsibsi et al., 2002; 
Tang et al., 2007).  Activation of PRRs such as TLRs results in an inflammatory 
response.  For example, lipopolysaccharide (LPS), a membrane component of gram-
negative bacteria such as Escherichia coli (E. coli), is a commonly-used pro-
inflammatory mediator that acts as a TLR-4 ligand and initiates transcription of pro-
inflammatory cytokines and chemokines through nuclear factor κ-light-chain-enhancer of 
activated B cells (NFκB) induction (Bailey et al., 2006).  It is important to note that Aβ 
itself can interact with TLRs as a PAMP molecule (Lotz et al., 2005; Reed-Geaghan et 
al., 2009).  Pro-inflammatory cytokines that are released include tumor necrosis factor-α 
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(TNF-α), interferon-γ (IFN-γ), interleukin-6 (IL-6), and IL-1β.  These serve to activate 
the release of specific chemokines as well as the vasculature so that recruited circulating 
lymphocytes can extravasate through the activated endothelium and then diffuse to the 
site of insult or injury.  Through subsequent initiation of the adaptive immune response, 
target antigens can then be recognized through B cell-mediated antibody production and 
tagged for removal by T cell-mediated destruction of pathogen-infected and/or damaged 
and stressed cells.   
 Inflammation resolution is initiated after pathogens are eliminated through a few 
mechanisms.  B cells and T cells both undergo apoptosis.  One mechanism is via the 
hypothalamo-pituitary-adrenal (HPA) axis which becomes activated during inflammation 
and increases production of glucocorticoids that suppress pro-inflammatory signaling.  It 
also leads to the production of anti-inflammatory cytokines such as IL-4, IL-10, and 
transforming growth factor-β (TGF-β) (Elenkov and Chrousos, 2002).  A second 
mechanism is through release of resolvins.  Resolvins are endogenous mediators that 
inhibit inflammation and neutrophil recruitment, reduce vascular permeability, and also 
promote tissue repair.  In this way, the immune response self-limits itself and halts further 
damage due to the pro-inflammatory response. 
 
2.2 Classification of Macrophage Activation: M1 versus M2 Phenotypes 
 2.2.1 Classical (M1) Activation: Pro-Inflammatory 
 As previously stated, macrophages are mononuclear phagocytes that act as the 
central regulators of the innate immune response, particularly for the periphery.  
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Macrophages adopt general activation phenotypes based on the state of the immune 
response.  There are two main phenotypes used to classify peripheral macrophages: 
classical and alternative, where classical activation is commonly referred to as an M1 
state, and alternative activation is referred to as an M2 state (Mills et al., 2000; Gordon, 
2003).  Classically activated M1 macrophages are induced by Th1 cell-derived cytokines, 
such as IFN-γ, TNF-α and IL-1β, and their activation causes them to release pro-
inflammatory molecules such as IL-6, nitric oxide synthase (NOS), and nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidases along with their corresponding toxic 
intermediates, reactive oxygen species (Gutteridge and Halliwell, 1989; Heinrich et al., 
1998; Brown, 2007; Benoit et al., 2008; Burton et al., 2011).  These toxic intermediates 
and inflammatory cytokines cause cell damage (Gutteridge and Halliwell, 1989) and 
release of proteolytic enzymes that can degrade the extracellular matrix and make it more 
susceptible to damage and destruction (Chandler et al., 1995; Maeda and Sobel, 1996; 
Rosenberg et al., 2001; Rosenberg, 2009; Shiryaev et al., 2009).  Long-term M1 
activation and increase in pro-inflammatory cytokines by LPS administration has been 
shown to decrease synaptic plasticity both in vitro and in vivo (Lynch, 2010) and 
accompany a deficit in spatial learning (Oitzl et al., 1993; Hein et al., 2010).  Therefore, 
although M1 macrophage activation is critical for the acute phase of the immune 
response for the destruction of pathogens and damaged cells, chronic M1 activation can 
be deleterious to neighboring cells. 
 2.2.2 Alternative (M2) Activation: Anti-Inflammatory 
 Alternative, or M2, activation of macrophages allows for inflammation resolution 
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through a negative feedback mechanism to dampen the inflammatory response and 
reduce bystander damage (Colton, 2009).  Alternatively activated M2 macrophages are 
induced by Th2 cell-derived cytokines and lead to the expression of genes for 
inflammation resolution, wound healing, angiogenesis, scavenging, and homeostasis.  
These include arginase 1 (ARG1) (Gomi et al., 2011) and chitinase 3-like 3 (YM1) (Raes 
et al., 2002), and they cause the release of anti-inflammatory cytokines, such as IL-10, 
IL-4, cluster of differentiation-200 (CD200), and TGF-β, and suppress the expression of 
pro-inflammatory cytokines.  M2 macrophage activation can be divided into further sub-
classifications known as M2a, M2b, and M2c.  Inflammation resolution and phagocytosis 
is conducted by M2a macrophages through the release of IL-4, CD200, IL-13, YM1, 
mannose receptor (MR), found in inflammatory zone 1 (FIZZ1), insulin growth factor-1 
(IGF-1), and ARG1.  M2b macrophages aid in the clearance of reactive oxygen species 
produced during M1 activation (Mantovani et al., 2004).  Finally, M2c macrophages 
conduct the process of wound repair and tissue remodeling through the release of IL-10, 
TGF-β, and glucocorticoid hormones (Mantovani et al., 2004). 
 
2.3 Classification of Microglial Activation 
 Microglia are the brain resident myeloid cells that regulate the immune response 
of the CNS.  They are distinct cell types from peripheral macrophages, but they adopt 
similar activation phenotypes in response to CNS insult with similar expression profiles 
in response to M1 or M2 ligands (see Table 1) (Varnum and Ikezu, 2012).  Despite the 
similarities in activation phenotypes and functions of both macrophages and microglia, 
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both cell types are of different origin, and the classification of peripheral macrophage 
activation phenotypes do not fully illustrate the activation phenotypes of resident 
microglia in the CNS.  Unlike macrophages, microglia originate from yolk sac 
progenitors only during embryonic development.  Microglial progenitors from the yolk 
sac enter the neurepithelium of the embryo where they differentiate into microglia, and 
there they reside throughout adulthood (Alliot et al., 1991; Ginhoux et al., 2010; 
Ransohoff, 2011).  In some neurodegenerative diseases, like AD, microglial activation 
phenotypes switch from the M2-like to the M1-like activation state during disease 
progression (Varnum and Ikezu, 2012).  Research suggests that therapeutic skewing of 
microglia to an M2 phenotype or, conversely, dampening of M1 activation may inhibit 
neurodegeneration and accessory inflammatory damage in diseases with inflammatory 
components.  These effects correlate with changes in performance on memory tasks, as 
determined by Morris water maze (MWM) or radial arm water maze (RAWM) tasks, and 
in neuronal function, as determined by elecrophysiological measurements of long-term 
potentiation (LTP) (Table 1). 
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Table 1. Characterized microglial activation states from in vitro and in vivo data 
 
Adapted from (Varnum and Ikezu, 2012) 
 Microglial Activation State 
Classification M1 M2a M2c 
Phenotype Classical/ pro-
inflammatory 
Alternative, anti-
inflammatory 
Deactivation/ 
Wound-healing 
Ligands IFN-γ1, TNF-α1, TLR 
ligands2,3, Aβ4,5,6 
IL-47,8,9,10,11, IL-
1312  
IL-107, 
glucocorticoid 
hormones8, 
TGF-β7 
Markers NOS213, TNF-α1, IL-
61, IL-1β1, CCL21  
ARG114,15, MR16,17, 
FIZZ116,17, 
YM116,17, IGF-
118,19  
MR16,17, IL-107, 
TGF-β7 
Neurogenic 
Effect 
Inhibition of neural 
stem cell 
differentiation and 
maturation12,20,21,22,23,24  
Enhanced neural 
stem cell 
differentiation18,19,25  
Enhanced 
neural stem cell 
proliferation26  
Neuroprotection Enhanced 
neurotoxicity, 
extracellular matrix 
damage13 
Anti-inflammatory 
neuroprotection, 
phagocytosis27,28 
Deactivation of 
glial 
inflammation8 
Synaptic 
Plasticity 
CA1 LTP29 CA1 LTP10 CA1 LTP30 
Spatial 
Learning 
MWM31,32 RAWM25 RAWM26 
Reference 1(Benoit et al., 2008),	  2(Nagai et al., 2002), 3(Nagai et al., 2002; Takeda and 
Akira, 2004), 4(Lotz et al., 2005), 5(Reed-Geaghan et al., 2009),	   6(McGeer 
and McGeer, 2010),	   7(Elenkov and Chrousos, 2002),	   8(Mantovani et al., 
2004),	  9(Maher et al., 2005),	  10(Nolan et al., 2005),	  11(Lyons et al., 2007a), 
12(Monje et al., 2003), 13(Gutteridge and Halliwell, 1989),	  14(Jimenez et al., 
2008), 15(Jimenez et al., 2008; Gomi et al., 2011),	   16(Raes et al., 2002), 
17(Raes et al., 2002; Colton et al., 2006),	   18(Butovsky et al., 2005), 
19(Butovsky et al., 2005; Butovsky et al., 2006a),	   20(Ekdahl et al., 2003), 
21(Hoehn et al., 2005), 22(Bastos et al., 2008),	   23(Deng et al., 2010), 
24(Ekdahl et al., 2003; Monje et al., 2003; Hoehn et al., 2005; Bastos et al., 
2008; Deng et al., 2010; Walter et al., 2011), 25(Butovsky et al., 2005; 
Butovsky et al., 2006a; Kiyota et al., 2010), 26(Kiyota et al., 2011b),	  27(Koenigsknecht-Talboo and Landreth, 2005),	   28(Carpentier and Palmer, 
2009), 29(Lynch, 2010), 30(Lynch et al., 2004), 31(Oitzl et al., 1993), 32(Hein 
et al., 2010) 
 
 
 
	  	  16	  
2.4 Phagocytosis in the M1 versus M2 Environment 
 Phagocytosis is required for the clearance of apoptotic cells, initiation of tissue 
repair, and maintenance of tissue homeostasis.  Both microglia and macrophages are 
efficient phagocytic cells, yet there is a discrepancy between the presence of activated 
microglia surrounding amyloid plaques in the AD brain and a failure to effectively 
phagocytose and clear these Aβ deposits.  Table 2 outlines studies in mouse models that 
provide evidence that manipulation of microglial activation toward an M2 phenotype 
tends to reduce β-amyloidosis.  Some labs have found that the inflammatory environment 
may play a critical role in the capability for microglia to initiate a phagocytic response.  
In a thorough study by Koenigsknecht-Talboo and Landreth, they saw that treating 
primary microglia with pro-inflammatory mediators, such as LPS, IL-1β, or IFN-γ, 
inhibits the ability of microglia to phagocytose Aβ42 (Koenigsknecht-Talboo and 
Landreth, 2005).  On the other hand, when primary microglia are treated with anti-
inflammatory mediators, such as IL-4, IL-10, or TGF-β, their phagocytosis of Aβ42 was 
neither inhibited nor enhanced.  This suggests that microglia are unable to mount a 
phagocytic response in the presence of inflammatory cytokines, but an anti-inflammatory 
environment supports microglial phagocytosis of Aβ.  A similar study showed that pro-
inflammatory cytokine IFN-γ suppresses Aβ degradation in microglia, but anti-
inflammatory mediators IL-4 or TGF-β1 enhance it (Yamamoto et al., 2008).  In 
summary, chronic neuroinflammation in the AD brain may suppress activation of 
phagocytosis and degradation of Aβ. 
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Table 2. Microglial activation states in AD mouse models 
 
Adapted from (Varnum and Ikezu, 2012) 
Modified 
Phenotype Model 
Cytokine 
Modified Inflammation Neurogenesis 
Spatial/ 
Contextual 
Learning Amyloidosis 
 APP  
↑ IFN-γ, IL-1β, 
IL-6, TGF-β, 
IL-10, IL-12,  ↓ 
IL-4 
↑↓  ↓  + 
 APP/PS1  
↑ TNF-α, IL-6, 
IL-12, IL-1β, 
IL-1α 
↓  ↓  ++ 
M1↓  APP 
x IFN-γR 
KO 
↓ TNF-α, astro/ 
microgliosis ND ND 
↓  
M1↑  APP IL-1β TG 
↑MHCII, 
astrogliosis ND ND 
↓  
M1↑  APP 
x NOS2 
KO ↑ TNF-α, IL-6 ND 
↓ ↑  
M1↓  APP/PS1 
x NOS2 
KO 
↓ astro/ 
microgliosis 
ND ↑ ↓  
M1↓  APP 
x TLR-4 
DN TG 
↑↓  
microgliosis, 
↓IL-1β, IL-6,   
ND ↓ ↑  
M1↓  APP 
x TNFR1 
KO 
↓ astro/ 
microgliosis ND 
↑ ↓  
M2a↑  APP/PS1 IL-4 GT 
↑ IL-4, ↓ astro/ 
microgliosis 
↑ ↑ ↓  
M2c↑  APP/PS1 IL-10 GT 
↓ astro/ 
microgliosis 
↑ ↑ ↓  
M2c↑  APP IL-10 GT ↓ microgliosis ND ↑ ↓  
M2c↑  APP 
x TGF-β1 
TG ↑microgliosis ND ND 
↓  
M2c↓  APP 
DN TGF-
βR TG ↑microgliosis ND ND 
↑  
M2c↓  APP 
DN TGF-
βR TG 
↑dendritic cells, 
↓astrogliosis ND 
↑  ↓  
DN= Dominant negative, GT= Gene transfer, ND= Not determined, TG= Transgenic, x= 
Cross-bred 
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2.5 Neuroinflammation in the Aged and the Alzheimer’s Disease Brain 
 The Amyloid Cascade Hypothesis states that the presence and build-up of Aβ in 
the brain can result in neuronal damage and activation of the innate immune response.  
Neuroinflammation has long been implicated (Holmes et al., 2008; Salloway et al., 2009) 
as a prominent factor, not only in the progression of AD, but also in the aging process in 
general.  Most of what we know about microglial activation in AD has been derived from 
studies of mouse models.  Table 2 outlines the characterization of microglial activation in 
mouse models after experimental manipulation.  Inflammatory responses to LPS are 
enhanced in aged animals in in vivo experiments (Sparkman and Johnson, 2008; Lynch, 
2010).  In both the serum and brains of AD patients, there are elevated levels of pro-
inflammatory cytokines, such as TNF-α in the serum (Fillit et al., 1991), and IL-6 in the 
brain (Bauer et al., 1991; Bauer et al., 1992).  Transcriptome analyses of brain tissue from 
normally aged humans and mice have also shown that there is a significant increase in the 
expression of inflammatory genes as the body ages (Prolla, 2002; Lu et al., 2004; Fraser 
et al., 2005; Yankner et al., 2008; Bishop et al., 2010).  However, these findings come 
with some caveats that will be discussed below.  There is likewise a reduction in 
expression of anti-inflammatory molecules, namely CD200, in the AD brain (Walker et 
al., 2009).  In histological staining of the AD brain, Aβ plaques are surrounded by a 
number of immune cells, including activated microglia, reactive astrocytes, and T cells 
(Haga et al., 1989; Wegiel and Wisniewski, 1990; Wisniewski and Wegiel, 1991; Ishii 
and Haga, 1992).  Left unchecked, release of inflammatory cytokines and reactive 
oxygen and nitrogen species can lead to widespread cell damage (Gutteridge and 
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Halliwell, 1989; Pratico et al., 2001; Pratico and Sung, 2004).  They have also shown 
reduced synaptic plasticity both in vitro and in vivo in rats by inhibiting long-term 
potentiation (LTP) (Lynch, 2010)  and a deficit in spatial learning in both rats and mice 
(Oitzl et al., 1993; Hein et al., 2010).  This evidence brings forth a new hypothesis that 
the aged brain may have a dysregulated inflammatory response to the presence of Aβ 
plaques and NFTs, and that the consequent increase in oxidative stress as a response 
compounds the neuronal damage seen in AD (McGeer et al., 1989; McGeer et al., 1994). 
 
2.6 The Relevance of Peripheral Macrophage Infiltration 
 Macrophages do not normally infiltrate the CNS during the resting, healthy state 
(Ajami et al., 2007).  In some studies of neuroinflammatory diseases, however, there is 
evidence that they infiltrate the CNS and play a role in the disease state (Huitinga et al., 
1990; Fife et al., 2000; Izikson et al., 2000; El Khoury et al., 2007; Mildner et al., 2007; 
Hawkes and McLaurin, 2009; Naert and Rivest, 2011).  Following a CNS insult, they can 
be recruited into the brain by chemokines, particularly monocyte chemoattractant protein-
1 (MCP-1, or CCL2), and cytokines.  These can stimulate them to differentiate into cells 
that resemble brain-resident microglia (Weitz and Town, 2012).  These peripheral 
macrophages then become closely associated with disease pathologies, including amyloid 
plaques (Stalder et al., 2005; Simard et al., 2006).  Even in a non-diseased state, it has 
been shown that within two weeks of depleting resident microglia, peripheral 
macrophages are capable of infiltrating the CNS through small blood vessels and 
capillaries and adopt microglia-like roles with similar, though not identical, morphologies 
	  	  20	  
to microglia (Varvel et al., 2012).  Depletion of macrophages has yielded differential 
results in different disease models.  In AD mouse models, depletion of peripheral 
macrophages exacerbated β-amyloid pathology (Hawkes and McLaurin, 2009), as did 
inhibition of their entry into the CNS by knock-down of the CCL2 receptor, CCR2 (El 
Khoury et al., 2007; Naert and Rivest, 2011).  In other studies, however, such as multiple 
sclerosis (MS) experimental autoimmune encephalitis (EAE) or Sandhoff disease models, 
their depletion or inhibition ameliorated disease symptomology (Huitinga et al., 1990; 
Fife et al., 2000; Izikson et al., 2000; Mahad et al., 2006; Kyrkanides et al., 2008).  This 
has made the role of peripheral macrophage infiltration into the CNS a difficult issue to 
interpret. 
 The importance of peripheral macrophage infiltration may be more clearly 
elucidated from some recent studies demonstrating an interesting differentiation between 
microglia and macrophages in the disease state.  As discussed, previous studies have 
shown that there is an overall shift from an M2 to an M1 phenotype in human AD and 
AD mouse model brains.  Transcriptome profiling of the aging human brain shows that 
there are significant age-related changes in gene expression starting from middle age, and 
several of these genes are involved in stress responses, including immune function 
(Prolla, 2002; Lu et al., 2004; Fraser et al., 2005; Yankner et al., 2008; Bishop et al., 
2010).  These studies, however, come from whole brain or region-specific brain tissue, 
and they encompass gene profile changes from a multitude of cell types including 
macrophages, microglia, and other glial cells.  Work from the El Khoury group at 
Massachusetts General Hospital somewhat dispute the general conclusion that the aged 
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brain is in an M1 activation state by characterizing the gene profile of exclusively 
microglia from young or aged WT mice.  From their use of specialized new RNA 
analyzing technology, they report that microglia in the aged brain actually shift towards 
an alternative neuroprotective phenotype with a significant increase in M2 activation 
markers and a down-regulation in M1 markers (Hickman et al., 2008).  Of particular 
interest for this project, microglia from the aged brains show a significant down-
regulation in expression of TGF-β1 (Hickman et al., 2008).  A recent publication from 
our lab presents a similar finding in the spinal cord of tau transgenic mice and reveals that 
resident microglia in the spinal cord likewise display an M2 phenotype in the aged mice, 
but infiltrating peripheral macrophages display an M1 phenotype (Asai et al., 2014).  It 
should be noted here that this kind of specific analysis of microglia from the aged brain 
has not been done in humans, and so it is not known if this neuroprotective phenotype in 
the aged mouse brain is reflected in that of aged humans.   
 It was recently reported that there is an overall reduction in the number of resident 
microglia in the aged brain and that this reduction is accelerated in AD (Butovsky, 
International Society of Neuroimmunology meeting, 2012).  These findings together 
suggest that 1) microglia switch to an M2 phenotype in the aged brain; 2) the total 
number of microglia is reduced in the aged brain; 3) the reduction in resident microglia is 
compensated by the infiltration of M1-activated peripheral macrophages that give the 
brain an overall M1 activation status; and 4) the accelerated reduction in microglia in the 
AD brain may also result in an infiltration of peripheral macrophages that may further 
exacerbate inflammatory immune responses to amyloid plaques and NFTs during disease 
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progression.  Infiltration of peripheral macrophages into the brain may not be the central 
cause of the disease, but instead an exacerbating factor that, if dampened or inhibited, 
may slow disease progression.    
 
2.7 Conclusions 
 The contribution of the innate immune response to the progression of AD is 
complex.  Neuroinflammation in AD patients may be due to the combined effect of toxic 
Aβ with normally occurring M1 microglia activation during aging.  It is not yet 
completely understood how much of an impact differential activation of microglia and 
peripheral macrophage infiltration have on neurodegeneration in the hippocampi of AD 
patients. The evidence suggests that reducing pro-inflammatory microglial activation and 
enhancing anti-inflammatory microglial survival will enhance phagocytosis of amyloid in 
the brain and reduce neuronal loss due to toxic substances from the inflammatory 
response.  This also suggests involvement of the anti-inflammatory cytokine TGF-β1 in 
the maintenance of phagocytic microglia.  These findings demonstrate that utilization of 
the “M1/M2” classification of microglia is insufficient to characterize the activation 
phenotype of microglia in the neurodegenerative brain.  A new category may be 
necessary to describe the functions of microglia in this environment, perhaps the “M2d” 
phenotype.  Establishing an alternative activation milieu in the brain by genetic over-
expression of the glycoprotein CD200 may restore microglial phagocytic capability and 
reduce neuronal loss in the AD brain.  
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III.  Neurogenesis 
3.1 Neurogenesis in the Dentate Gyrus  
 Neurogenesis is the process of neuronal proliferation, differentiation, and 
maturation, and it occurs primarily in only two regions of the adult brain in both humans 
and mice (see Fig. 2): the subventricular zone (SVZ) of the lateral ventricles (Fig. 2A), 
where neuroblasts migrate to the olfactory bulbs, and the subgranular zone (SGZ) of the 
hippocampal dentate gyrus (DG) (Fig. 2B and C), where neurons play an important role 
in short-term memory formation and learning (Ming and Song, 2005; Farina et al., 2007; 
Franklin and Ffrench-Constant, 2008). Both regions have a high demand for neuron 
production due to their constant exposure to new stimuli (Carpentier and Palmer, 2009).  
In studies, environmental enrichment, physical activity, and the act of learning itself 
promoted the production of new neurons (Emsley et al., 2005; Duan et al., 2008).  In this 
study, we examine neurogenesis within the DG due to its involvement in memory 
formation and because it undergoes significant neuronal loss in AD, likely explaining 
why patients suffer from progressive memory impairment (Scheff et al., 2006; Scheff et 
al., 2007).   
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Figure 2. Neurogenesis in the adult brain occurs in the SVZ and the DG of the 
hippocampus.  These images show the location of the SVZ and DG of the hippocampus 
in the adult mouse brain.  (A) The subventricular zone of the lateral ventricles (SVZ) is 
highlighted in blue.  (B) The hippocampus, highlighted in magenta, contains the dentate 
gyrus (DG), highlighted in blue, where new neurons play a role in short-term memory 
formation.  Specific hippocampal regions are labeled in (C), which is magnified from the 
boxed region in (B).  New neurons are formed from proliferating cells in the subgranular 
zone (SGZ).  
 
 
 Local signaling within the brain strictly controls the differentiation of neural 
progenitor cells (NPCs) into neurons, astrocytes, and oligodendrocytes, and it keeps the 
production of new neurons in these regions at a very low level (Dayer et al., 2005; 
Tamura et al., 2007).  The majority of newborn cells in the SGZ will undergo apoptosis 
within the first four days, meaning very few progenitor cells will reach maturity and 
integrate into the neural network (Sierra et al., 2010).  Excess cells undergoing apoptosis 
may have an exposed phosphatidylserine that acts as an “eat me” signal to resident 
phagocytes, such as microglia, for recognition and removal by phagocytosis (Elliott and 
Ravichandran, 2010; Nagata et al., 2010; Gregory and Pound, 2011).  Inhibiting 
phagocytosis inhibits clearance of apoptotic cells and also reduces neuronal 
differentiation and survival in the SGZ (Lu et al., 2011).  It should also be mentioned that 
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microglia engulf and eliminate synapses in the hippocampus during development, and are 
thus involved in synapse maturation (Paolicelli et al., 2011).  Knocking out fractalkine 
Cx3cr1 signaling in the mouse delays synaptic pruning by microglia and results in an 
excess of dendritic spines and immature synapses as shown by electrophysiological 
measurements (Paolicelli et al., 2011).  However, the caveat to this is that knock-down of 
Cx3cr1 may also induce an increase in M1-activated microglia, suggesting that a pro-
inflammatory environment may induce an increase in synaptogenesis as a response 
(Harrison et al., 1998; Jung et al., 2000; Ransohoff et al., 2007; Wolf et al., 2013).  
Another study found that doublecortin (Dcx)-positive NPCs, a marker of newly 
differentiated neurons, are also capable of phagocytosis within both neurogenic niches 
(Lu et al., 2011), suggesting NPCs themselves may play an active role in phagocytosing 
excess NPCs. Inhibiting this activity likewise results in an accumulation of apoptotic 
cells and impaired neuronal differentiation in the adult SGZ (Lu et al., 2011).  This could 
possibly be an artifact of the study as Dcx+ cells are not known to migrate toward 
apoptotic cells in vivo, suggesting they may only do so if they are adjacent to an apoptotic 
cell and is a more passive function than active.  The neurodegeneration seen in the 
hippocampi of AD patients and the concomitant deficit in short-term memory formation 
makes neurogenesis an important target of study for finding a way to replenish neuronal 
loss within the DG and restore working memory function. 
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3.2 The Effects of Neuroinflammation on Neurogenesis 
 Reports of altered neurogenesis in the AD hippocampus are contradictory.  In pre-
senile post-mortem AD hippocampi, investigators see an increase in cellular proliferation 
in the hippocampus countered by a reduction in neuronal maturation (Jin et al., 2004; 
Boekhoorn et al., 2006).  Neuroinflammation has already been shown to have a 
profound effect on the process of neurogenesis.  The chronic infusion or single injection 
of LPS activates microglia and inhibits neurogenesis in the hippocampi of adult rodents 
(Ekdahl et al., 2003; Monje et al., 2003; Walter et al., 2011).  This LPS-induced 
inflammation has no effect on the production and proliferation of neural stem cells 
(NSCs), but it does reduce their ability to mature into neurons and survive (Ekdahl et al., 
2003; Bastos et al., 2008).  Expression of IFN-γ in in vitro NSC cultures shows the same 
reduction in differentiation (Ekdahl et al., 2003; Monje et al., 2003; Walter et al., 2011).  
The neuroinflammatory cascade, however, does not affect the ability of microglia to clear 
apoptotic cells by phagocytosis (Sierra et al., 2010).  In in vitro cultures of NPCs, 
addition of aggregated Aβ42 inhibits neuronal differentiation (Haughey et al., 2002), 
suggesting that AD pathology, or the accumulation of toxic Aβ, may contribute to the 
reduction of NSC renewal and maturation (see Fig. 3).   
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Figure 3. The build-up of Aβ42 may reduce neuronal differentiation and survival. 
Aβ42 may suppress neural differentiation and survival by causing neuronal damage and 
inducing the release of M1 pro-inflammatory mediators.  This can increase NSC 
proliferation, while simultaneously reducing neuronal differentiation and survival by 
reducing levels of ATP required for differentiation and synaptic formation in neurons.  
M2 mediators inhibit the production of M1 mediators and dampen inflammation.  This 
promotes neuronal differentiation and survival as well as phagocytosis by microglia, 
which may reduce accumulation of Aβ42.    
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 It is not yet known how this maturation is disrupted.  It has been shown that 
neurons differentiated during a pro-inflammatory state have abnormal synaptic 
morphology, and this may reduce their ability to survive (Jakubs et al., 2008).  Another 
possibility is that mitochondrial damage caused by pro-inflammatory mediators such as 
TNF-α and IL-6 during inflammation (Stadler et al., 1992; Zell et al., 1997; Behrens et 
al., 2008; Samavati et al., 2008) can then disrupt adenosine triphosphate (ATP) 
production by mitochondria, which is the energy form required by NPCs to differentiate 
into neurons (Bernstein and Bamburg, 2003).  Mitochondrial dysfunction may also affect 
the ability of the electron transport chain to reduce the generation and release of toxic 
reactive oxygen species (Bishop et al., 2010). 
 Suppression of pro-inflammatory microglial activation may be able to restore 
neurogenesis in the SGZ.  An in vitro study utilizing NPCs from adult WT C57Bl/6 mice 
demonstrated that adult NPCs co-cultured with LPS-stimulated microglia suppresses 
neurogenesis, whereas treatment with IL-4-stimulated microglia greatly enhances 
neurogenesis and maturation of neurons (Butovsky et al., 2006b).  This may be mediated 
by IL-4’s known induction of IGF-1, a pro-neurogenic factor that supports neurogenesis 
(Butovsky et al., 2005; Butovsky et al., 2006a).  This effect requires the presence of 
microglia as direct stimulation of NPCs has no effect, underlining the importance of 
microglial activation status in neurogenesis.  Another study demonstrated that gene 
delivery of IL-4 into the bigenic APP+PS1 mouse brain pre-symptomatically (3 months 
of age) is also able to restore neurogenesis in the SGZ of the aged mouse (8 months of 
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age) (Kiyota et al., 2010).  This makes microglial activation status and 
neuroinflammation important therapeutic targets for restoration of neurogenesis in AD. 
 
3.3 Conclusions 
 Neuroinflammation clearly has a significant impact on neurogenesis within the 
DG.  M1 microglial activation suppresses neuronal differentiation as well as 
phagocytosis, which may in turn contribute to further reductions in neurogenesis.  
Reduced neuronal differentiation within the DG may explain the loss of memory 
formation in AD patients.  Thus, restoring or maintaining neurogenesis to prevent that 
loss by maintaining M2 microglial activation is a prime target in this study. 
 
IV.  Cluster of Differentiation 200 (CD200) 
4.1 CD200 and the CD200R 
 CD200 is a type I transmembrane glycoprotein with an immunoglobulin 
superfamily (IgSF) domain (Clark et al., 1985).  It is expressed on a number of cells, 
including T cells, B cells, and neurons (McMaster and Williams, 1979; Barclay, 1981; 
Webb and Barclay, 1984), and its receptor (CD200R) is expressed largely on cells of the 
myeloid lineage, including microglia, macrophages, astrocytes, dendritic cells, and 
oligodendrocytes (Barclay, 1981; Chitnis et al., 2007; Koning et al., 2010).  The CD200 
protein has a short cytoplasmic tail, indicating that its CD200R recognition domain is 
likely extracellular (Clark et al., 1985).  Although the CD200R does not contain an 
immunotyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain (Ravetch and 
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Lanier, 2000), interaction between the extracellular domains of the CD200 and CD200R 
negatively modulates myeloid cells (Hatherley and Barclay, 2004; Chen and Gorczynski, 
2005) likely through binding of downstream of tyrosine kinase 2 (Dok2) to the 
phosphorylated tyrosine on the cytoplasmic NPxY motif on the CD200R (Fig. 4) (Wright 
et al., 2000; Hatherley and Barclay, 2004).  This recruits RAS p21 protein activator 1 
(RasGAP) (Zhang et al., 2004) and leads to subsequent inhibition of extracellular signal-
regulated kinase (ERK), p38 mitogen-activated protein kinase (MAPK), and c-Jun N-
terminal kinase (JNK) pathways (Mihrshahi et al., 2009), which will suppress 
downstream NFκB signaling. 
 CD200 also elicits anti-inflammatory signaling through an alternate mechanism.  
There are additional CD200R-like proteins, one of which is known as CD200R3 (Fig. 5).  
This receptor contains a positively charged amino lysine within its transmembrane region 
that can interact with adaptor molecules that contain an immunoreceptor tyrosine-based 
activation motif (Nagai et al.), such as TYRO protein tyrosine kinase binding protein, or 
TYROBP (also known as DNAX-activating protein of 12 kD, or DAP12) (Wright et al., 
2003; Kojima et al., 2007).  TYROBP functioning is associated with downstream 
signaling of interactions with triggering receptor expressed on myeloid cells 2 (TREM2), 
a gene known to be associated with susceptibility to AD when under-expressed 
(Guerreiro et al., 2013a; Jonsson et al., 2013; Neumann and Daly, 2013).  TREM2 may 
promote phagocytosis by microglia (Takahashi et al., 2005; Hsieh et al., 2009; Melchior 
et al., 2010), inhibit production of pro-inflammatory cytokines by microglia (Takahashi et 
al., 2005; Hsieh et al., 2009), and maintain immune homeostasis and inflammation 
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resolution (Neumann and Takahashi, 2007).  TYROBP signaling mediates several 
processes, including cell migration and phagocytosis.  It inhibits TLR signaling through 
inhibition of the ERK pathway downstream of TLR-4 (Hamerman et al., 2005).  The 
roles of TREM2 and TYROBP in Alzheimer’s disease will be discussed in more detail 
below.  In both these ways, CD200R via Dok2 and CD200R3 via TYROBP, CD200 can 
suppress inflammation. 
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Figure 4. CD200R1 signaling via Dok2 promotes anti-inflammatory activation. 
CD200R signaling via Dok2 inhibits NFκB activation, and thus inhibits the release of 
pro-inflammatory mediators NOS2, IL-1β, and IFN-γ, among others.  This reduction in 
pro-inflammatory signaling may enhance phagocytosis by microglia. 
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Figure 5. Proposed interaction between CD200R3 and TYROBP may reduce pro-
inflammatory cytokine release and promote phagocytosis similar to TREM2. 
Alternative signaling via CD200R-like protein, CD200R3, interacts with TYROBP to 
inhibit NFκB activation, thus inhibiting release of pro-inflammatory mediators.  This 
interaction may also promote an interaction between TREM2 and TYROBP, thus 
promoting phagocytosis by microglia in addition to reducing inflammation. 
 
 
 
 
4.2 The Role of CD200 in Microglial Activation in the Aged and the AD Brain 
 CD200 is an important regulator in the immune response.  Mice deficient in 
CD200 show an enhanced inflammatory response to injurious stimuli (Hoek et al., 2000), 
and mice lacking the CD200R likewise have enhanced production of TNF-α and 
downstream inflammatory responses to LPS treatment (Boudakov et al., 2007).  In mouse 
models of inflammatory diseases, such as EAE mice for MS or experimental autoimmune 
uveoretinitis (EAU) mice, blocking CD200 or CD200R increases inflammation and tissue 
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damage after EAE or EAU induction (Banerjee and Dick, 2004; Chitnis et al., 2007; 
Copland et al., 2007).  Blocking CD200R signaling in macrophages harvested from EAU 
mice in vitro likewise enhances IFN-γ-induced release of IL-6 and subsequent cell death 
(Copland et al., 2007).  The CD200-CD200R interaction is required for mediation of the 
immune response.     
 The age-related increase in pro-inflammatory gene expression is accompanied by 
an age-related reduction in anti-inflammatory mediators.  In aged rats, there is a 
progressive increase in pro-inflammatory IFN-γ along with a reduction in anti-
inflammatory IL-4 (Nolan et al., 2005; Maher et al., 2006).  Like IL-4, CD200 expression 
decreases with age and is simultaneously associated with increased microglial activation 
(Lyons et al., 2007b).  It is also reduced in the AD brain and the brains of Aβ-treated 
mice (Lyons et al., 2009; Walker et al., 2009).  As stated in the previous section, M1 
microglial activation is suppressive to neuronal differentiation as well as microglial 
phagocytic capability.  Reduced CD200 expression may likewise contribute to M1 
microglial activation and reduced neurogenesis in the DG.  This is significant because in 
mice that lack CD200, their hippocampi demonstrate significant impairments in synaptic 
plasticity, as indicated by deficits in LTP (Costello et al., 2011), which may be indicative 
of an association between the reduced ability to form new memories and the age-
dependent decrease in CD200 in AD patients. 
 
4.3 CD200 Regulation by IL-4 
 IL-4 has been shown to regulate the expression of CD200.  Both in vitro and in 
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vivo studies from mouse and human brain tissue have shown that an increase in IL-4 is 
associated with an increase in CD200, and a reduction in IL-4 likewise reduces CD200 
(Lyons et al., 2007b; Lyons et al., 2009).  Treatment of AD animal models with IL-4 is 
able to restore the Aβ-induced decrease in CD200 expression (Lyons et al., 2007b; Lyons 
et al., 2009).  In another study, IL-4 gene delivery into the hippocampus of APP+PS1 
mice restores the deficit in neurogenesis in the SGZ, enhances clearance of Aβ, and 
restores impaired spatial learning, but only in the pre-symptomatic disease stages (Kiyota 
et al., 2010).  Reductions in Aβ plaque area may be due to the induction of TGF-β, an 
M2c ligand that will be discussed in further detail below.  This data is indicative of 
compromised IL-4 signaling in the later disease stages, possibly due to the decreased 
expression of CD200.  These findings support the hypothesis that CD200 gene delivery 
into the APP mouse model at the later disease stages may restore neurogenesis in the 
aged brain and reduce Aβ plaque area through an anti-inflammatory signaling 
mechanism. 
 Unpublished work done in the Ikezu lab has also examined the connection 
between IL-4 and CD200.  From work done by Dr. Tomomi Kiyota, we found that 
CD200 expression is strong in the pyramidal neurons at the stratum radiatum of the CA1 
region and in the SGZ of the DG of the hippocampus of non-transgenic mice and in 
adeno-associated virus (AAV)-IL-4-injected APP+PS1 mice (regions outlined in Fig. 6A 
and magnified in B and C).  This expression is not as strongly immunoreactive in the 
same areas in mice injected with AAV for the expression of green fluorescent protein 
(GFP) or IL-10-injected APP+PS1 mice.  IL-10 is an M2c resting microglial marker 
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known to dampen glial activation (Plunkett et al., 2001; Mantovani et al., 2004).  
Intensity of the CD200 expression is shown in Figure 6D (stratum radiatum) and E 
(SGZ) and demonstrates that there is an increase in CD200 expression in the APP+PS1 
mouse compared to WT levels when treated with AAV-IL-4.  The same can be seen in 
vitro from primary cultured neurons.  Immunoblotting for CD200 in primary cultured 
neurons after IL-4 stimulation shows a pronounced increase in CD200 protein levels, 
which is not seen after IL-10 stimulation (Fig. 7A and B).  IL-4 stimulation of primary 
cultured neurons treated with Aβ likewise restores CD200 protein levels (Fig. 7C).   
 These experiments support previous findings that indicate CD200 is regulated by 
IL-4 (Lyons et al., 2007b; Lyons et al., 2009) and suppressed by the presence of Aβ 
(Lyons et al., 2007b), as seen in APP+PS1 mice. Aβ-induced reductions in CD200 have 
been shown in Aβ-treated rats and in neuron cultures (Lyons et al., 2007b), as well as in 
human AD brains (Walker et al., 2009).  The same reduction has been shown here in a 
transgenic mouse model with high amyloid deposition due to an APP mutation (Holcomb 
et al., 1998).  This also demonstrates that this mouse model undergoes the same IL-4-
induced restoration in CD200 expression proposed by previous investigators (Lyons et 
al., 2007b; Lyons et al., 2009), and we can restore it with our AAV-IL-4 gene delivery 
system.  We also demonstrate that this restoration in CD200 expression in our APP+PS1 
mice is specific to IL-4, and not anti-inflammatory cytokine expression in general.  This 
makes the APP mouse a good model for studying the effects of over-expression of 
CD200. 
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Figure provided by Dr. Tomomi Kiyota 
 
Figure 6. IL-4, but not IL-10, increases CD200 expression in the hippocampus in 
vivo. (A) CD200 expression in the neuropil of the hippocampus of non-transgenic mice 
(NTg). (B, C) Magnification of regions B and C in A; strong immunoreactivity of CD200 
in pyramidal neurons at the stratum radiatum of the CA1 region (B, arrowheads) and the 
SGZ of the dentate gyrus (C, arrowheads) in non-Tg and AAV-IL-4-injected APP+PS1 
(IL-4), but not in AAV-GFP (GFP), or -IL-10-injected (IL-10) APP+PS1 mice. (D, E) 
Intensity of CD200 expression in the stratum radiatum of the CA1 region (D) and SGZ 
(E) *** or ### denotes p<0.001 vs. non-Tg or AAV-GFP group (n = 5 per group, 5 
sections per brain). Scale bars represent 200 µm in a and 100 µm in (B). 
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Figure provided by Dr. Tomomi Kiyota 
 
Figure 7. IL-4, but not IL-10, increases CD200 expression in primary cultured 
neurons in vitro.  (A) Immunoblotting of CD200 and β-actin in primary cultured murine 
cortical neurons after IL-4 or IL-10 stimulation. (B) Quantification of immunoreactive 
bands in (A). * denotes p<0.05 vs. non-treated controls as determined by one-way 
ANOVA and Newman–Keuls post-test, respectively (n=3).  (C) IL-4 stimulation restores 
CD200 expression that was slightly reduced by Aβ treatment in primary cultured 
neurons.  Statistical analysis shows no significant difference by one-way ANOVA (n=3).   
        
	  	  39	  
4.4 The Role of CD200 in Other Disease Models 
 It is worth mentioning here the role CD200 may play in other diseases that have 
some immune component to their progression or maintenance.  In cancer, for instance, 
the function of CD200 to suppress the pro-inflammatory response may actually be 
detrimental as a means for tumor cells to evade T-cell-mediated cytotoxicity (Kretz-
Rommel et al., 2007; Moreaux et al., 2008; Siva et al., 2008).  Many different cancer 
cells over-express CD200.  In myeloma cells, for instance, CD200 expression negatively 
correlates with patients’ likelihood for survival (Moreaux et al., 2006; Petermann et al., 
2007; Siva et al., 2008).  Therefore, most cancer research investigating CD200 attempts 
to inhibit its activity.  Although there are correlations between CD200 and aging or 
disease, including MS, AD, and cancer, the importance of CD200 is still not completely 
defined.  CD200 has never been tested for its therapeutic potential in AD models.  
Despite its disadvantage in cancer, it may prove to be an effective therapeutic in AD. 
 
4.5 Conclusions 
 CD200 is an anti-inflammatory glycoprotein that is reduced during normal aging 
and in AD or Aβ-treated brains.  Its reduction is associated with increases in M1 
microglial activation and release of pro-inflammatory mediators. These may contribute to 
neuronal loss and reductions in neuronal differentiation and reduced microglial 
phagocytosis of amyloid. CD200 expression inhibits Aβ-induced increases in M1 
cytokines, including IL-1β (Lyons et al., 2012).  Interestingly, Aβ42 and NFκB-induced 
increases in IL-1β expression can inhibit TGF-βR signaling, suggesting that reductions in 
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IL-1β release by CD200 may support anti-inflammatory microglial survival through 
induction of TGF-β1.  This has not yet been investigated in microglia cells.  In this way, 
anti-inflammatory signaling by CD200R may reduce M1 microglial activation, increase 
neuronal differentiation, and enhance amyloid phagocytosis.  
 
V.  Transforming Growth Factor-β (TGF-β1) and Triggering receptor expressed on 
myeloid cells 2 (TREM2) 
5.1 TGF-β and Its Role in Phagocytosis 
 As previously mentioned, TGF-β is an M2c ligand involved in wound repair and 
tissue remodeling.  Studies show that TGF-β1 is an important component of the immune 
system for its involvement in microglial activation and phagocytosis.  Differential 
regulation of TGF-β1 has also been implicated as therapeutics for AD (Wyss-Coray et al., 
2001; Town et al., 2008).  TGF-β1 was shown to promote amyloid clearance and 
reduce plaque deposition in the hAPP mouse (Wyss-Coray et al., 2001), possibly through 
the alternative Smad1/5/8 pathway (Town et al., 2008). A recent gene array study of 
adult primary murine microglia revealed that TGF-β1 is critical for the development and 
survival of microglia in vivo and in vitro (Butovsky et al., 2014).  TGF-β is also required 
for microglia to maintain an M2c phenotype (Schilling et al., 2001).   
 In the study by Koenigsknecht-Talboo and Landreth, primary microglia in an anti-
inflammatory milieu were more capable of phagocytosing Aβ42 than were microglia 
treated with pro-inflammatory mediators (Koenigsknecht-Talboo and Landreth, 2005).  
This may be mediated through induction of TGF-β1.  In vitro analyses of microglia show 
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that the survival of phagocytic microglia and their ability to uptake Aβ peptide is both 
mediated and enhanced by TGF-β1 (Ryu et al., 2012; Tichauer and von Bernhardi, 2012).  
There is no evidence thus far of a direct correlation between CD200 and TGF-β induction 
in primary microglia.  However, IL-4 treatment of primary microglia does increase the 
expression and secretion of TGF-β2 (Zhou et al., 2012), and in non-microglial or -
macrophage myeloid cells, it has been shown that the CD200-CD200R interaction 
supports the release of TGF-β (Clark et al., 2008; Memarian et al., 2013).  This makes 
TGF-β a likely mediator of IL-4- or CD200-induced phagocytosis of Aβ through 
induction of an M2 microglial environment, and it requires further investigation. 
 
5.2 TREM2 and TYROBP Signaling 
 TREM2 is a member of the immunoglobulin superfamily and is located on 
chromosome 6 (chromosome 17 in mice).  It is expressed by cells of the myeloid lineage, 
including macrophages and microglia (Schmid et al., 2002; Klesney-Tait et al., 2006).    
TREM2 is mainly found in intracellular stores, but it can rapidly translocate to be 
expressed on the cell surface (Sessa et al., 2004).  The adaptor protein TYROBP is 
required for TREM2 signaling [see (Klesney-Tait et al., 2006) and (Ivashkiv, 2008) for 
review].  Upon receptor ligation, tyrosine residues within the TYROBP ITAM region 
undergo phosphorylation by Src kinases, which allows for the tyrosine kinase Syk to bind 
to the ITAM region.  Syk phosphorylates scaffolding molecules that then recruit 
signaling molecules to initiate downstream signaling cascades.  Ultimately, this leads to 
the activation of Akt, protein kinase C, and MAPK or calcium-activated protein kinases 
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followed by reorganization of the actin cytoskeleton (Vicente-Manzanares and Sanchez-
Madrid, 2004). 
 
5.3 TREM2 and Its Role in Alzheimer’s Disease and Phagocytosis 
 The functions of TREM2 and TYROBP were first highlighted by the rare 
autosomal recessive disorder Nasu-Hakola disease.  Patients with this disease present 
with joint swelling, bone cysts, frequent bone fractures, and dementia, and have a high 
number of activated microglial cells in the brain (Kitajima et al., 1989).  Early studies 
showed that patients with Nasu-Hakola disease had loss-of-function mutations in either 
TYROBP or TREM2 (Mizuno et al., 1975; Kondo et al., 2002; Paloneva et al., 2002).  
These deficiencies result in exaggerated responses to TLR activation and increased 
cytokine production (Hamerman et al., 2005; Hamerman et al., 2006; Turnbull et al., 
2006).  In EAE mouse models of MS, blockade of TREM2 exacerbated disease 
progression (Piccio et al., 2007), similar to the effect of CD200 knock-out in the same 
models, revealing an important immune regulatory function of TREM2.  More recent 
studies reveal that homozygous or heterozygous missense mutations in TREM2 also 
increase the risk for developing late-onset AD, Parkinson’s disease (PD), amyotrophic 
lateral sclerosis (ALS), and frontotemporal dementia (FTD) (Guerreiro et al., 2013a; 
Guerreiro et al., 2013b; Jonsson et al., 2013; Rayaprolu et al., 2013; Borroni et al., 2014; 
Cady et al., 2014; Cuyvers et al., 2014).    
 Although it is still not clear how these mutations result in a loss-of-function of 
TREM2 or TYROBP, a recent collaborative study in Germany suggests that they lead to 
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a reduction in TREM2 processing and maturation (Kleinberger et al., 2014).  Soluble 
forms of TREM2 (sTREM2) are detected in the cerebrospinal fluid (CSF) and plasma of 
healthy normal patients, as well as in cell culture medium in vitro.  They found that levels 
of sTREM2 in the CSF were significantly lower in AD and FTD patients (Kleinberger et 
al., 2014).  While still debated, this study provides evidence that AD-associated 
mutations in TREM2 result in impaired TREM2 maturation, secretion, and induction of 
phagocytosis in human embryonic kidney (HEK293) cells as indicated by impaired cell 
surface transport and shedding of mutant TREM2 and its accumulation in the cytoplasm 
of BV2 cells (Kleinberger et al., 2014).  In addition to this, they showed that these 
mutations impaired expression of mature membrane-bound TREM2 also impaired 
phagocytosis of Aβ1-42, specifically, in three independent cell lines (BV2, HEK293, and 
primary microglia) (Kleinberger et al., 2014).  This suggests that TREM2 may function 
as a soluble protein. 
 In vitro studies elucidate why dysfunctional TREM2 expression may result in 
progressive neurodegeneration.  In a study using primary microglial cells, TREM2 
promoted phagocytosis of apoptotic neurons without stimulating cytokine production, 
suggesting that mutations in TREM2 impair phagocytosis of apoptotic neurons and 
increase proinflammatory cytokine release (Takahashi et al., 2005).  Although still 
debated, research suggests that TREM2 induces phagocytosis of apoptotic neurons via 
direct recognition by microglia of TREM2-ligands specifically induced by apoptotic 
neurons (Hsieh et al., 2009).  This has only been shown in vitro, however, and the 
identity of these ligands is unknown.  In support of this, however, TREM2 does not 
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promote general phagocytosis, as loss of TREM2 in BV2 microglial cells only reduces 
phagocytosis of apoptotic cells but not microbeads (Hsieh et al., 2009). In aged APP23 
transgenic mice, researchers found that TREM2 expression was increased in microglia 
that were associated with amyloid plaques (Frank et al., 2008).  This suggests that if a 
loss of function mutation is present, reductions in TREM2/TYROBP expression reduce the 
phagocytic capability of plaque-associated microglia and increase M1 activation, thus 
resulting in exacerbated neurodegeneration, secondary necrosis due to build-up of 
apoptotic debris, and chronic inflammation (Takahashi et al., 2005; Neumann and 
Takahashi, 2007). This may be the mechanism by which genetic mutations in TREM2 or 
TYROBP increase the risk of developing late-onset AD.   
 
5.4 Conclusions 
 The roles of TGF-β1 and TREM2 in AD have become popular targets of 
investigation after genetic screening provided strong evidence of their involvement in 
neurodegenerative diseases. They have never been shown to work in concert with CD200 
in microglia in the brain.  However, a recent review article on alveolar macrophages 
introduces a complex network of signals from CD200R, TREM2, and TGF-βR1, that are 
activated in response to inflammation to block the release of pro-inflammatory cytokines 
and maintain homeostasis (Hussell and Bell, 2014).  Research suggests that they function 
to reduce the TLR response, and it is known that Aβ itself can act as a TLR-4 ligand.  
Both TGF-β1 and TREM2 appear to play a role in activating microglia to phagocytose 
apoptotic neurons and debris and perhaps Aβ itself, without initiating a pro-inflammatory 
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response.  Therefore, they may both play a role in inducing an alternative microglial 
activation state supportive of phagocytosis (Neumann and Takahashi, 2007; Takahashi et 
al., 2007). TREM2, TGF-β,  and CD200 may act synergistically to dampen inflammation 
and promote phagocytosis of Aβ in the APP mouse model.   
 
VI.  Overall Rationale, Hypothesis, and Objectives 
 More than five million Americans are currently suffering from AD, the sixth 
leading cause of death in the United States (Alzheimer’s Association 2014).  There is 
currently no preventative or inhibitory therapeutic available to treat this disease or slow 
its progression.  Patients with AD exhibit a progressive decline in cognitive function and 
memory impairment.  The brains of AD patients exhibit a characteristic neuropathology 
that includes amyloid plaques and NFTs (Dickson et al., 1988; Alzheimer et al., 1995; 
Minati et al., 2009).  Aggregates of Aβ are known to be toxic to neurons and synapses 
and can activate the innate immune response (McGeer and McGeer, 2010) as well as 
inhibit neuronal differentiation (Haughey et al., 2002).  It is known that AD patients 
exhibit chronic neuroinflammation in the brain, and this can contribute to the suppression 
of neurogenesis in the SGZ of the hippocampus (Monje et al., 2003; Hoehn et al., 2005; 
Deng et al., 2010).  Patients with polymorphisms in genes such as TREM2 show 
increased levels of inflammation in the brain that correlates with a higher risk of 
developing AD and other neurodegenerative diseases (Guerreiro et al., 2013a; Guerreiro 
et al., 2013b; Jonsson et al., 2013; Rayaprolu et al., 2013; Borroni et al., 2014; Cady et 
al., 2014; Cuyvers et al., 2014), showing a clear link between inflammation and neuronal 
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degeneration.  Neurogenesis in the SGZ of the adult hippocampus is involved in the 
maintenance of the CNS and formation of new memories (Bruel-Jungerman et al., 2007; 
Deng et al., 2009; Deng et al., 2010; Tronel et al., 2010), making it an important 
therapeutic target in AD.  The reduced neuronal maturation seen in the pre-senile post-
mortem AD hippocampus is accompanied by an increase in cellular proliferation (Jin et 
al., 2004; Boekhoorn et al., 2006), which is indicative of a suppressive impact of the pro-
inflammatory cascade on the maturation and survival of new neurons (Ekdahl et al., 
2003; Monje et al., 2003; Bastos et al., 2008).  Pro-inflammatory microglial activation 
also inhibits their ability to phagocytose Aβ42, possibly explaining the build-up of Aβ 
into plaques in AD patients (Koenigsknecht-Talboo and Landreth, 2005). A loss of 
function in TREM2/TYROBP results in reduced phagocytic capability of plaque-
associated microglia, again tying uninhibited M1 activation with reduced phagocytosis 
and subsequent risk of neurodegeneration (Takahashi et al., 2005; Neumann and 
Takahashi, 2007). Our overall hypothesis is that the chronic neuroinflammation seen in 
AD suppresses neurogenesis and phagocytosis in the hippocampus, thus leading to 
reduced new memory formation and enhanced Aβ deposition. 
 CD200 is a neuronal glycoprotein involved in immune modulation and anti-
inflammatory signaling.  Its expression decreases with age when it is simultaneously 
associated with an increase in microglial activation (Lyons et al., 2007b).  It is likewise 
decreased in the brains of AD patients and Aβ-treated mice (Lyons et al., 2009; Walker et 
al., 2009).  CD200 expression is positively regulated by IL-4 (Lyons et al., 2007b; Lyons 
et al., 2009; Koning et al., 2010), and IL-4 treatment is able to restore the age-related 
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decrease in CD200 expression in AD mouse models (Lyons et al., 2007b; Lyons et al., 
2007a; Kiyota et al., 2010).  Although IL-4 gene delivery into the hippocampus of an AD 
mouse model is able to restore the deficit in neurogenesis in the SGZ and enhance 
clearance of Aβ, it does so only in the pre-symptomatic stages of the disease (Kiyota et 
al., 2010), suggesting compromised IL-4 signaling in the late disease stage due to reduced 
CD200 expression.  This makes CD200 a more plausible therapeutic for treatment of AD 
than IL-4.  In addition to this, CD200, unlike IL-4, is endogenously expressed in neurons 
and will not induce an allergic reaction.  We hypothesize that age-related reductions in 
CD200 lead to a pro-inflammatory microglial environment, which reduces neurogenesis 
in the hippocampus, impairs working memory, and reduces phagocytosis and clearance 
of Aβ.  We further hypothesize that these deficits can be restored by genetic over-
expression of CD200.  We tested this hypothesis with the following specific aims: 
 
Specific Aim 1. To determine if CD200 gene delivery into the CA1 region of the 
hippocampus restores neurogenesis in the dentate gyrus of the APP mouse model in vivo. 
Sub-Aim 1.1. To determine if CD200 gene delivery into the hippocampus restores 
working memory formation in the APP mouse model. 
Specific Aim 2. To determine if CD200 gene delivery into the CA1 region reduces 
amyloid plaque area in the hippocampus of the APP mouse model. 
Sub-Aim 2.1. To determine if CD200 gene delivery alters microglial number and 
activation phenotypes in the hippocampus of APP mice. 
Specific Aim 3. To determine if CD200 enhances neuronal maturation in vitro through 
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alteration of microglial activation.  
Specific Aim 4. To determine if CD200 enhances microglial phagocytosis of Aβ in vitro.  
Sub-Aim 4.1. To determine if CD200 enhances phagocytosis of Aβ via TREM2 
induction. 
 
 To test these specific aims, we constructed a tetracycline-inducible AAV for the 
over-expression of CD200.  This was used to determine if CD200 gene delivery into the 
hippocampus of the APP mouse restores neurogenesis in the DG in vivo and if this 
restored neurogenesis correlates with an improvement in working memory formation.  
We also examined Aβ plaques in the hippocampus to determine if establishing an anti-
inflammatory milieu reduces plaque area in this model.  Lastly, we examined the effects 
of CD200 on neurogenesis and phagocytosis in vitro and measured whether its effects 
correlate with expression of TGF-β, a ligand important for the survival of phagocytic 
microglia.  We also measured the impact of CD200 on TREM2 coupling with TYROBP.  
Our findings indicate that there is therapeutic value to the use of CD200, but more work 
must be done to determine the most effective way in which to administer CD200 in order 
to maintain memory function. 
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Chapter 2: CD200 RESTORES NEUROGENESIS IN THE DENTATE GYRUS  
OF THE APP MOUSE 
 
I. Rationale 
 The DG is one of the few regions in the adult brain where neurogenesis occurs, 
and neurons in the DG are involved in memory formation and learning (Ming and Song, 
2005; Farina et al., 2007; Franklin and Ffrench-Constant, 2008).  In Alzheimer’s disease, 
there is an increase in cellular proliferation in the DG that is trounced by a reduction in 
neuronal maturation (Jin et al., 2004; Boekhoorn et al., 2006).  This is likely the major 
contributor to the devastating progressive dementia that is the clinical hallmark of AD 
and an important therapeutic target to replenish neuronal loss.  Pro-inflammatory 
microglial activation and Aβ42 suppress differentiation of neural stem cells into neurons, 
whereas anti-inflammatory microglial activation supports it.  Therefore, we hypothesize 
that induction of an anti-inflammatory microglial environment by gene delivery of 
CD200 restores neurogenesis in the DG of the APP mouse and that this restoration 
restores spatial memory formation.  To test this hypothesis, we increased the expression 
of CD200 using an AAV gene delivery system in six month-old APP mice that were in 
the early post-symptomatic stages of disease.  We tested CD200 gene delivery in the 
post-symptomatic phase of the disease because it is a more therapeutically relevant 
approach.  We used markers of proliferating and differentiating neurons to determine if 
over-expression of CD200 countered the Aβ-induced reduction in neurogenesis in the 
DG.  In addition to this, we did behavioral testing for working memory formation on 
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these mice to determine if CD200 over-expression also countered previously reported 
memory impairments.    
 
II. Materials and Methods 
2.1 Animals 
 Tg2576 (APP) mice expressing the Swedish mutation of human APP695 were 
obtained from Drs. G. Carlson and K. Hsiao-Ashe through the Mayo Medical Venture 
(Hsiao et al., 1996).  Male Tg2576 mice were back-crossed to the B6/129 strain.  Age-
matched non-transgenic (wild-type (WT)) mice of the B6/129 F1 strain or C57Bl/6 were 
purchased from Jackson Laboratories (Bar Harbor, ME) and maintained at the Laboratory 
Animal Science Center at Boston University.  All animal procedures were strictly 
reviewed by the Institutional Animal Care and Use Committee of Boston University 
School of Medicine.  Genotyping was done with DNA samples were prepared for each 
individual mouse pup from tail tips, and genomic DNA was extracted using the DNeasy 
Blood and Tissue kit (Qiagen, Valencia, CA).  Polymerase chain reaction technique 
(PCR) was used to identify APP mice using the methods described previously (Hsiao et 
al., 1995).  Numbers of animals for each group can be seen below in Table 3.  
 
Table 3.  Animal groups and numbers  
Genotype Injection N 
WT Saline 6 
APP  Saline 9 
APP  AAV2/1-GFP 8 
WT AAV2/1-CD200 6 
APP  AAV2/1-CD200 9 
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2.2 Plasmid Construction and AAV2/1 Generation 
 For this study, we constructed an AAV serotype 2/1 (AAV2/1) expressing 
tetracycline-controlled transactivator (tTA)-inducible full-length CD200 or GFP.  To 
construct the AAV2/1-GFP and AAV2/1-CD200, pAAV2-cytomegalovirus-tetracycline-
controlled transactivator (pAAV2/1-CMV-tTA), AAV2 inverted terminal repeats 
flanking tetracycline-response element (TRE)/ minimal CMV promoter, multiple cloning 
site (MCS) and Woodchuck hepatitis post-transcriptional regulatory element (WPRE), 
and the bovine growth hormone polyadenylation site (pAAV2-TRE-MCS-WPRE), and 
pAAV2-TRE-GFP were constructed as previously described (Stone et al., 2012). We 
have shown in our previous publications that this CMV promoter and AAV1 combination 
tends to express primarily in neurons but is rarely positive in astrocytes as well (Kiyota et 
al., 2009b).  The promoter is shorter than a CMV/chicken β-actin hybrid promoter, which 
allows the CD200 cDNA to be inserted into our AAV2 vector.  The total length of the 
AAV gene cassette is therefore less than 4.7 kb, allowing for AAV packaging (Grieger 
and Samulski, 2005). The AAV2/1-CMV-tTA contains a CMV promoter that controls the 
expression of the tetracycline transactivator protein, which, in this co-injection paradigm, 
activates any genes under the tetracycline response element (see AAV scheme in Fig. 8).  
In this way, we activate expression of TRE-controlled GFP or CD200 (AAV2/1-TRE-
GFP or AAV2/1-TRE-CD200) by co-injection with AAV2/1-CMV-tTA.   
	  	  52	  
 
Figure provided by Dr. Tomomi Kiyota 
 
Figure 8. AAV2/1-TRE-CD200/ AAV2/1-CMV-tTA-co-administration paradigm. 
Schematic for our AAV2/1-CMV-tTA and AAV2/1-TRE-GFP or AAV2/1-TRE-CD200 
gene induction system.  tTA gene expression under the CMV promoter induces 
expression of GFP or CD200 under the control of the TRE.  This can be controlled by 
administration of doxycycline as a Tet-off system. 
 
 
 For pAAV2-TRE-CD200 construction, a PCR fragment containing a murine full-
length CD200 coding sequence was amplified using the following primers: For: 5’-
GGCGGATCCGCCACCATGGGCAGTCTGGTATTC-3’ and Rev: 5’-
GGGCTCGAGTTATTTCATTCTTTGCATCCC-3’ and murine cDNA (clone 6413363, 
Open Biosystems, GE Dharmacon, Lafayette, CO) was used for template DNA.  This 
was digested with Bam HI and Xho I and inserted into the MCS of pAAV2-TRE-MCS-
WPRE.  Co-transfection was performed with cis plasmid pAAV2-CMV-tTA, pAAV2-
TRE-GFP, or pAAV2-TRE-CD200 vectors with an AAV1 trans plasmid, p5E18RXC1, 
and a helper plasmid, pAdΔF6 (Stratagene, Carlsbad, CA) into AAV-293 cells 
(Stratagene, Carlsbad, CA).  An AAV2/1 hybrid virus was used to allow for strong 
neuron-specific transfection with the AAV2 serotype and more widespread gene delivery 
with the AAV1 serotype.  These were harvested for extraction, purification, and titration 
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of the virus as described (Kiyota et al., 2009b; Kiyota et al., 2010; Stone et al., 2012).  
Optimal viral particle (VP) doses for both AAV2/1-CMV-tTA and AAV2/1-TRE viruses 
for in vivo studies were determined experimentally by transfection of primary cultured 
neurons with serial dilutions of AAV2/1-CMV-tTA and AAV2/1-TRE-GFP and 
measuring resulting GFP intensity after 7 days (Fig. 9). 
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2.3 Stereotactic Injection 
 AAV2/1 viruses were bilaterally injected into the CA1 region of the hippocampus 
as described (Kiyota et al., 2009b).  Briefly, at six months of age, which is the post-
symptomatic disease stage, mice were anesthetized with isoflurane and given pre-emptive 
analgesic by sub-cutaneous injection of Carprofen (4.5 mg/kg).  Mice were then 
immobilized in a stereotaxic apparatus (David Kopf Instruments, Tujunga, CA).  An 
incision was made over bregma, and a 1-mm burr hole was drilled through the skull 2.1 
mm posterior and 1.6 mm lateral to bregma on each side using a hand-held drill 
(Dremel).  2 µl (1 µl/ side) of AAV2/1-GFP (2 x 109 VP) or AAV2/1-CD200 (2 x 109 
VP) with AAV2/1-CMV-tTA (2 x 109 VP) or 2 µl saline were injected 1.8 mm below the 
skull surface into the CA1 region at a rate of 0.5 µl/ min using a 10 µl Hamilton syringe 
and an automated microinjector (Stoelting, Wood Dale, IL).  Approximate injection 
locations are shown in below in Figure 10A.  The needle was removed from the brain 
five minutes after each injection to allow for diffusion of the virus.  A total of 6-9 mice 
were injected per group.   
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Figure 10. Experimental paradigm for in vivo examination of AAV2/1-CD200 
administration. (A) The scheme depicts the location of the bilateral stereotactic 
injections into the CA1 region of the hippocampus. (B) Experimental paradigm for in 
vivo study of AAV2/1 injection into WT and APP mice.  Reference image obtained from 
©2015 Allen Institute for Brain Science. Allen Mouse Brain Atlas [Internet]. Available 
from: http://mouse.brain-map.org/ . 
 
 
2.4 Morris Water Maze  
 MWM testing was performed to measure spatial reference memory improvements 
in the APP mice.  The MWM task was run as described previously with some minor 
modification (Morris, 1984) six months after AAV2/1 injection when subjects were 12 
months-old (see experimental paradigm in Fig. 10B and MWM paradigm in Fig. 11).  
Testing was done in a large circular tank filled with opaque tepid water.  Water was made 
opaque using non-toxic white paint.  Spatial cues were placed into each of four quadrants 
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to aid the mouse in orientation.  A 10 cm circular plexiglass platform was used for escape 
from the water. On day one of testing, mice were given three training trials with the 
platform visible above the water.  After training, the platform was submerged to 1 cm 
below the surface of the water, and mice were given four one-minute maximum trials 
separated by 30-second rest periods, followed by a fifth trial separated by a 30-minute 
rest period.  The starting location of the mice changed with each trial except for trials 
four and five, when starting location was kept the same.  The platform remained in the 
same quadrant all five days of testing.  After this first period of testing, the capability of 
the mice for reversal learning was tested by placing the platform into a different quadrant, 
where it then remained throughout the next five days of testing.  The same experimental 
paradigm was used as the first five days.  Mice were first trained with a visible platform 
followed by five trials per day with the platform hidden for five days.  Trial lengths and 
rest periods were kept the same. Mice were recorded using the Ethovision digital imaging 
system (Noldus, Leesburg, VA), and latency for the mice to reach the hidden platform 
was measured automatically.  On days five and ten of testing, a probe test was conducted 
where the platform was removed and the amount of time the mice spent in the target 
quadrant was recorded over one minute.   
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Figure 11. Experimental paradigm for Morris water maze testing of APP mice for 
spatial memory followed by reversal learning. In our MWM behavioral test, we 
perform one week of testing for short-term spatial reference memory formation followed 
by one week of testing the ability of APP mice for reversal learning.  The platform is 
visible during training and is then submerged for testing under opaque water.  During the 
reversal learning phase, the location of the escape platform is changed to a different 
location from Days 1-5 of testing.   
 
 
2.5 Bromodeoxyuridine Administration   
 Bromodeoxyuridine (BrdU) is a thymidine analog that is incorporated into DNA 
as cells are undergoing mitosis.  After sacrifice, tissue can be incubated with a specific 
antibody against BrdU, thus marking cells that have recently divided. Six months after 
AAV2/1 injection and after MWM testing, BrdU was injected intraperitoneally (50 
mg/kg body weight) twice daily eight hours apart for 2.5 days  to mark proliferating cells 
as described with some modification (Butovsky et al., 2006a).  Mice were euthanized 
three weeks after the last injection.     
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2.6 Tissue Preparation  
 After deep anesthetization by intraperitoneal injection of a ketamine/xylazine 
cocktail (100 mg/kg / 20 mg/kg, respectively), mice were perfused transcardially with 
phosphate-buffered saline (PBS).  For western blot, brains were rapidly removed and 
frozen on dry ice, and stored in -80°C.  For immunohistochemistry, PBS perfusion was 
followed by transcardial perfusion with 4% paraformaldehyde (PFA).  The brain was 
then rapidly removed and immersed in 4% PFA at 4°C for 24 hours followed by 24-hour 
serial dilutions in sucrose.  Brains were mounted in cryoprotectant cutting medium and 
serially sectioned coronally at 30 µm using a Leica cryostat (Leica Biosystems, 
Bannockburn, IL), then stored at 4°C in PBS for immunohistochemistry.   
 
2.7 BrdU Staining 
 For labeling of BrdU in the hippocampus, brain sections were first incubated in a 
50% formamide/ 50% 2XSSC solution following by rinsing in 2XSSC.  After this, tissue 
was then incubated in 2M hydrochloric acid followed by rinsing in 0.1M borate buffer.  
Tissue was permeabilized in 0.1% Triton X-100 in PBS (PBS-T) before blocking in 2% 
donkey serum in PBS-T.  Primary antibody incubation was done overnight using specific 
antibodies to BrdU in blocking buffer at 4°C.  Secondary antibody incubation was done 
using Alexa Fluor®594-conjugated anti-goat or anti-rat IgG (Invitrogen, Carlsbad, CA) 
at 1:600 in blocking buffer.  This was followed by total nuclei staining using Hoechst 
counter-stain (AnaSpec, Inc, San Jose, CA) at 1:10,000.  Sections were then mounted on 
slides and coverslipped using fluorescence mounting medium (DAKO, Caprinteria, CA). 
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2.8 Immunohistochemistry  
 Conventional immunohistochemistry was be used to examine neurogenesis, Aβ 
pathology, and neuroinflammation.  For immunofluorescence, sections were placed in 
80°C 10 mM tri-sodium citrate for antigen retrieval followed by permeation with 0.1% 
Triton X-100.  Blocking was done for one hour with 2% donkey or normal goat serum in 
PBS.  Primary antibody incubation for CD200, BrdU, and Dcx was done overnight at 4°C 
in blocking buffer using specific antibodies at the dilutions given in Table 4.  
Immunofluorescence was visualized with secondary antibody incubation with Alexa 
Fluor®488- or 594-conjugated anti-rat or anti-goat IgG (Invitrogen, Carlsbad, CA) at 
1:600 in blocking buffer.  This was followed by total nuclei staining using Hoechst 
counter-stain (AnaSpec, Inc, San Jose, CA) at 1:10,000.  Sections were then mounted on 
slides and coverslipped using fluorescence mounting medium (DAKO, Caprinteria, CA). 
Three to five 30 µm sections at 150 µm intervals per mouse were quantified from four to 
five brains per group using image analysis software (ImageJ, NIH, Bethesda, MD).  The 
numbers of BrdU+ or Dcx+ cells were counted over the length of the SGZ of the DG. 
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Table 4. Antibodies used for immunochemistry 
 
Antibody Use Dilution Source 
β-III Tubulin, β3T mature neuronal 
marker 
1:500 Promega 
Bromodeoxyuridine, BrdU cellular proliferation 1:250 Abcam 
CD11bAPC (APC-tagged) activated microglia 1 µg/ml eBioscience 
CD16/CD32 block non-specific 
Fc-mediated 
interactions 
0.5 µg/ml BD Biosciences 
CD169 (Siglec-1) peripheral 
macrophages 
1:100 AbD Serotec 
Chitinase 3-like 3, YM1 M2 marker 1:1000 StemCell 
Cluster of Differentiation-200, 
CD200 
CD200 1:100 BD Pharmingen 
Doublecortin, Dcx newly differentiated 
neurons 
1:500 Santa Cruz 
Biotechnology 
F4/80 mononuclear 
phagocytes 
1:1000 eBioscience 
Glial Fibrillary Acidic Protein, 
GFAP 
astrocytes 1:500 Dako 
Ionized Calcium Binding 
Adapter Molecule-1, Iba1 
mononuclear 
phagocytes 
1:1000 Wako 
Nitric Oxide Synthase-2, NOS2 M1 marker 1:200 Santa Cruz 
Biotechnology 
p2ry12 resident microglia 1:500 Kindly provided 
by Oleg Butovsky 
Pan-Aβ β-amyloid peptide 1:1000 Zymed/Invitrogen 
Triggering receptor expressed 
on myeloid cells (TREM2, 
Phycoerythrin (PE)-tagged) 
cell surface and 
intracellular TREM2 
10 µl/  
1x106 
cells 
R&D Systems 
TYRO protein tyrosine kinase 
binding protein (TYROBP, aka 
DAP12) 
cell surface and 
intracellular 
TYROBP 
5 µg/  
1x106 
cells 
Santa Cruz 
Biotechnology 
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2.9 Cell Culture 
 2.9.1 For AAV2/1 Transduction: AAV-293 Cells and Mouse Primary Neurons 
 AAV-293 cells were maintained in complete Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen, Carlsbad, CA) in 5% CO2.  
Primary neurons were cultured as described previously (Yamamoto et al., 2007).  Briefly, 
mouse cortical neurons were prepared from WT embryonic E16-E17 mice and 
maintained in Neurobasal media with 1x B27 supplement and 1 mM sodium pyruvate (all 
from Invitrogen, Carlsbad, CA).  Cells were allowed to differentiate for seven days 
before AAV2/1 transduction.  For AAV2/1 transduction, 100,000 AAV-293 cells/ well or 
200,000 primary neurons/ well were seeded in tissue culture media in a 48-well plate.  
AAVs were added directly to the media as indicated.  After 14-day incubation, cells were 
harvested, lysed with lysis buffer (10 mM Tris-HCL pH 7.4, 100 mM NaCl, 1 mM 
EDTA, 1 mM EGTA, 1 mM NaF, 2 mM Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% 
SDS, 0.5% deoxycholate, and a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, 
MO)), briefly sonicated, and subjected to immunoblot analysis. 
 
2.10 Immunoblot  
 20-30 µg protein was analyzed by electrophoresis on 16% SDS-polyacrylamide 
Tris-Tricine gels and electroblotted to 0.45 µm-sized pore PVDF membranes 
(Immobilon-P, Millipore, Billerica, MA).  Membranes were blocked in 5% non-fat milk 
in 0.05% Tris-buffered saline with Tween-20 (TBS-T).  This was followed by overnight 
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incubation in primary antibody in blocking buffer using the following antibodies: CD200 
monoclonal antibody (1:200, BD Biosciences), anti-GFP (1:1000, Abcam), β-Actin 
(1:2500, Sigma-Aldrich, St. Louis, MO).  Secondary antibody incubation was done with 
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA), biotinylated anti-rat IgG plus HRP-conjugated 
streptavidin (ThermoScientific, Rockford, IL), or HRP-conjugated anti-mouse IgG 
(Santa-Cruz Biotechnologies).  Immunoreactive bands were detected with SuperSignal 
West Pico Chemiluminescent substrate (ThermoScientific, Rockford, IL) and analyzed 
using ImageJ software (NIH, Bethesda, MD) and normalized to band intensities of 
control β-Actin. 
 
2.11 Statistics 
 All data are presented as mean values ± standard error of the mean (SEM).  For 
comparison between two groups, data were analyzed by Student’s t-test.  For multiple 
mean comparisons, data were analyzed by one-way analysis of variance (ANOVA) 
followed by Tukey post-hoc analysis or two-way ANOVA followed by Bonferroni’s 
post-tests using statistics software (Prism 4.0, Graphpad Software, Inc., San Diego, CA).  
Significance is considered anything of p ≤ 0.05. 
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III.  Results 
3.1 Dox-inducible AAV2/1-GFP or –CD200 increases protein levels of GFP or CD200, 
respectively, in vitro 
 AAV-293 cells and primary cultured mouse neurons were transfected with AAV-
CMV-tTA and AAV-TRE-GFP or AAV-TRE-CD200 and then harvested 14 days post-
transfection for immunoblot analysis.  GFP and CD200 were expressed in both AAV-293 
cells and in primary neurons (Fig. 12A and B).  This demonstrated that our gene delivery 
system works in vitro. 
 
 
Figure provided by Dr. Tomomi Kiyota 
 
Figure 12. AAV2/1-TRE-CD200/ AAV2/1-CMV-tTA co-administration induces 
CD200 expression in vitro. (A,B) The columns follow the given code: 1) Un-transfected, 
2) AAV2/1-TRE-GFP (1 x 109 VP/ml), and 3) AAV2/1-TRE-CD200 (4 x 108 VP/ml) 
transfected cells.  (A) AAV293 cells (1 x 105 cells) and (B) primary murine cortical 
neurons (1 x 105 cells) were lysed 14 days after virus transfection in RIPA buffer for 
CD200, GFP, or β-actin immunoblot.  n.s.= non-specific bands.  
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3.2 AAV2/1-CD200 injection into the CA1 region increases CD200 expression in the 
hippocampus  
 To determine if our AAV gene delivery system worked in vivo, 6 month-old WT 
or APP mice were given bilateral stereotactic co-injections of AAV2/1-CMV-tTA and 
AAV2/1-TRE-GFP or AAV2/1-TRE-CD200 (hereafter, abbreviated as AAV2/1-GFP or 
AAV2/1-CD200) or saline directly into the CA1 region of the hippocampi (Fig. 13).  
This was followed by BrdU injection at 12 months and euthanasia three weeks after the 
first BrdU injection (see Fig. 10B for experimental paradigm).  Basal CD200 expression 
in 12 month-old WT saline- and AAV2/1-GFP-injected APP mice was very low in the 
hippocampi as shown by CD200 immunostaining (Fig. 13A-C).  However, there was 
relatively higher CD200 expression in the SGZ and the suprapyramidal and 
infrapyramidal mossy fiber neurons in both groups.  AAV2/1-CD200 injection into APP 
mice greatly increased CD200 levels in the hippocampus, particularly within the SGZ, 
pyramidal neurons in the stratum radiatum of the CA1 region, and the suprapyramidal 
and infrapyramidal mossy fiber neurons.  This sustained enhancement of CD200 
immunoreactivity six months after injection demonstrates long-term expression of our 
recombinant CD200 protein within the DG.   
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Figure 13. AAV2/1-TRE-CD200/ AAV2/1-CMV-tTA co-administration induces 
CD200 expression in vivo. (A-C) Hippocampal images from 12 month-old WT or APP 
mice injected at six months of age with saline, AAV2/1-GFP, or AAV2/1-CD200.  
Sections were immunostained for CD200 (green) and counter-stained with Hoechst 
33342 (blue).  Mice injected with AAV2/1-CD200 show increased intensity of CD200 
staining in pyramidal neurons of the stratum radiatum of the CA1 (arrowheads, B) and in 
the SGZ (arrowheads, C).  These mice also showed increased CD200 intensity in 
infrapyramidal and suprapyramidal mossy fiber neurons of the DG (arrows, C).  Scale 
bars represent 100 µm. 
 
 
3.3 AAV2/1-CD200 restores proliferation in the DG of the APP mouse 
 To determine if AAV2/1-CD200 gene delivery increased proliferation in the 
hippocampi of APP mice, we administered i.p. injections of BrdU to label newly divided 
cells.  BrdU immunostaining and quantification revealed a significantly lower number of 
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BrdU+ cells in the SGZ and granular cell layer (GCL) in saline- and AAV2/1-GFP-
injected APP mice compared to WT saline-injected mice (Fig. 14A and B).  This is 
contrary to some previous research in human AD patients, which show an increase in 
cellular proliferation in the DG (Jin et al., 2004; Boekhoorn et al., 2006).  AAV2/1-
CD200 injection restored BrdU+ cell number in the DG of APP mice to WT levels.  This 
indicates an effect of CD200 expression that is supportive of proliferation of NSCs in the 
DG, although it is not known how many of these BrdU+ cells differentiate and mature 
into neurons.   
 
 
Figure 14. AAV2/1-CD200 injection restores hippocampal proliferation in vivo. Mice 
were injected with bromodeoxyuridine (BrdU) three weeks before sacrifice and 
immunostained for BrdU (red).  (A) BrdU immunoreactivity in the DG marks newly 
divided cells in the SGZ and GCL.  (B) Quantification of number of BrdU+ cells in the 
SGZ and GCL of the DG.  *** or ### denote p<0.001 vs WT Saline or APP Saline and 
APP GFP groups, respectively, as determined by one-way ANOVA and Tukey’s post-test 
(n=5/group).  Scale bars represent 100 µm in (A). 
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3.4 AAV2/1-CD200 restores neuronal differentiation in the DG of the APP mouse 
 Dcx expression was used as a marker of newly differentiated neurons.  AAV2/1-
CD200 injection restored the number of Dcx+-differentiated neurons in the DG of APP 
mice (Fig. 15A and B).  It should be noted that these regional increases in BrdU and Dcx 
coincided with the regional increase in CD200 expression in the SGZ after AAV2/1-
CD200 gene delivery, as shown in Figure 13.  These results demonstrate that increasing 
CD200 expression in post-symptomatic APP mice promotes both proliferation and 
differentiation of neural stem cells in the DG and restores neurogenesis to WT mouse 
levels.  
 
Figure 15. AAV2/1-CD200 injection restores hippocampal neural differentiation in 
vivo. Mice were immunostained for doublecortin (Dcx, a newly synthesized neuronal 
marker, green).  (A) Dcx immunoreactivity in the hippocampus to mark newly 
differentiated neurons.  (B) Quantification of the number of Dcx+ cells in the SGZ and 
GCL of the DG.  ** and *** denote p<0.01 and 0.001, respectively, as determined by 
one-way ANOVA and Tukey’s post-test vs WT Saline mice.  ### denotes p<0.001 as 
determined by one-way ANOVA and Tukey’s post-test vs APP Saline and APP GFP 
mice.  Scale bars represent 100 µm in (A). 
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3.5 AAV2/1-CD200 does not enhance spatial reference memory function in APP mice  
  Although we saw a restoration in neurogenesis in the DG, this did not coincide 
with an enhancement in spatial reference memory formation in the MWM task.  APP 
mice, regardless of AAV injection, did not show impairment in spatial learning formation 
as compared to WT saline-injected mice, although there was a trend for them to have 
longer latency to reach the hidden platform during the reversal learning phase (Fig. 16A).  
APP mice tended to have increased latency to reach the hidden platform during the first 
2-3 days of the reversal learning phase with the largest difference seen on the first day of 
testing during that phase.  AAV2/1-CD200 gene delivery failed to improve performance 
of these mice during this phase.  Probe tests likewise showed no significant difference 
between groups (Fig. 16B and C).  This demonstrates that our APP mouse model no 
longer displays a deficit in short-term memory formation and also that our AAV2/1-
CD200 gene delivery does not enhance spatial learning in these mice.     
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Figure 16. APP mice show no deficit in spatial memory formation and no 
improvement by AAV2/1-CD200 injection in reversal learning.  WT and APP mice 
were tested for short term memory formation and reversal learning (indicated by the 
arrow) in the Morris water maze (MWM) (A) followed by probe tests (B,C).  Two-way 
analysis of variance (ANOVA) and Bonferroni’s post-tests revealed no significant 
differences between groups neither by time nor treatment in MWM (A) and no 
differences between groups by one-way ANOVA for both probe test 1 (B) and probe test 
2 (C).  * denotes the target quadrant on the x-axis. 
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IV.  Discussion 
 In order to determine the neurogenic effects of CD200 in the APP mouse model 
of AD, we developed an AAV2/1-CMV-tTA/AAV2/1-TRE-CD200 co-injection system 
that successfully increased expression and protein levels of CD200 both in vitro and in 
vivo.  In vivo we saw a site-specific increase in CD200 expression in the pyramidal 
neurons of the stratum radiatum, in the SGZ, and in the infrapyramidal and 
suprapyramidal mossy fiber neurons of the DG after injection of AAV2/1-CD200 into the 
CA1 region in APP mice.  CD200 over-expression in the hippocampus of the APP mouse 
coincided with restoration of both proliferation and differentiation in the DG as compared 
to APP mice injected with saline or AAV2/1-GFP.   
 Of note, AAV2/1-GFP injection into APP mice reduced both proliferation and 
differentiation in the DG compared to APP saline-injected mice. This indicates either a 
toxic effect of the GFP or tTA protein expressed from the AAV cassette. Since we did 
not observe such toxic effect by GFP expression itself, it is likely to be the effect of tTA 
or the combination of GFP and tTA expression in the same cells.  Research has suggested 
that transgenic expression of tTA itself is cytotoxic in certain mouse strains, and this 
cytotoxicity can actually be exacerbated by concomitant transgenic expression of APP 
(Han et al., 2012).  Nonetheless, our AAV2/1-CD200-injected WT and APP mice did not 
exhibit a reduction in BrdU+ or Dcx+ cells in the dentate gyrus, suggesting that the 
CD200 expression can overcome any tTA-induced toxicity. Interestingly, increasing 
CD200 expression did not enhance cellular proliferation or differentiation in WT mice, 
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indicating that CD200 is only effective in the presence of neuroinflammation as seen in 
APP mice. 
 This is the first study to demonstrate that CD200 expression increases 
neurogenesis.  As previously stated, research shows that neuroinflammation is 
suppressive to neuronal survival and maturation, whereas an M2a-activation status is 
supportive of neurogenesis.  This study supports that hypothesis.  However, the 
mechanism by which CD200 enhances both proliferation and differentiation in the APP 
mouse in this study has not been elucidated.   
 One possible mechanism is through induction of the neurotrophic protein IGF-1.  
This pleiotropic protein has been shown to protect against neurotoxicity and promote 
proliferation, differentiation, maturation, and survival of neurons and glial cells in several 
brain regions, including the hippocampus [for review, see (Dore et al., 1997) ].  IGF-1 
has been implicated as a protein with strong therapeutic potential for the treatment of 
many neurodegenerative diseases, including ALS, MS, AD, and PD.  Similar to CD200, 
it is involved in regulating the inflammatory response in the brain (Dore et al., 1997; 
Dantzer et al., 1999) and circulating levels naturally decline with age (Bando et al., 
1991).  Its levels are likewise reduced in neurodegenerative conditions (Busiguina et al., 
2000).  Multiple studies show that IGF-1 mediates the neuroprotective effects of IL-4 on 
microglia (Butovsky et al., 2005; Butovsky et al., 2006b).  Though IGF-1 mediates the 
neurogenic effects of IL-4, it is not required for IL-4-induced neurogenesis (Butovsky et 
al., 2006b), suggesting IL-4 increases the release of other growth factors in addition to 
IGF-1.  Because CD200 expression is regulated by IL-4, it is possible that CD200 
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expression also increases IGF-1 expression levels, thus supporting the neuroprotective 
and neurogenic effects of CD200.   
 Unfortunately, this restoration of neurogenesis did not coincide with an 
improvement in performance in the MWM task.  There are two main issues that arise 
from these findings.  The first is that our APP mice did not show the predicted deficit in 
spatial reference memory during the initial test phase.  Several studies have yielded 
contradictory results considering the performance of this mouse model in memory tasks, 
and it is debated whether they reliably display memory impairment depending on what 
behavior test is used and at what timepoint.  It appears that some behavioral tests have 
proven more effective at detecting memory deficits in the APP mouse than others, 
including the Y-maze, the RAWM, or the Barnes maze, and these tests should be 
considered before the MWM for some experimental paradigms.     
 The second issue is that, despite the lack of memory impairment during the first 
test phase, our APP mice did tend to perform more poorly during the reversal learning 
phase of the task compared to WT mice, and this was not restored by hippocampal 
AAV2/1-CD200 injection.  It is possible that our post-symptomatic injection time-point 
of six months is not sufficient for restored neurogenesis to be effective, and pre-
symptomatic gene delivery may be necessary to see a functional effect.  We also focused 
on a very specific region within the brain, the SGZ and the GCL of the DG, and it is 
likely that other regions within the hippocampus and the rest of the brain play a role in 
behavioral performance in the MWM.  These regions may not have been affected by our 
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focal injection into the CA1, and it is possible that upstream or downstream signaling 
deficits mask the effects of restored neurogenesis in the DG.   
 Studies suggest that, although the hippocampus is clearly required for spatial 
learning in the MWM task, other brain regions may be involved as well.  Separate lesions 
within the rat thalamus, striatum, amygdala, locus coeruleus, raphe nuclei, and cortical 
regions, including the entorhinal and perirhinal cortices, and the prefrontal cortex, 
resulted in impaired performance in the MWM [for review, see (D'Hooge and De Deyn, 
2001) ].  Amyloid plaques can be found in the frontal, temporal, and entorhinal cortices 
of the APP mouse, in addition to the hippocampus (Hsiao et al., 1996).  Cortical regions 
may be involved in other aspects of the MWM task, such as executive functions and 
planning.  The presence of plaques in these regions may also impair the performance of 
the APP mouse in the MWM.  Lesions to the fimbria and fornix, which process input 
from the hippocampus to the nucleus accumbens and cholinergic input to the 
hippocampus (Gage et al., 1983; Blaker et al., 1988), also impairs MWM acquisition in 
rats (Nilsson et al., 1987; Eichenbaum et al., 1990; Whishaw and Jarrard, 1995) and make 
their ability to learn more inflexible (Eichenbaum et al., 1990).  The presence of plaques 
in the APP mouse may disrupt this connection to the hippocampus and may explain the 
failure of the APP mice in this study to perform well in the reversal learning phase of the 
MWM task.   
 Overall, these findings indicate that CD200 is effective at enhancing neurogenesis 
by increasing proliferation and differentiation in the hippocampus of the APP mouse, but 
this does not improve their working memory formation.  This makes CD200 a promising 
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therapeutic for replenishing the loss of neurons in the DG of Alzheimer’s patients, but 
additional therapy is required to target deficiencies in other brain regions.  
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Chapter 3: CD200 ENHANCES AMYLOID PHAGOCYTOSIS  
IN THE HIPPOCAMPUS 
 
I. Rationale 
 The Amyloid Cascade Hypothesis posits that the accumulation of toxic Aβ42 in 
the brain results in a chronic pro-inflammatory immune response that leads to, and is 
likely exacerbated by, neuronal death and subsequent memory dysfunction.  Aβ 
aggregates are toxic to neurons in experimental models and may contribute to 
suppression of neurogenesis in the DG due to their induced release of pro-inflammatory 
mediators by microglia.  Researchers have long attempted to reduce levels of Aβ in the 
brains of AD patients and animal models in an effort to halt or reverse progression of the 
disease but had little success.  This suggests that reduction of Aβ in the late symptomatic 
disease stage is too late for effective therapeutic use and that another mechanism may 
contribute to the progression of AD.   
 Research suggests that anti-inflammatory microglia may be more favorable if 
attempting to reduce the levels of Aβ in AD.  Gene delivery of anti-inflammatory IL-4 
into AD mouse models reduced Aβ during the pre-symptomatic disease stage and 
restored neurogenesis and spatial learning (Kiyota et al., 2010).  In another study, M2-
activated microglia were more capable of phagocytosis of Aβ than their M1-activated 
counterparts (Koenigsknecht-Talboo and Landreth, 2005).  It is possible, as evidenced by 
recent research, that there is a reduction in microglial survival in the aged or diseased 
brain (Butovsky, International Society of Neuroimmunology meeting, 2012) that is 
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compensated by the infiltration of peripheral macrophages, which are more likely to 
display a pro-inflammatory (Asai et al., 2014) and therefore, less phagocytic phenotype.  
This suggests that the maintenance anti-inflammatory phagocytic microglia in the AD 
brain is a worthwhile therapeutic target.  We therefore hypothesized that induction of an 
anti-inflammatory glial environment by CD200 over-expression would reduce amyloid in 
the early post-symptomatic disease stage of APP mice.   
 To test this hypothesis, we utilized our AAV2/1-CD200 gene delivery system to 
determine if over-expression of CD200 reduced levels of fibrillar and non-fibrillar, 
diffuse Aβ in the aged APP mouse hippocampus.  We also used inflammatory markers to 
determine if amyloid levels were associated with pro- or anti-inflammatory microglial 
activation in the DG.  Morphology of microglia-like cells was characterized and 
quantified to determine the activation phenotype and number of this cell type in the 
hippocampus, and preliminary staining was done to determine if peripheral macrophages 
were present in these animals.  Because CD200 is regulated by IL-4 signaling, we 
predicted that CD200 over-expression would also reduce levels of both non-fibrillar and 
fibrillar Aβ species in the hippocampus, even in the post-symptomatic disease stage.  As 
an inhibitor of NFκB, we also predicted that CD200 would maintain anti-inflammatory 
microglial activation and enhance microglial survival.   
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II.Materials and Methods 
2.1 Animals 
 The same mice used for assessment of the effects of AAV2/1-CD200 injection on 
neurogenesis in the DG were used to determine the effects of increased CD200 
expression on amyloid in the hippocampus.  Mice were given bilateral stereotaxic 
injections of saline, AAV2/1-CD200, or AAV2/1-GFP into the CA1 region of the 
hippocampus at 6 months of age and amyloid plaque deposition was assessed at 12 
months of age.  Brains were harvested and preserved as previously stated for enzyme-
linked immunosorbent assay (ELISA) or immunohistochemistry. 
 
2.2 Immunohistochemistry  
 Conventional immunohistochemistry was used to examine Aβ pathology, 
neuroinflammation, and microglial morphology and number.  For immunofluorescent 
staining of NOS2, YM1, F4/80, glial fibrillary acidic protein (GFAP), Ionized Calcium 
Binding Adapter Molecule-1 (Iba1), peripheral macrophage marker CD169, and resident 
microglia-specific marker p2ry12 sections were placed in 80°C 10 mM tri-sodium citrate 
for antigen retrieval followed by permeation with 0.1% Triton X-100.  It should be noted 
here that both F4/80 and Iba1 stain both microglia as well as peripheral macrophages, 
making us incapable of differentiating between the two.  We can therefore only conclude 
that the characteristics found in this study were from “microglia-like” cells.  Blocking 
was done for one hour with 2% normal goat serum in PBS.  Primary antibody incubation 
was done overnight at 4°C in blocking buffer using specific antibodies at the dilutions 
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given in Table 4.  Immunofluorescence was visualized with secondary antibody 
incubation with Alexa Fluor®488-, 594-, or 647-conjugated anti-rat, anti-mouse, or anti-
rabbit IgG (Invitrogen, Carlsbad, CA) at 1:600 in blocking buffer.  This was followed by 
total nuclei staining using Hoechst counter-stain (AnaSpec, Inc, San Jose, CA) at 
1:10,000.  Sections were then mounted on slides and coverslipped using fluorescence 
mounting medium (DAKO, Caprinteria, CA). The numbers of F4/80+/NOS2+, 
F4/80+/YM1+ cells were counted over the area of the GCL and SGZ combined from 
three to eight hippocampal sections from four to five mice per group. 
 For pan-Aβ staining, endogenous peroxides were first blocked with 3% hydrogen 
peroxide in PBS before permeabilization, blocking, and overnight primary antibody 
incubation.  Immunodetection was visualized first with Envision Plus solution (DAKO, 
Carpinteria, CA) followed by 3,3’-diaminobenzidine (Vector Laboratories, Burlingame, 
CA).  0.1% Thioflavin-S (TS) (Sigma-Aldrich, St. Louis, MO) in 50% ethanol was used 
for counter-staining of compact plaques.  Sections were then mounted on slides and 
coverslipped using Permount (FisherSci, Pittsburgh, PA).  Three to five 30 µm sections at 
150 µm intervals per mouse were quantified from three to five brains per group using 
image analysis software (ImageJ, NIH, Bethesda, MD).  Total plaque area was quantified 
by measuring percent occupied area of plaques over total area of the hippocampus.  
 To determine if AAV2/1-CD200 injection altered the number of microglia in the 
DG, the number of Iba1+ cells in the SGZ and GCL was manually counted from two to 
ten hippocampal sections at 150 µm intervals per mouse from three brains per group 
using image analysis software (ImageJ, NIH, Bethesda, MD).  Microglial morphology 
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was assessed based on criteria outlined in Torres-Platas et al. (Torres-Platas et al., 2014).  
In this paper, the authors provide the first comprehensive morphometric analysis of 
microglia phenotypes from post-mortem samples of human adults and mouse cortical 
tissue.  Based on their criteria, microglia were sub-divided into the following four 
categories on a spectrum from resting to activated: ramified, primed, reactive, amoeboid 
(Figure 17).  Ramified microglia have small, defined spherical cell bodies with several 
highly branched processes.  Primed microglia are also highly ramified, but have fewer 
higher-order branches in the processes and a more ellipsoid soma.  Reactive microglia 
have amoeboid-shaped cell bodies with less extensive processes that are longer than the 
diameter of the cell body.  Lastly, amoeboid microglia have amoeboid-shaped cell 
bodies, but are either devoid of processes or have few unramified processes within the 
length of the cell body.  All Iba1+ cells in the SGZ and GCL region were assessed from 
two to ten hippocampal sections at 150 µm intervals per mouse from three brains per 
group.  The number of CD169+ peripheral macrophages or p2ry12+ resident microglial 
cells was not quantified, but three to eight sections were assessed from one to four mice 
for whether or not they contained each cell type. 
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Figure 17.  Criteria used for assessment of microglial morphology in the mouse 
brain.  The microglia pictured above are immunostained with Iba1 and are exemplary of 
each category.  “Ramified” microglia are considered to be a resting phenotype, while 
activated microglia are on a spectrum from “primed” to “reactive” to “amoeboid”.  
Microglia were characterized by these four categories based on their morphology six 
months after AAV2/1 injection when mice were 12 months-old.   
 
 
2.3 ELISA  
 Protein extraction and biochemical analyses of hippocampal brain tissue for 
detection of Aβ40 and Aβ42 were performed using commercially available ELISA kits 
according to the manufacturer’s instruction (Invitrogen, Carlsbad, CA).  We used APP 
mice injected with AAV2/1-GFP (n=5) or AAV2/1-CD200 (n=2) for this assay and did 
technical duplications for each measure.  Protein concentration was quantified with a 
BCA assay kit (Pierce, Rockford, IL).  
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2.4 Statistics 
 All data are presented as mean values ± SEM.  For comparison between two 
groups, data were analyzed by Student’s t-test.  For multiple mean comparisons, data 
were analyzed by one-way ANOVA followed by Tukey post-hoc analysis using statistics 
software (Prism 4.0, Graphpad Software, Inc., San Diego, CA).  Significance is 
considered anything of p ≤ 0.05. 
 
III. Results 
3.1 AAV2/1-CD200 does not affect fibrillar Aβ deposits in the hippocampi of APP mice 
 We analyzed APP mice for compact amyloid plaques using a Thioflavin-S 
counterstain and measured the percent occupied area of plaques over the total area of the 
hippocampus.  AAV2/1-CD200-injected APP mice exhibited no change in percent 
occupied area of TS+ fibrillar Aβ deposits as compared to AAV2/1-GFP-injected APP 
mice (Fig. 18A and B).  Over-expression of CD200 had no effect on TS+ insoluble 
amyloid plaque load.   
 
3.2 AAV2/1-CD200 reduces total Aβ in the hippocampi of APP mice 
 Total soluble and insoluble Aβ was measured by pan-Aβ immunostaining and 
also quantified by percent occupied area over the total area of the hippocampus.  Total 
Aβ was significantly reduced in AAV2/1-CD200-injected APP mice as compared to 
AAV2/1-GFP-injected APP mice (Fig. 18C and D).    
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Figure 18. AAV2/1-CD200 injection reduces hippocampal Aβ load in APP mice. 
Brain sections (n=5/group) were stained for compact, insoluble Aβ plaques (Thioflavin-
S, green) or total amyloid (Aβ, DAB).  (A,B) Thioflavin-S staining in the hippocampus 
demonstrates insoluble plaque area in APP mice (A) and quantification was measured by 
percent-occupied area (NS, as determined by Student’s t-test) (B).  (C,D) DAB staining 
in the hippocampus shows total amyloid in APP mice (C) and quantification was 
performed by measuring percent-occupied area of the whole hippocampus (D).  *** 
denotes p<0.001 as determined by Student’s t-test.  Dotted lines delineate the SGZ of the 
DG, and scale bars represent 100 µm for both (A) and (C) and for insets. 
 
 
3.3 AAV2/1-CD200 reduces Aβ42, but not Aβ40, protein levels in the hippocampus 
 Hippocampal tissue lysate levels of Aβ40 and Aβ42 were measured by ELISA.  
Although there was no change in Aβ40 protein levels, there was a trend for a reduction in 
Aβ42 levels in the hippocampi of AAV2/1-CD200-injected APP mice, though the 
difference was not statistically significant (Table 5).  Unfortunately, we had a low 
number of AAV2/1-CD200-injected hippocampi samples for this assay, which may 
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account for the lack of statistical significance.  These data suggest that AAV2/1-CD200 
injection into APP mice reduces soluble Aβ42.    
 
Table 5. Hippocampal protein levels of Aβ40 and Aβ42 as determined by ELISA 
 
 APP  
AAV2/1-GFP  
Mean±SEM (ng/mg) 
APP  
AAV2/1-CD200 
Mean±SEM (ng/mg) 
t, df p-value 
Aβ40 2.29 ± 0.56 1.89 ± 0.38 0.46, 10 0.65 
Aβ42 0.29 ± 0.08 0.16 ± 0.05 0.97, 12 0.35 
 
 
3.4 AAV2/1-CD200 reduces M1 activation in the DG of APP mice 
 We analyzed APP mice for markers of M1 and M2 activation with NOS2 and 
YM1, respectively, in F4/80+ cells.  As predicted by our hypothesis, APP mice injected 
with AAV2/1-CD200 had a reduced number of NOS2+/F4/80+ microglia-like cells in the 
SGZ and GCL compared to both saline-injected WT and AAV2/1-GFP-injected APP 
mice (Fig. 19A and B), though the difference was not statistically significant.  This 
demonstrates that CD200 over-expression can suppress pro-inflammatory signaling even 
in the aged APP mouse brain. 
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Figure 19. AAV2/1-CD200 injection reduces NOS2+ microglia-like cells in APP 
mice. (A) Brain sections were immunostained for pro-inflammatory marker NOS2 
(green) and mononuclear phagocyte marker F4/80 (red).  Insets depict NOS2 expression 
is predominantly in microglia-like cells. (B) The number of NOS2+ cells was quantified 
over the area of the GCL and SGZ from n= 4-5 brains per group. Scale bars represent 100 
µm in (A). 
 
 
3.5 AAV2/1-CD200 induces M2 activation in the DG of APP mice 
 AAV2/1-CD200-injected APP mice did have a significant increase in the number 
of YM1+/F4/80+ microglia-like cells in the same regions (Fig. 20A and B).  F4/80 
immunostaining showed that both NOS2 and YM1 expression was predominantly from 
mononuclear phagocytes (insets in Fig. 20A).  This indicates that over-expression of 
CD200 establishes an anti-inflammatory milieu in the aged APP mouse brain. 
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Figure 20. AAV2/1-CD200 injection increases YM1+ microglia-like cells in APP 
mice.  (A) Hippocampal sections were immunostained for anti-inflammatory marker 
YM1 (green) and mononuclear phagocyte marker F4/80 (red).  Insets show that YM1 
expression is predominant in microglia-like cells. (B) Quantification of the number of 
YM1+ cells in the GCL and SGZ.  ** denotes p<0.01 vs WT Saline mice as determined 
by one-way ANOVA and Tukey’s post-test (n= 4-5/group). Scale bars represent 100 µm 
in (A). 
 
 
3.6 AAV2/1-CD200 does not increase number of microglia-like cells in the DG of the 
APP mouse by 12 months 
 We first wanted to determine if AAV2/1-CD200 would be associated with an 
increased number of microglia-like cells in the DG of the APP mouse brain.  
Quantification of the number of Iba1+ cells in the SGZ and GCL revealed no significant 
difference between both WT and APP mice, despite AAV2/1 injection (Fig. 21A and B).  
This indicates that over-expression of CD200 may not enhance survival or production of 
microglia in the DG of APP mice.  It should be noted that Iba1 is not specific to resident 
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microglia, which means our quantification could be capturing infiltrating peripheral 
macrophages as well.  These results also suggest that it is not possible to detect a change 
in this parameter six months after AAV2/1 injection.   
 
 
Figure 21. AAV2/1-CD200 does not alter number of microglia-like cells in the APP 
mouse brain.  6 month-old WT or APP mice were injected with saline, AAV2/1-GFP, or 
AAV2/1-CD200 and sacrificed at 12 months-old. (A) Brain sections including the DG 
were immunostained for the microglial marker, Iba1 (green). (B) The number of Iba1+ 
cells over the area of the SGZ and GCL was counted from 2-10 hippocampal sections 
from n=3 mice/group.  Counts yielded no significant differences between groups 
(p=0.08) as indicated by one-way ANOVA and Tukey’s post-test. Scale bars represent 
100 µm in (A). 
 
 
3.7 AAV2/1-CD200 does not maintain microglia in a resting state in APP mice 
 Our Iba1+ cell counts revealed no difference in the number of microglia in the 
SGZ/GCL of our APP mice.  Iba1+ cells were further characterized by morphology to 
determine if AAV2/1-CD200 maintained microglia in a resting, or ramified, state.  
Quantification revealed no significant difference between the percentage of ramified and 
activated phenotypes for all groups (Fig. 22A).  It should be noted, however, that all 
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groups had significantly more activated microglia versus ramified.  Activated microglia 
were further classified as primed, reactive, or amoeboid (Fig. 22B).  As before, there was 
no significant differences between groups, but all groups had significantly more primed 
cells over reactive and amoeboid, and significantly more reactive than amoeboid.  These 
results indicate that AAV2/1-CD200 injection does not maintain or enhance the number 
of microglia in a resting state.  As previously stated, this may also not be the ideal 
timepoint to detect changes in microglia morphology. 
 
 
Figure 22.  AAV2/1-CD200 does not maintain microglia in a resting state in the 
SGZ/GCL.  Mice were stereotaxically injected at 6 months-old and microglia 
morphology was assessed at 12 months.  (A) Microglia were characterized as ramified or 
activated based on criteria described in Fig. 17.  (B) Microglia characterized as activated 
were further separated as primed, reactive, or amoeboid.  *** denotes p<0.001 as 
determined by two-way ANOVA and Bonferroni post-tests. 
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3.8 There are peripheral macrophages in the DG of saline, AAV2/1-GFP, and AAV2/1-
CD200 WT and APP mice  
 We observed only a minor population of CD169+ peripheral monocytes in 
addition to several microglia-specific p2ry12+ microglia in our WT and APP mouse 
brains, irregardless of CD200 or GFP gene delivery (Fig 23).  Figure 23 depicts 
representative staining seen in the mice of CD169 (Fig. 23A and B) and p2ry12 (Fig. 
23C and D).  We therefore can only conclude that the NOS2+ and YM1+ staining are 
mononuclear phagocytes (brain microglia and perivascular macrophages), but we can 
conclude that gene delivery of CD200 does not block the infiltration of peripheral 
macrophages at this stage.    
 
 
Figure 23.  There are both resident microglia and peripheral macrophages in the 
SGZ/GCL of both WT and APP mice.  Iba1+ cells (green) were assessed for either 
CD169 or p2ry12 immunoreactivity in the dentate gyrus.  Images depict magnifications 
of regions outlined in (A) for CD169 (red) (B) and in (C) for p2ry12 (red) (D).   Scale 
bars represent 100 µm in (A) and (C). 
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IV.  Discussion 
 In summary, we found that over-expression of CD200 in the APP mouse 
hippocampi reduced the amount of soluble amyloid and aggregate-prone Aβ42 species in 
the hippocampus.  As stated above, the Aβ42 species is more prone to aggregate into 
fibrils and accumulate with age	  (Jarrett et al., 1993; Iwatsubo et al., 1995; Lemere et al., 
1996), making the reduction of Aβ42 over Aβ40 more therapeutically relevant.  This 
reduction was associated with an M2-skewed microglial environment.  Interestingly, this 
study differs from the findings in APP+PS1 mice, where AAV-IL-4 gene delivery 
reduced both soluble and compact TS+ plaques (Kiyota et al., 2010).  Because CD200 is 
regulated by IL-4 expression, we predicted that CD200 would likewise reduce TS+ 
plaques in the hippocampus.  It is possible that IL-4 has a more widespread effect in the 
brain compared to CD200, and can thus have more capability to reduce compact plaque 
load.  This AAV-IL-4 study also performed gene delivery of IL-4 in the pre-symptomatic 
disease stages, whereas this study performs gene delivery of CD200 in the post-
symptomatic disease stage, suggesting that only early therapeutic intervention can inhibit 
the production of compact plaques.  Performing a time-course intervention study ranging 
from the pre-symptomatic to late post-symptomatic disease stages is necessary to 
determine the effectiveness of both IL-4 and CD200 gene delivery for this purpose. 
 There is some debate as to which conformation of Aβ is the more neurotoxic in 
AD.  Aβ exists in many conformations: monomeric, soluble and insoluble oligomeric, 
protofibrillar, and fibrillar (Pike et al., 1991; Lorenzo and Yankner, 1994; Hartley et al., 
1999; Walsh et al., 2000; Kayed et al., 2003).  Unstable monomers form into soluble 
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oligomers, which then aggregate into insoluble oligomeric aggregates in diffuse plaques.  
Protofibrils are soluble precursors that can form into mature, insoluble Aβ fibrils.  Aβ 
plaques consist primarily of nonfibrillar insoluble oligomers, whereas compact plaques 
consist of fibrillar Aβ (Wisniewski et al., 1989; Mann et al., 1990).  Some research 
suggests that soluble Aβ oligomers are more synaptotoxic because they reduce 
synaptophysin in presynaptic terminals in certain APP mouse models, even in the 
absence of insoluble Aβ plaque formation (Mucke et al., 2000).  Another study 
demonstrated that the Arctic APP mutation (AβE22G) accelerated formation of 
protofibrillar Aβ and protofibril fibrillization in vitro while reducing nonfibrillar Aβ 
formation (Nilsberth et al., 2001; Lashuel et al., 2003; Johansson et al., 2006).  
Incorporating the Arctic APP mutation into the human APP mouse model accelerated Aβ 
aggregation and the formation of plaques, reduced soluble Aβ oligomers, and improved 
their performance in learning and memory tasks (Cheng et al., 2007).  Therefore, 
formation of aggregated Aβ into insoluble plaques may actually be a protective 
mechanism that prevents soluble oligomeric Aβ from inducing synaptotoxicity.  CD200 
may inhibit the formation of soluble Aβ oligomers and favor the formation of insoluble 
plaques by skewing the immune response to less pro-inflammatory and more 
neuroprotective action.  Establishment of an anti-inflammatory milieu likely supports this 
response and may also enhance phagocytosis of soluble Aβ oligomers. 
 The reduction in Aβ42 and soluble amyloid was associated with an increase in 
YM1 expression and a reduction in NOS2 in mononuclear phagocytic cells in the DG.  
These findings confirm that our AAV2/1-CD200 gene delivery leads to the anti-
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inflammatory effects expected of CD200 expression.  The function of CD200 signaling is 
to reduce NFκB activation and downstream release of pro-inflammatory mediators, such 
as NOS2.  The increased expression of YM1 demonstrates the active establishment of an 
anti-inflammatory microglial environment.   
 Despite an increase in the number of YM1+ glia, we did not observe an increase in 
the number of mononuclear phagocytes in our 12 month-old APP mice injected with 
AAV2/1-CD200 as indicated by no signficant difference in the number of Iba1+ cells in 
the dentate gyrus.  There is also no difference in morphology at this timepoint.  These 
data should be interepreted with some caution. It should be noted that other cell types, 
including astrocytes, oligodendrocytes, and dendritic cells, are known to express the 
CD200Rs (Barclay, 1981; Chitnis et al., 2007; Koning et al., 2010). Thus, it is likely that 
other CD200R+ cells may also contribute to the beneficial effects of CD200 gene delivery 
in the APP mouse hippocampus. A recent paper by [Butovsky et al] (Butovsky et al., 
2014) characterized the gene expression profile of adult microglia and found that P2ry12 
is a novel microglia-specific maker. Using their custom antibody and CD169 (as a 
peripheral monocyte marker), we observed both microglia and infiltrating monocytes in 
the mouse brain, which are structurally similar. We therefore cannot discount the 
contribution of infiltrating peripheral monocytes, as both WT and APP mice were 
positive for P2ry12 (resident microglia) and CD169 (peripheral monocyte) staining in the 
DG. As stated above, peripheral macrophages that infiltrate the CNS tend to display an 
M1 phenotype, as indicated by their positive expression of NOS2 (Asai et al., 2014).  
Preliminary staining and quantification confirmed the presence of peripheral 
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macrophages in all our subjects.  It would be interesting to determine if the CD169+/Iba1+ 
cells seen in the stained sections are the main source of NOS2 expression in the dentate 
gyrus.  Our data suggest, however, that CD200 either supports the survival of YM1+ 
microglia or be less effective at reducing M1 activation or infiltration of peripheral 
macrophages. 
 In conclusion, our data demonstrate that over-expression of CD200 is capable of 
reducing soluble Aβ levels in the APP mouse brain, likely through establishment of an 
anti-inflammatory and pro-phagocytic microglial milieu.  Further experimentation is 
required to determine the mechanism by which CD200 induces these effects in order for 
it to be considered a therapeutic for AD.  It is not yet clear if a reduction in soluble Aβ 
with no change in insoluble plaque levels is sufficient for halting the progression of AD, 
particularly in humans.  In order to reduce formation of both soluble and insoluble 
aggregates, CD200 may need to be expressed in addition to an inhibitor of insoluble Aβ 
fibril formation.  Although additional experiments are required, the results suggest that 
CD200 is effective at reducing inflammation in the APP mouse brain and warrants 
consideration as an inhibitor of soluble Aβ oligomer formation.   
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Chapter 4: CD200 ENHANCES NEURONAL MATURATION IN VITRO  
VIA ANTI-INFLAMMATORY ACTIVATION  
AND GROWTH FACTOR RELEASE 
 
I. Rationale 
 Our in vivo results presented in Chapter 2 demonstrated an increase in 
neurogenesis in the DG of the APP mouse by genetic over-expression of CD200.  This 
increase was associated with a reduction in pro-inflammatory NOS2+ and an increase in 
anti-inflammatory YM1+ mononuclear phagocytes. Research from our lab has shown that 
in vitro, when microglia are directly co-cultured with neural stem cells, there is a 
significant anti-apoptotic effect and a reduction in glial differentiation as indicated by a 
reduction in fragemented nuclei and number of astrocytes, respectively  (Kiyota et al., 
2011b). Additionally, when IL-4-treated microglia are co-cultured either indirectly or 
directly with neural stem cells, there is a siginficant increase in neuronal differentiation 
(Kiyota et al., 2011b), suggesting that IL-4 signaling may have a neurogenic effect. 
Because CD200 is down-stream of IL-4 signaling, this implicates CD200 in the positive 
effects of M2-activated microglia on neuronal differentiation.  We therefore hypothesized 
that the effects of CD200 expression on neurogenesis can be mediated through microglia 
in vitro as they are known to express the CD200R (Chitnis et al., 2007), and that 
microglia may induce these effects via direct support of neurogenesis or indirectly 
through reduction of inflammation. 
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 In order to examine the role of inflammation in CD200-stimulated microglia, we 
examined the expression of certain genes known to be involved in microglial activation, 
including CD200R1, CD200R3, TREM2, TYROBP, TGF-β1, and TGF-βR1.  Both 
CD200R1 and CD200R3 signaling inhibit activation of NFκB through binding to adaptor 
proteins Dok2 and TYROBP, respectively (Wright et al., 2003; Kojima et al., 2007).  
Mutations in TREM2 and TYROBP have resulted in disorders that have enhanced 
inflammatory responses and inflammation (Hamerman et al., 2005; Hamerman et al., 
2006; Turnbull et al., 2006), suggesting these proteins play an important role in immune 
homeostasis in addition to phagocytosis.  TGF-β1 has also been found to be an important 
regulator of microglial activation (Schilling et al., 2001) and is required for the survival 
of microglia both in vivo and in vitro (Butovsky et al., 2014).  Examination of the 
expression of these genes may elucidate the role microglial activation has on 
neurogenesis.    
  Interestingly, conditioned media from microglia also promotes neuronal survival 
in vitro (Nagata et al., 1993).  In addition to several pieces of evidence that suggest 
inflammation has a detrimental effect on neuronal differentiation and survival (Ekdahl et 
al., 2003; Monje et al., 2003; Bastos et al., 2008; Walter et al., 2011), the expression and 
release of growth factors by microglia may also directly initiate or support neurogenesis. 
Such growth factors include IGF-1, brain-derived neurotrophic factor (BDNF), 
neurotrophin-3 (NT3), and glial cell-derived neurotrophic factor (GDNF).  IGF-1 is 
primarily recognized as a pro-survival factor by inducing anti-apoptotic and 
neuroprotective signaling pathways (Dudek et al., 1997; Peruzzi et al., 1999; Carro et al., 
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2003).  IL-4 can induce the expression of IGF-1 in microglia (Butovsky et al., 2005), 
suggesting CD200 may have a similar effect in vitro.  Modulation of BDNF expression 
by microglia appears to play a role in synaptic plasticity and learning or memory 
formation in the brain (Chakravarthy et al., 2006; Bekinschtein et al., 2008; Parkhurst et 
al., 2013).  Both BDNF mRNA and protein levels are reduced in the hippocampi of AD 
brains [see (Murer et al., 2001) for review].  NT3 is also highly expressed in the 
hippocampus and helps regulate the survival of specific neuronal populations (Chao et 
al., 2006). It can induce proliferation and phagocytic activity of rat microglial cells in 
vitro (Elkabes et al., 1996).  Lastly, GDNF has primarily been studied for its therapeutic 
potential for PD as a promoter of dopaminergic neuron survival [for review, see 
(d'Anglemont de Tassigny et al., 2015) ].  It also acts as a trophic factor for spinal 
motoneurons and noradrenergic neurons (Henderson et al., 1994; Arenas et al., 1995), 
giving it promising therapeutic potential for the treatment of other neurodegenerative 
diseases as well.  CD200 has never been shown to increase growth factor expression or 
protein levels, but it is possible that this is one of the mechanisms by which it restores or 
supports neurogenesis.  We sought examine the effects of CD200-stimulated microglia on 
neuronal differentiation in vitro and analyzed the expression of these growth factors and 
microglial activation factors in microglia in order to elucidate the role of microglia in the 
neurogenic effects of CD200.   
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II.Materials and Methods 
2.1 Cell Culture 
 2.1.1 Primary Neural Stem Cells 
 Primary neural stem cells were prepared from embryonic E14 WT mice as 
described (Kiyota et al., 2011a).  Briefly, cortices were dissected and placed in cold 
HBSS with 2% glucose (Invitrogen, Carlsbad, CA).  Tissue was then mechanically 
dissociated in complete proliferation media (Stem Cell Technologies, Vancouver, BC, 
Canada) with 20 ng/ml epidermal growth factor (Stem Cell Technologies), 100 U/ml 
Penicillin and 10 µ/ml Streptomycin (Invitrogen, Carlsbad, CA), and then filtered through 
a 70 µm cell strainer.  Cells were cultured as neurospheres for seven days until spheres 
reached 100-150 µm in diameter.    
 2.1.2 Mouse Primary Microglia and Mixed Glia Isolation  
 Primary microglia or mixed glia were isolated from P0 pups from CD-1 mice 
(Charles River Laboratories, Wilmington, MA) as described (Kiyota et al., 2009a).  
Briefly, brains were dissected from euthanized pups in cold Hank’s balanced salt solution 
(HBSS, Invitrogen, Carlsbad, CA), and meninges were removed.  The brain was then 
mechanically minced using sterile razor blades for 15 minutes.  Minced tissue was then 
subjected to two serial digestions for nine minutes each at 37°C in HBSS with 0.1% 
deoxyribonuclease I from bovine pancreas (Sigma-Aldrich, St. Louis, MO), 0.25% 
trypsin (Invitrogen, Carlsbad, CA), 50 mM magnesium chloride, and 10 mM calcium 
chloride.  FBS (Invitrogen, Carlsbad, CA) was used to quench the trypsin reaction each 
time.  The cellular suspension was filtered through a 70 µm-pore size nylon cell strainer 
	  	  98	  
(BD Falcon, San Jose, CA).  Glia were then isolated by density gradient centrifugation 
for 40 minutes at 200 x g with isotonic Percoll® (70%-37%-30%-0% in HBSS, GE 
Healthcare, Fairfield, CT) as described (Cardona et al., 2006).  Glia were collected from 
between the 70-37% layer and washed twice with PBS before counting and plating.  Glia 
were plated at about 2 × 106 for one hour in DMEM with 10% FBS and 100 U/ml 
penicillin and 10 µ/ml streptomycin (Invitrogen, Carlsbad, CA) at 37°C in 5% CO2.  
After one hour, non-adherent cells (mixed glia fraction) were removed and plated in a 
new plate in DMEM with 10% FBS, and 100 U/ml penicillin and 10 µ/ml streptomycin 
(Invitrogen, Carlsbad, CA).  Adherent cells (~85% enriched primary microglia fraction) 
were cultured in DMEM with 10% FBS, 100 U/ml penicillin and 10 µ/ml streptomycin 
(Invitrogen, Carlsbad, CA), and 10 ng/ml each of murine macrophage-colony stimulating 
factor and murine granulocyte macrophage-colony stimulating factor (Abazyme, 
Cambridge, MA).  Cells were incubated for 5-7 days prior to stimulation.    
    
2.2 Neurogenesis Assay 
 For the co-culture neural differentiation study, neural stem cells were plated onto 
poly-D-lysine- and laminin- coated coverslips (Sigma-Aldrich, St. Louis, MO) in 24-well 
plates at 100,000/ well for two wells/group.  Media was changed to fresh differentiation 
media (Neurobasal media, B27, 1x Penicillin/ Streptomycin; Invitrogen) one hour after 
plating.  Primary microglia cells were pre-treated for one hour with 100 ng/ml soluble 
CD200Fc ligand in differentiation media before being transferred to transwell inserts at 
10,000/ well in differentiation media and co-cultured with neural stem cells for seven 
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days (see experimental paradigm in Fig. 24).  After, neural stem cells were fixed with 4% 
PFA for immunocytochemistry. 
 
 
 
 
Figure 24. Experimental scheme for examination of the effects of CD200 stimulation 
of microglia on neuronal differentiation.  Primary microglia were pre-treated with 
CD200 prior to co-culture with NSCs for seven days.  
 
 
2.3 Growth Factor and Microglial Activation Assay 
 For analysis of growth factor release and microglial activation, primary microglia 
were plated at 0.5 x 106 per well of a 24-well plate for a n of 2-3 wells per group.  Prior to 
CD200 treatment, cells were serum-starved overnight in DMEM with 1% Penicillin/ 
Streptomycin (Invitrogen, Carlsbad, CA).  Cells were then treated with 100 ng/ml soluble 
CD200Fc ligand for 5 hours in fresh serum-free media followed by RNA isolation for 
reverse transcription-PCR (RT-PCR) as described below (see experimental scheme in 
Fig. 25 below).    
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Figure 25. Experimental scheme for growth factor and microglial activation 
analysis.  Primary microglia were serum-starved overnight prior to five-hour incubation 
with CD200.  This was follwed by RNA isolation and RT-PCR. 
 
 
 
2.4 Immunocytochemistry 
 Immunocytochemistry of neural stem cells and astroglia was done to examine 
neural differentiation.  Cells were permeabilized with 1% Triton X-100 in PBS followed 
by blocking in 5% normal goat serum and primary antibody incubation for β-III tubulin 
(β3T), and GFAP overnight at the concentrations given in Table 4.  Immunofluorescence 
was visualized using Alexa Fluor®488- or 647-conjugated anti-mouse or anti-rabbit IgG 
(Invitrogen, Carlsbad, CA) at 1:400 in blocking buffer. This was followed by total nuclei 
staining using Hoechst counter-stain (AnaSpec, Inc, San Jose, CA) at 1:5,000.  
Differentiation was examined by quantifying the percentage of β3T+ cells or GFAP+ cells 
over total cell number from five fields per well for two wells per group (total 10 fields 
per group quantified).  Neuronal complexity was measured using NeuronJ (Meijering et 
al., 2004), an ImageJ plug-in, to measure the length of axons and number of dendrites 
emanating from the cell soma.  At least 50 neurons per group were analyzed.  
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2.5 RT-PCR 
 After stimulation, total RNA was isolated from cells using the RNeasy Mini Kit 
(Qiagen, Valencia, CA) according to manufacturer’s instructions.  cDNA conversion was 
transcribed from 50 ng mRNA using the Quantitect Reverse Transcription kit followed 
by RT-PCR using the Rotor-Gene SYBR Green PCR kit according to the manufacturer’s 
instructions (both kits from Qiagen, Valencia, CA) and using 1 µM of both forward and 
reverse primer pairs (Invitrogen, Carlsbad, CA) outlined in Table 6.  RT-PCR was 
performed for CD200R1, CD200R3, TREM2, TYROBP, TGF-β1, and TGF-βR1 using the 
Rotor-Gene Q cycler (Qiagen, Valencia, CA) with the followed cycling program: 95°C 
for 5 minutes followed by 40 amplification cycles by denaturation at 95°C for 5 seconds 
to annealing and extension at 60°C for 10 seconds.  For analysis of IGF-1, BDNF, NT3, 
and GDNF, the following cycle was performed: initial activation at 95°C for 5 minutes, 
followed by amplification with 55 cycles of 95°C for 15 seconds to 60°C for 30 seconds 
to 72°C for 45 seconds.  Expression of all target genes was normalized to the 
housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  Gene 
expression was compared relative to expression in untreated cells using the comparative 
CT method (ΔΔCT method).  Two to three samples were measured per group and results 
were replicated in a duplicate experiment.  Data was pooled from both experiments for 
final analyses.     
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Table 6. Primer design for RT-PCR 
Primer Sequence Product 
Length 
Reference 
For 5’-ATGGGACTCTGGAGAGCCTGAA BDNF 
Rev 3’-CGCCAGCCAATTCTCTTTTTGC 
552 NM_001285416.1 
(Huang et al., 
2015) 
For 5’-GGAAAACCAGAAAACCGAAATG CD200R1 
Rev 3’-CCCCCATATTAAGAGCACTGCTA  
70 NM_021325.3 
For 5’-AGTGCCACAGGGAGAAAAACA  CD200R3 
Rev 3’-
TCCAGTTATCAGTCAAATGGGAGAT 
69 NM_029018, 
(Masocha, 2010) 
For 5’-AAGCGCCCGCTGAAGACCAC GDNF 
Rev 3’-AGGAAGCGCTGCCGCTTGTT 
173 NM_010275.3 
For 5’-ATCTGCCTCTGTGACTTCTGA IGF-1 
Rev 3’-GCCTGTGGGCTTGTTGAAGT 
176 NM_010512.4 
For 5’-
CCGTCAGCCAGGATAATGATGAGATCT 
NT3 
Rev 3’-GCTGTTGCCTTGGATGCCACG 
77 NM_008742.3 
For 5’-AGAGGTCACCCGCGTGCTAA TGF-β1 
Rev 3’-TCCCGAATGTCTGACGTATTG 
108 NM_011577.1 
For 5’-TGCCATAACCGCACTGTCA TGF-βR1 
Rev 3’-AATGAAAGGGCGATCTAGTGATG 
72 NM_009370.2, 
(Li et al., 2011) 
For 5’-GCCTTCCTGAAGAAGCGGAA TREM2 
Rev 3’-GAGTGATGGTGACGGTTCCA 
73 NM_031254.3, 
(Hickman and El 
Khoury, 2014) 
For 5’-AGCCCTCCTGGTGCCTTCT TYROBP 
Rev 3’-GGCCTGTACGGGACTTAATC 
68 NM_011662.2, 
(Kiialainen et al., 
2005) 
For 5’-ACGGCCGCATCTTCTTGTGCA  GAPDH 
Rev 3’-CCAGGCGCCCAATACGGCC 
71 NM_008084.3 
 
2.6 Statistics 
 All data are presented as mean values ± SEM.  For comparison between two 
groups, data were analyzed by Student’s t-test.  For multiple mean comparisons, data 
were analyzed by one-way ANOVA followed by Tukey post-hoc analysis (Prism 4.0, 
Graphpad Software, Inc., San Diego, CA).  Significance is considered anything of p ≤ 
0.05. 
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III.  Results  
3.1 CD200-treated microglia enhance neuronal differentiation of neural stem cells 
 We investigated the effects of CD200 on neuronal maturation in vitro with a co-
culture study using primary murine microglia and primary murine neural stem cells.  
Primary murine microglia were pretreated with or without CD200 prior to indirect co-
culture with primary murine neural stem cells in differentiation conditions for seven days 
(see Fig. 26A for experimental scheme).  Microglia pretreated with CD200 enhanced 
neuronal differentiation of neural stem cells as compared to neural stem cells co-cultured 
with untreated microglia (Fig. 26B and C).  There was a higher proportion of β3T+ 
mature neurons over GFAP+ glial differentiated cells.  This suggests that CD200 is 
beneficial for restoring neurogenesis in vivo, but may also support neuronal maturation 
over glial differentiation in vitro.  In addition to this, it suggests that the effects of CD200 
on neurogenesis are mediated through microglia.      
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Figure 26. CD200-stimulated microglia increase neural differentiation of neural 
stem cells in vitro. (A) Scheme depicts the experimental paradigm used for in vitro co-
culture study.  Neural stem cells were co-cultured with CD200-pre-treated microglia in 
transwells for seven days.  (B) Images of neural stem cells after co-culture with CD200-
treated microglia and stained for astrocytic marker, GFAP (red) and mature neuronal 
marker, β3T (green). (C) Quantification of cellular differentiation was measured by 
percentage of β3T+ or GFAP+ cells over total number of cells (Hoechst 33342).  * and ** 
denote p<0.05 and 0.01, respectively, as determined by Student’s t-test. Scale bars 
represent 100 µm in (B). 
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  3.2 CD200-treated microglia enhance neuronal complexity of mature neurons 
 β3T+ neurons were further examined by their morphology to determine if CD200 
enhanced neuronal complexity.  We quantified both the length of the axons and the 
number of dendrites emanating from the cell soma for each neuron analyzed. β3T+ 
neurons in the CD200-treated groups exhibited more complex morphologies with longer 
axon lengths and more dendrites (Fig. 27A-C).  This demonstrates that CD200-treated 
microglia enhance both neuronal maturation and complexity in vitro.   
 
 
Figure 27. CD200-stimulated microglia increase neuronal complexity of neural stem 
cells in vitro. (A) β3T+ neurons were quantified for complexity by measuring axon 
length (B) and total number of dendrites emerging from the cell soma (C) using NeuronJ 
(n= ~50/group).  * denotes p<0.05 as determined by Student’s t-test. 
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3.3 CD200 increases microglial expression of the growth factor GDNF in vitro 
 We observed an increase in neural differentiation and complexity when microglia 
pre-treated with CD200 were indirectly co-cultured with neural stem cells.  This led us to 
hypothesize that CD200 could induce the release of growth factors from primary 
microglia that would support neuronal survival, growth, or axon elongation.  RNA 
expression analysis revealed no increase in the expression of IGF-1, BDNF, or NT3 after 
treatment of primary microglia with CD200 (Fig. 28).  However, we did measure a 
significant increase in the expression of the growth factor, GDNF.  This suggests that 
CD200 may support neuronal survival and maturation in vitro through release of GDNF 
by microglia.     
 
 
 
Figure 28. CD200-stimulated microglia show increased expression of GDNF in vitro.  
Primary microglia were incubated with 100 ng/ml soluble CD200Fc ligand prior to gene 
expression analysis of IGF-1, BDNF, NT3, and GDNF.  RNA from primary microglia 
were analyzed by RT-PCR using specific primers for growth factor expression. Data are 
represented as ΔΔCt values of CD200-treated microglia versus Control PBS-treated 
microglia (n= 2-3 samples per group tested in duplicate).  * denotes p<0.05 compared to 
Control samples as determined by one-way ANOVA and Tukey’s post-test of ΔCt values 
normalized to GAPDH.  
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3.4 CD200 alters microglial activation in vitro 
 In order to examine the effects of CD200 on microglial phagocytotic mechanism, 
we analyzed the expression of CD200R1 and CD200R3 (Fig. 29A), TREM2 and TYROBP 
(Fig. 29B), and TGF-β1 and TGF-βR1 (Fig. 29C) in CD200-treated microglia in vitro.  
We found that CD200 treatment increased the expression of CD200R1, but significantly 
reduced the expression of CD200R3 compared to untreated Control cells.  Despite the 
reduction in CD200R3 expression, we observed a large increase in the expression of the 
CD200R3 adaptor molecule, TYROBP.  TREM2, a phagocytic molecule, which also 
couples to TYROBP, did not show an alteration in gene expression.  We also observed a 
reduction in both TGF-β1 and TGF-βR1 expression, though the changes were likewise 
not significant.  These trends may be indicative of a feedback alteration in receptor 
expression and a skewing into an M2a microglial activation phenotype upon down-
regulation of TGF-β1 signaling. 
 
 
 
Figure 29. CD200Fc induces an alteration in primary microglial activation in vitro.  
Primary microglia were incubated with 100 ng/ml soluble CD200Fc ligand prior to gene 
expression analysis of CD200R1 and CD200R3 (A), TREM2 and TYROBP (B), and TGF-
β1 and TGF-βR1 (C).  Data are represented as ΔΔCt versus untreated Control samples.  * 
denotes p<0.05 compared to untreated Control cells as determined by Student’s t-test vs 
GAPDH. 
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IV. Discussion 
 Our results demonstrate that CD200 is able to enhance neuronal differentiation 
and complexity in vitro.  These data support our in vivo findings and further suggest that 
CD200 induces neurogenesis possibly by establishing a neuroprotective environment.  In 
addition to this, we demonstrate that the effects of CD200 on neuronal differentiation are 
mediated through microglia.  However, as we did not test the contribution of other cell 
types known to express CD200R (e.g. astrocytes, dendritic cells, and oligodendrocytes), 
we cannot claim that the effects of CD200 are mediated primarily through microglia. 
 Because we saw enhanced neuronal differentiation after indirect co-culture of 
CD200-treated microglia and neural stem cells, this suggested that CD200 can induce the 
expression of molecules that induce or support neuronal growth and survival. It is 
possible that, although we saw reduced expression of specific growth factors IGF-1, 
BDNF, and NT3 in CD200-treated microglia, there may have been increased growth 
factor protein if analyzed by western blot.  The reduction in RNA expression may be due 
to a feedback mechanism from increased protein levels induced by CD200.  We found 
that treatment of primary microglia with CD200 increases the expression of the growth 
factor GDNF in vitro.  GDNF is more commonly recognized as a survival factor for 
dopaminergic neurons, as it was shown to promote their survival, size, and neurite length 
(Lin et al., 1993).  However, GDNF is also known to alter microglial activation and 
protect neurons in the hippocampus from excitotoxic insult (Boscia et al., 2009), and may 
play a role in both survival and proliferation of microglia as well (Honda et al., 1999; 
Chang et al., 2006). Interestingly, studies examining the relationship of CD200 and 
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CD200R expression in PD have also shown an age-related reduction in CD200 mRNA 
and protein in the substantia nigra of rats (Wang et al., 2011).  Deficits in CD200-
CD200R signaling are associated with enhanced microglial activation and loss of 
dopaminergic neurons in the substantia nigra (Wang et al., 2011; Zhang et al., 2011a; 
Sung et al., 2012).  Our data suggest that CD200 may be implicated in the protection of 
dopaminergic neurons in PD due to its suppression of pro-inflammatory microglial 
activation and the production of GDNF.  CD200 therefore has potential benefits as a 
therapeutic for both AD and PD.  
 Since a pro-inflammatory environment is posited to suppress neurogenesis (Ekdahl 
et al., 2003; Monje et al., 2003; Hoehn et al., 2005; Bastos et al., 2008; Deng et al., 
2010), our data suggest that expression of CD200 alters microglial activation status from 
pro- to anti-inflammatory and restores microglial supportive activities for neural 
differentiation and maturation. This is similar to our previous findings, where direct co-
culture of neural stem cells with IL-10-treated microglia increased neuronal 
differentiation and cell survival and reduced glial differentiation (Kiyota et al., 2011b). 
We also showed that CD200 treatment of microglia increased expression of CD200R1 
while significantly reducing CD200R3, and moderately reducing TREM2, TGF-β1, and 
TGF-βR1 expression.  Despite this, we saw an increase in expression of TYROBP, 
suggesting that there is a switch in microglial activation that reduces CD200R3 while 
simultaneously increasing CD200R1, perhaps as part of a feedback mechanism in 
response to TYROBP activation.  As it is known that downstream TYROBP signaling 
after CD200R3 activation leads to inhibition of NFκB (Hamerman et al., 2005), this 
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suggests that CD200 stimulation of microglia is likely inhibiting the production of pro-
inflammatory cytokines, which allows for the support of neurogenesis and neuronal 
differentiation in vitro.  These data provide support for CD200 to influence neuronal 
differentiation both directly by expression of growth factors and indirectly through 
skewing toward pro-neurogenic microglial activation.        
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Chapter 5: CD200 ENHANCES AMYLOID PHAGOCYTOSIS IN VITRO: 
EVALUATION OF THE ROLE OF TREM2  
 
I. Rationale 
 Our in vivo results presented in Chapter 3 demonstrated a reduction in levels of 
diffuse amyloid in the DG of the APP mouse by genetic over-expression of CD200.  This 
was associated with a reduction in pro-inflammatory NOS2+ and an increase in anti-
inflammatory YM1+ mononuclear phagocytes. CD200 is known to induce M2 microglial 
activation by signaling through CD200R1 or CD200R3 to reduce NFκB-induced 
production of pro-inflammatory mediators (Hatherley and Barclay, 2004; Chen and 
Gorczynski, 2005; Takahashi et al., 2005; Hsieh et al., 2009; Mihrshahi et al., 2009).  
Research shows that M2 microglial activation with IL-4, for example, supports 
phagocytosis of Aβ42 by primary microglia (Koenigsknecht-Talboo and Landreth, 2005).  
It is possible that the anti-inflammatory milieu established by AAV2/1-CD200 in vivo 
supports microglial phagocytosis of Aβ42, and we sought to determine this in vitro.  
Because microglia are the resident immune cells of the CNS, and they have a primary 
role in phagocytosis as part of this immune function, we hypothesized that the effects of 
CD200 expression on amyloidogenesis in this study could be partially mediated through 
increased phagocytosis of Aβ42 by microglia.    
 CD200R3 signaling utilizes the adaptor protein TYROBP to inhibit activation of 
NFκB (Wright et al., 2003; Kojima et al., 2007).  TYROBP is the same adaptor protein 
utilized by TREM2 to induce its own anti-inflammatory and phagocytic functions 
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(Takahashi et al., 2005; Hamerman et al., 2006; Turnbull et al., 2006; Hsieh et al., 2009; 
Melchior et al., 2010; Jiang et al., 2014).  In primary microglia from WT mice, RNA and 
protein levels of TREM2 are positively correlated with increasing levels of Aβ42, and 
levels of TREM2 are also significantly elevated in the hippocampi of aged APP+PS1 
mice (Jiang et al., 2014).  Researchers identified several genetic mutations in TREM2 
that are associated with increased risk for AD and other neurodegenerative diseases, 
including PD, ALS, and FTD, as well as the rare autosomal recessive disorder, polycystic 
lipomembranous osteodysplasia with sclerosing leukoencepthalopathy, or Nasu-Hakola 
disease (Paloneva et al., 2002; Guerreiro et al., 2013a; Jonsson et al., 2013; Rayaprolu et 
al., 2013; Borroni et al., 2014; Cady et al., 2014; Cuyvers et al., 2014).  Nasu-Hakola 
disease is characterized as a bone morphology disorder resulting in frequent bone 
fractures and the eventual development of an FTD-like syndrome (Klunemann et al., 
2005). Data suggest that TREM2 is processed by ADAM proteases, specifically 
ADAM10, and this results in the production of sTREM2 (Kleinberger et al., 2014). 
Reduced levels of sTREM2 can be detected in the CSF of patients with AD and FTD 
(Kleinberger et al., 2014), suggesting that mutations that affect the processing of TREM2 
may play a role in the loss of function of TREM2. Mutations in TREM2 appear to result 
in a loss of function of TREM2 from reduced ligand binding and downstream TYROBP 
signaling (Guerreiro et al., 2013b; Jonsson et al., 2013). TREM2 and TYROBP protein 
are increased in microglia in the vicinity of plaques in the APP23 mouse model of AD 
(Frank et al., 2008; Guerreiro et al., 2013a), supposedly as a response to the presence of 
amyloid.  Kleinberger et al actually showed in BV2 microglial cells and HEK293 Flp-In 
	  	  113	  
cells transfected with loss-of-function TREM2 mutants and with primary microglial cells 
derived from mice lacking TREM2, that a loss of function in TREM2 results in impaired 
phagocytosis of Aβ42 (Kleinberger et al., 2014). We therefore investigated TREM2 and 
its disease-associated mutants in this study and examined the potential of CD200 to 
stimulate the TYROBP interaction with TREM2 as a possible therapeutic method to 
enhance phagocytosis of Aβ42.     
 One mutation we study is R47H, in which a single point mutation results in the 
substitution of a guanine for adenine in the CGC codon (Borroni et al., 2014).  
Heterozygous mutations for R47H are associated with AD (Guerreiro et al., 2013a; 
Jonsson et al., 2013) and FTD (Borroni et al., 2014) and result in slightly reduced 
secretion of sTREM2 and accumulation of immature mutant and surface TREM2 in 
transfected HEK293 cells as well as impaired phagocytosis in BV2 cells (Kleinberger et 
al., 2014).  The T66M mutation is caused by a single point mutation in the ACG codon 
that results in the substitution of a threonine with methionine (Borroni et al., 2014). 
Heterozygous missense T66M mutations are associated with FTD (Borroni et al., 2014), 
and homozygous missense mutations are associated with the development of FTD-like 
syndrome (Guerreiro et al., 2013b).  This mutation resulted in a strong reduction in 
sTREM2 from transfected HEK293 cells in vitro and an accumulation of membrane-
bound full-length mutant TREM2 (Kleinberger et al., 2014).  T66M mutations showed a 
failure in TREM2 maturation, which also resulted in an accumulation of immature 
TREM2 intracellularly with reduced cell surface expression compared to WT TREM2 
(Kleinberger et al., 2014).  These findings, and those of the R47H mutation, were 
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replicated in BV2 microglial cells (Kleinberger et al., 2014).  As with the R47H mutant, 
the T66M mutation also results in impaired phagocytic capability in BV2 cells 
(Kleinberger et al., 2014).  Lastly, the S116C mutation is associated with FTD alone and 
is caused by the substitution of an adenine with a thymine (Borroni et al., 2014).  This 
mutation has not been previously characterized.  The significant occurrence of these 
mutations in patients who suffer from neurodegenerative diseases, particularly FTD and 
AD, suggest an important role for TREM2 in the maintenance of homeostasis in the 
aging brain. 
 In order to investigate the effect of CD200 on coupling of TREM2 with 
TYROBP, we developed a bioluminescence-based assay that allowed us to monitor real-
time TREM2 coupling to TYROBP in vitro with a construct that utilized split-luciferase 
complementation technology.  This split luciferase system was developed by Fujikawa 
and Kato, who fused the C- and N-terminal fragments of Renilla luciferase to “bait” and 
“prey” proteins, allowing reconstitution of luciferase activity and emission of 
luminescence during protein-protein interaction (Fujikawa and Kato, 2007).  This 
luminescence can be measured with high sensitivity by a microplate luminometer (Deng 
et al., 2011).  We hypothesize that this assay can be used to measure the TREM2-
TYROBP interaction in response to specific stimulations and that, because CD200 can 
induce the activation of TYROBP signaling, it may enhance the interaction between 
TREM2 and TYROBP as a possible mechanism for CD200-associated increases in 
microglial phagocytosis of Aβ42. 
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II. Materials and Methods 
2.1 Cell Culture 
 2.1.1 Mouse Primary Microglia and Mixed Glia Isolation  
 Primary microglia or mixed glia were isolated from P0 pups from CD-1 mice 
(Charles River Laboratories, Wilmington, MA) as described (Kiyota et al., 2009a).  
Briefly, brains were dissected from euthanized pups in cold HBSS (Invitrogen, Carlsbad, 
CA), and meninges were removed.  The brain was then mechanically minced using sterile 
razor blades for 15 minutes.  Minced tissue was then subjected to two serial digestions for 
nine minutes each at 37°C in HBSS with 0.1% deoxyribonuclease I from bovine pancreas 
(Sigma-Aldrich, St. Louis, MO), 0.25% trypsin (Invitrogen, Carlsbad, CA), 50 mM 
magnesium chloride, and 10 mM calcium chloride.  FBS (Invitrogen, Carlsbad, CA) was 
used to quench the trypsin reaction each time.  The cellular suspension was filtered 
through a 70 µm-pore size nylon cell strainer (BD Falcon, San Jose, CA).  Glia were then 
isolated by density gradient centrifugation for 40 minutes at 200 x g with isotonic 
Percoll® (70%-37%-30%-0% in HBSS, GE Healthcare, Fairfield, CT) as described 
(Cardona et al., 2006).  Glia were collected from between the 70-37% layer and washed 
twice with PBS before counting and plating.  Glia were plated at about 2 × 106 for one 
hour in DMEM with 10% FBS and 100 U/ml penicillin and 10 µ/ml streptomycin 
(Invitrogen, Carlsbad, CA) at 37°C in 5% CO2.  After one hour, non-adherent cells 
(mixed glia fraction) were removed and plated in a new plate in DMEM with 10% FBS, 
and 100 U/ml penicillin and 10 µ/ml streptomycin (Invitrogen, Carlsbad, CA).  Adherent 
cells (~85% enriched primary microglia fraction) were cultured in DMEM with 10% 
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FBS, 100 U/ml penicillin and 10 µ/ml streptomycin (Invitrogen, Carlsbad, CA), and 10 
ng/ml each of murine macrophage-colony stimulating factor and murine granulocyte 
macrophage-colony stimulating factor (Abazyme, Cambridge, MA).  Cells were 
incubated for 5-7 days prior to stimulation.    
 2.1.2 Murine BV2 Cells 
 Murine microglia BV2 cells were maintained in DMEM/F12 media supplemented 
with 10% FBS and 1% Penicillin/ Streptomycin (Invitrogen, Carlsbad, CA) at 1.5 x 106/ 
well in 6-well plates.  BV2 cells were used because we found that they have endogenous 
expression of CD200R1 and CD200R3 induced by CD200Fc stimulation, as 
demonstrated by RT-PCR shown in Figure 30.    
 
 
 
Figure 30. BV2 cells express both CD200R1 and CD200R3. Murine BV2 cells were 
incubated with 100 ng/ml soluble CD200Fc ligand for six hours prior to gene expression 
analysis of CD200R1 and CD200R3. Data are represented as ΔΔCt versus untreated 
Control samples compared to GAPDH. 
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 2.1.3 Human Embryonic Kidney Cells 293 (HEK293) 
 HEK293 cells were maintained in DMEM media supplemented with 10% FBS 
and 1% Penicillin/ Streptomycin (Invitrogen, Carlsbad, CA) at 2.2 x 106/ well in 10 cm 
dishes.  HEK293 cells were used for there lack of endogenous TREM2 expression, as 
demonstrated in Figure 39B. 
 
 
2.2 Phagocytosis Assay 
 To determine the effects of CD200 stimulation on microglial phagocytosis of 
Aβ42, primary microglia were plated at 0.2 x 106 per well in a 12-well plate for n= 3 per 
group.  After plating, microglia were pre-treated with 5 µM untagged Aβ42 (rPeptide, 
Bogart, GA) for 18 hours in fresh serum-free DMEM with 1% Penicillin/ Streptomycin 
(Invitrogen, Carlsbad, CA). Aβ42 was provided as ultra pure peptide pre-treated with 
hexafluoroisopropanol (HFIP) from the manufacturer and resuspended in 1% NH4OH at 
1 mg/ml prior to resuspension in buffer for experimentation, as recommended by 
manufacturer.  Treatment of Aβ42 with HFIP is used to break apart fibrillar Aβ, but can 
also produce the formation of Aβ oligomers	   (Pachahara et al., 2012), however 
resolubilizing in NH4OH produces a more homogenous, monomeric solution (Ryan et al., 
2013).  Microglia were then treated with 100 ng/ml soluble CD200Fc ligand prior to 
stimulation with 5 µM fluorescein isothiocyanate (Fitc)-tagged Aβ42 (Aβ42Fitc) for 30 
minutes to allow for phagocytosis (Fig. 31). Aβ42Fitc was fibrillized prior to stimulation 
by spinning overnight at room temperature on a magnetic stir plate. We previously 
showed that uptake of oligomeric Aβ42 by mononuclear phagocytes is neglible compared 
	  	  118	  
to uptake of fibrillar Aβ42 (Yamamoto et al., 2008).  This ensures that any reductions in 
phagocytosis of Aβ42Fitc were not due to prior consumption of Aβ42 during pre-
treatment.    After 30 minutes, microglia were trypsinized and prepared for flow 
cytometric analysis.   
 
 
 
 
Figure 31. Experimental scheme for the effects of CD200 on primary microglial 
phagocytosis of Aβ42 in vitro.  Primary microglia were pre-treated with Aβ42 followed 
by one-hour treatment with CD200 prior to stimulation with Fitc-tagged Aβ42 for 
phagocytosis.  After 30 minutes, microglia were labeled with APC-tagged CD11b for 
flow cytometry. 
 
 
2.3 Development of the TREM2-CLuc-TYROBP-NLuc Construct  
 2.3.1 Plasmid Design 
 For examination of the interaction between CD200, TREM2, and TYROBP we 
utilized the split luciferase complementation assay (Deng et al., 2011) to monitor the 
TREM2-TYROBP interaction.  This mammalian expression vector utilizes the “bait-
prey” luciferase complementation assay developed by Fujikawa and Kato in 2007 
(Fujikawa and Kato, 2007), which applies the split Renilla luciferase method 
(Paulmurugan and Gambhir, 2003).  Renilla luciferase catalyzes the oxidation of 
coelenterazine, a luciferin, to emit light (Matthews et al., 1977).  The amount of light 
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emitted as relative light units (RLU) can be directly correlated to the magnitude of 
protein-protein interaction.  We chose an internal ribosome entry site (IRES) backbone 
vector (Clontech Laboratories, Mountain View, CA) to allow for two cloning sites for the 
expression of both TREM2 and TYROBP as split luciferase fusion proteins from a single 
mRNA (Fig. 32).  All restriction sites are unique for each insert. 
 
  
Adapted from Clontech Laboratories, Inc. 
Figure 32. Gene construction for TREM2-CLuc-TYROBP-NLuc plasmid.  In this 
paradigm, the resulting plasmid has the C-terminal of the Renilla luciferase gene fused to 
the cytoplasmic region of TREM2 (TREM2-CLuc) and the N-terminal region of the 
Renilla luciferase gene fused to the N-terminal region of TYROBP (TYROBP-NLuc).  
The unique restriction sites used are depicted here.  When TREM2 interacts with 
TYROBP, this reconstitutes luciferase activity by coupling of the C- and N-terminal 
regions of the Renilla luciferase gene.   
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 All amplifications by PCR were done using ReadyMix top Taq PCR reaction mix 
(Sigma-Aldrich, St. Louis, MO).  TREM2 and TYROBP were amplified by PCR from 
host vectors, whereas CLuc was amplified by PCR from pDuex-Bait vector and NLuc 
was amplified from pDuex-prey vector using the primer sequences given in Table 7.  All 
primers were ordered from Invitrogen (Carlsbad, CA).  TREM2 was digested in two steps 
with Nhe1 and EcoR1.  TYROBP was double digested with Sal1 and Xho1.  CLuc was 
digested in two steps with EcoR1 and Mlu1.  NLuc was digested in two steps with Xho1 
and Not1.  All restriction enzymes were from New England Biolabs (NEB, Ipswich, 
MA).  All two-step digestions were purified between steps using the QIAquick PCR 
Purification Kit (Qiagen, Valencia, CA).   
 
Table 7. Primer sequences for PCR amplification 
 
Primer Sequence 
For 5’- AAAGCTAGCATGGAACCTCTCCGGCTGCTC TREM2 
Rev 3’- TTGAATTCGAGCTCTCTAGACGTGTCTCTCAGCCCTGGCA 
For 5’- TTGTCGACATGGGGGGACTTGAACCCTGCA TYROBP 
Rev 3’- TTGCGGCCGCCTCGAGTTTGTAATACGGCCTCTGTGT 
For 5’-TTGAATTCGGTGGTGGCGGTTCAGGCGGA CLuc 
Rev 3’-TTACGCGTTAGCAGCACCCGGGGCAGCA 
For 5’-TTCTCGAGGGTGGTGGCGGTTCAGGCGGAGGTGGCTCT NLuc 
Rev 3’-TTGCGGCCGCCTACTTAACGAGAGGGATCTCGCGAG 
 
 
 After PCR amplification, TREM2, TYROBP, CLuc, and NLuc were purified by 
electrophoresis on 1% agarose gels and extracted using the QIAquick Gel Extraction Kit 
(Qiagen, Valencia, CA).  Each insert was ligated into the TOPO® TA cloning pCR2.1 
vector (Invitrogen, Carlsbad, CA) and then plated on 50 µg/ml Kanamycin LB plates.  
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Sequencing was done by the Tufts University Core Sequencing Laboratory with the 
capillary Sanger method of sequencing to check for mutations after each TOPO® TA 
cloning insertion.  No mutations were found in the inserts.  Inserts were then digested 
with the respective restriction enzymes and purified by gel electrophoresis and inserted 
into the pIRES vector.  Ligation was done by T4 DNA Ligase (NEB, Ipswich, MA).  
Following ligation, the vector was transfected into DH5α E. coli cells (Invitrogen, 
Carlsbad, CA) by heat shock at 42°C for 30 seconds.  Transfected bacteria were then 
plated on 100 µg/ml Ampicillin LB agar plates, and surviving colonies were shaken 
overnight in LB containing 50 µg/ml Ampicillin.  An endotoxin-free maxiprep was 
performed using the Endo-Free Plasmid Maxi Kit (Qiagen, Valencia, CA).   
 2.3.2 Incorporation of TREM2 Mutants 
 The complete coding sequence for Homo sapien TREM2 was derived from 
GenBank accession number DQ217932.1 (NIH, Bethesda, MD).  Point mutations for 
R47H (Jonsson et al., 2013; Borroni et al., 2014), T66M (Borroni et al., 2014), and 
S116C (Borroni et al., 2014) were incorporated into the reporter gene construct by 
GenScript (Piscataway, NJ).  Point mutations in the coding sequence are shown below in 
Figure 33A-D.  Constructs were amplified using the Endo-Free Plasmid Maxi Kit 
(Qiagen, Valencia, CA).   
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Figure 33. Sequences for WT TREM2 and point mutations for disease-associated 
TREM2. The sequence for WT TREM2 (A) is depicted with locations of point mutations 
highlighted in green for R47H (B), yellow for T66M (C), and blue for S116C (D). 
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 2.3.3 Testing the TREM2-CLuc-TYROBP-NLuc Constructs 
 We designed chemiluminescence-based assays to determine the effects of our 
TREM2-CLuc-TYROBP-NLuc and mutant constructs.  For this purpose, we utilized the 
HEK293 cell line for its lack of endogenous TREM2 expression.  HEK293 cells were 
plated at 4 x 104/ well for n= 3/ group in poly-D-lysine-coated wells in a 96-well plate.  
Cells were then transfected with either 100 ng pRL Renilla Luciferase Reporter Vector, 
pRL-TK (Promega, Madison, WI), as an internal control reporter, or 200 ng TREM2-
CLuc-TYROBP-NLuc or mutant constructs in Opti-MEM media (Invitrogen, Carlsbad, 
CA) utilizing the Lipofectamine 2000 (Invitrogen, Carlsbad, CA) transfection system 
according to the manufacturer’s recommendations.  For testing of TREM2 mutants, we 
included an additional control group with 200 ng construct containing only the C-
terminal of Renilla luciferase attached to TREM2 (TREM2-CLuc-TYROBP).  This 
construct should not emit luminescence even in the presence of TREM2-TYROBP 
coupling due to the lack of the N-terminal component of the Renilla luciferase gene.  24 
hours after transfection, stimulation conditions were added to each well.  These included 
10, 30, or 100 µg/ml Aβ42; 5, 10, or 20 µg/ml biotinylated anti-TREM2 antibody (R&D 
Systems, Minneapolis, MN); or 5, 10, or 20 µg/ml anti-TYROBP antibody (Santa Cruz 
Biotechnology, Dallas, TX).  Constructs containing point mutations associated with 
neurological disease were tested in a similar manner with the exclusion of Aβ dose-
response and TYROBP antibody, as these showed little to no effect in testing of our WT 
TREM2-CLuc-TYROBP-NLuc construct.  Only 10 µg/ml Aβ was used for mutant 
TREM2 assays.  Immediately after addition of these ligands, 30 µM ViviRen Live Cell 
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Renilla Luciferase substrate (Promega, Madison, WI) was injected into each well and 
luciferase activity was measured using the CentroXS3 luminometer (Berthold 
Technologies, Bad Wildbad, Germany) at 0.5 sec integration per well repeatedly over 30 
minutes.  Research suggests that TREM2 activation may be increased in response to the 
presence of Aβ due to its increased expression in amyloid plaque-associated microglia in 
the APP mouse brain (Frank et al., 2008), and so we expected a dose-dependent increase 
in luciferase activity in response to increasing concentrations of Aβ.  It has also 
previously been shown that a TREM2-cross-linked antibody can activate TREM2 
(Takahashi et al., 2007), and we therefore expected a similar dose-dependent response.   
2.3.4 Transfection Efficiency of TREM2-Luc-TYROBP-NLuc and Mutant 
Constructs 
 In order to determine if the differences in effects seen between our WT and 
mutant TREM2 constructs was not due to differences in transfection efficiency, we 
verified that transfection efficiency was equal amongst all our constructs. HEK293 cells 
were plated at 0.5 x 106/ well in a 6-well plate for n=1 per construct.  Cells were then 
transfected with 1600 ng our TREM2-CLuc-TYROBP-NLuc (WT TREM2) construct or 
TREM2-CLuc-TYROBP (NC TREM2) control plasmid, or R47H, T66M, or S116C 
mutants in Opti-MEM media (Invitrogen, Carlsbad, CA) utilizing the Lipofectamine 
2000 (Invitrogen, Carlsbad, CA) transfection system according to the manufacturer’s 
recommendations. 24 hours after transfection, cells were trypsinized and harvested 
analysis of cell surface and intracellular TREM2 and TYROBP by flow cytometry.   
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2.4 TREM2-TYROBP Crosslinking Assay  
 In order to confirm that luciferase activity measured in our luminescence assays is 
due to a physical interaction between TREM2 and TYROBP, we performed a 
crosslinking assay followed by protein quantification with ELISA.  We utilized a 
protocol adapted from HEK293 cells were plated at 2x106 cells in a 10 centimeter dish 
and allowed to grow to 70% confluency.  Cells were then transfected with 10 µg of 
TREM2-CLuc-TYROBP-NLuc with 30 µl Lipofectamine 2000 in Opti-MEM medium 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.  48 hours after 
transfection, cells were stimulated with 20 µg/ml anti-TREM2 antibody (R&D Systems, 
Minneapolis, MN) in DMEM at 37°C for 20 minutes to induce TREM2 coupling to 
TYROBP.  In order to stabilize the TREM2-TYROBP interaction so that it could be 
measured by ELISA, protein crosslinking had to be performed utilizing adapted protocols 
(Bouchon et al., 2001; Daws et al., 2001; Rizvi and Raghavan, 2010).  Briefly, we 
replaced media with DMEM containing 4 mM dimethyl 3,3’-dithiobispropionimidate 
(DTBP, Sigma-Aldrich, St. Louis, MO), an amidine protein crosslinker with an 11.9 Å 
spacer arm and 10 mM phosphatase inhibitor, sodium vanadate and 0.6% hydrogen 
peroxide (pervanadate, Na3O4V), for 10 minutes at 37°C.  This media was then aspirated 
and cells were washed with PBS before lysing in lysis buffer (50 mM Tris-hydrochloride, 
150 mM sodium chloride,  1 mM ethylenediaminetetraacetic acid, 0.1% sodium dodecyl 
sulfate, 0.5% sodium deoxycholate, and 1% Nonidet P-40) containing 1% Triton X-100, 
1% protease inhibitor phenylmethylsulfonyl fluoride (PMSF), and 1 mM sodium 
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pervanadate for one hour on ice.  The lysate was centrifuged at 14,000 rpm for 30 
minutes at 4°C.  Protein was quantified by BCA Protein Assay Kit (Pierce, Rockford, IL) 
according to the manufacturer’s instructions. 
 2.4.1 TREM2-TYROBP “Sandwich” ELISA 
 50 µl of anti-TYROBP antibody (Santa Cruz Biotechnology, Dallas, TX) at 1 
µg/ml in coating buffer (0.2 M sodium bicarbonate, pH 9.4) was incubated in the wells of 
a 96-well plate overnight at 4°C (n= 4 wells per group).  After washing wells with PBS, 
TYROBP-coated wells were blocked with 10% normal goat serum in PBS for one hour at 
room temperature.  Blocker was then removed and 100 µg of protein from HEK293 cell 
lysates in 100 µl lysis buffer was incubated in TYROBP-coated wells overnight at 4°C.  
To label TYROBP protein crosslinked with TREM2, wells were then incubated with a 
biotinylated anti-TREM2 antibody (R&D Systems, Minneapolis, MN)- HRP-conjugated 
Streptavidin (Life Technologies, Grand Island, NY) complex (0.5 µg/ml each) in 0.1% 
Triton X-100 in PBS for one hour at room temperature.  After extensive washing with 
PBS, wells were then incubated with 100 µl stabilized chromogen for 30 minutes in the 
dark at room temperature followed by addition of 100 µl Stop solution.  Optical density 
was read at 450 nm with a SpectraMax M2 microplate reader (Molecular Devices, 
Sunnyvale, CA).  Figure 34 illustrates the experimental scheme used for measuring 
concentration of TREM2-TYROBP protein complexes.  Wells coated with anti-TYROBP 
labeled directly with gradual dilutions of anti-rabbit HRP were used as positive controls.        
 
 
	  	  127	  
Figure 34. Protein complexes of TREM2 crosslinked to TYROBP were quantified 
by “Sandwich” ELISA. HEK293 cells were transfected with TREM2-CLuc-TYROBP-
NLuc followed by anti-TREM2 antibody stimulation to induce TREM2 coupling to 
TYROBP and protein crosslinking with DTBP and phosphatase inhibitor, sodium 
pervanadate (Na3O4V).  Following cell lysis, protein was incubated in TYROBP-coated 
wells then labeled for TREM2 with biotinylated anti-TREM2/ HRP-conjugated 
Streptavidin for quantification of TREM2-TYROBP protein complexes by ELISA. 
 
 
2.5 Flow Cytometry 
 Following trypsinization of primary microglial cells used in the phagocytosis 
assay, cells were thoroughly washed in flow cytometry staining buffer (PBS containing 
1% bovine serum albumin) to remove excess media, trypsin, and Aβ42Fitc that was not 
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phagocytosed.  Microglia were then incubated in 1 µg/ml anti-mouse CD16/CD32 in 
buffer for 20 minutes to block non-specific Fc-mediated interactions during the staining 
procedure.  Cells were then labeled for microglia-specific activation marker CD11b 
tagged with allophycocyanin (APC) (CD11bAPC) in staining buffer for 30 minutes. This 
was followed by thorough washing to remove unbound antibody and examination by 
flow cytometry using a BD LSR II instrument with BD FACS Diva 6.2.1 software (BD 
Biosciences, San Jose, CA) and analyzed with FlowJo software (FlowJo LLC, Ashland, 
OR).  Gating was aided by analysis of single positive Aβ42Fitc-only and CD11bAPC-only 
cells as well as negative control cells that were treated with neither Aβ42Fitc nor 
CD11bAPC.   
 For analysis of intracellular TREM2 and TYROBP expression to test transfection 
efficiency, cells were first fixed in 4% PFA for 15 minutes followed by washing and 
permeabilization with 0.5% Tween-20 in PBS containing 1% bovine serum albumin for 
20 minutes.  Cells were then incubated in phycoerythrin- (PE-) conjugated TREM2 
antibody and anti-TYROBP for one hour.  This was followed by washing and then 
secondary antibody incubation with donkey anti-rabbit conjugated to Alexa-fluor 647 at 
10 µg/ml for fluorescent labeling of TYROBP for 30 minutes.  All incubations were done 
in the presence of 0.5% Tween-20.  For cell surface staining of TREM2 and TYROBP, 
all the same procedures were executed with the exclusion of Tween-20 to maintain the 
integrity of the membrane.  At least 10,000 cells were then analyzed by flow cytometry 
using a BD LSR II instrument with BD FACS Diva 6.2.1 software (BD Biosciences, San 
Jose, CA) and FlowJo software (FlowJo LLC, Ashland, OR).  Gating was aided by 
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analysis of single positive PE-TREM2 only and TYROBP-647-only cells as well as 
negative control cells that were treated with neither TREM2 nor TYROBP antibodies. 
 
2.6 CD200/ TREM2-CLuc-TYROBP-NLuc Chemiluminescence Assay 
 To determine if CD200 could induce or enhance TREM2 coupling to TYROBP in 
vitro, BV2 cells were plated at 4 x 104 in poly-D-lysine-coated wells in a 96-well plate 
for a total of three wells per group.  BV2 cells were used in place of HEK293 cells 
because of their endogenous expression of CD200R3 that we observed by RT-PCR (data 
not shown).  Cells were then transfected with 200 ng TREM2-CLuc-TYROBP-NLuc in 
reduced serum Opti-MEM media with the Lipofectamine-2000 system (both from 
Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.  48 hours after 
transfection, cells were stimulated with 20 µg/ml TREM2 antibody, 40 ng/ml, 100 ng/ml, 
or 200 ng/ml soluble CD200Fc ligand or Goat IgG as control, and/or 10 µg/ml Aβ42.  
The concentrations of ligand used were determined by preliminary TREM2-CLuc-
TYROBP-NLuc experiments.  Immediately after adding ligand, 30 µM ViviRen Live 
Cell Renilla Luciferase substrate (Promega, Madison, WI) was injected into each well 
and luciferase activity was measured using the CentroXS3 luminometer (Berthold 
Technologies, Bad Wildbad, Germany) at 0.5 sec integration per well repeatedly over 30 
minutes.   
 
2.7 Statistics 
 All data are presented as mean values ± SEM.  For comparison between two 
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groups, data were analyzed by Student’s t-test.  For multiple mean comparisons, data 
were analyzed by one-way ANOVA followed by Tukey or Bonferroni post-hoc analysis 
using statistics software (Prism 4.0, Graphpad Software, Inc., San Diego, CA).  
Significance is considered anything of p ≤ 0.05. 
 
III.  Results  
3.1 CD200 enhances the survival of CD11b+ primary microglia in vitro 
 Flow cytometry analysis of microglia labeled with the activation marker CD11b 
revealed that those microglia treated with CD200 had an increased percentage of CD11b+ 
microglia compared to Control group and compared to microglia pre-treated with Aβ42 
(Fig. 35A and B).  Interestingly, pre-treatment of microglia with Aβ42 reduced the 
percentage of CD11b+ microglia compared to Control, though not significantly.  Aβ42-
pre-treated microglia did have significantly fewer CD11b+ microglia compared to 
CD200-treated microglia, but this was partially restored in cells treated with CD200 prior 
to fibrillar Aβ42Fitc stimulation.      
 
3.2 CD200-treated microglia have enhanced phagocytosis of Aβ42 in vitro 
 We performed an in vitro experiment to determine if CD200 enhanced the ability 
of primary microglia to phagocytose Aβ42Fitc.  Examination of only CD11b+ microglia 
revealed that CD200 significantly enhanced the percentage of microglia that 
phagocytosed Aβ42Fitc compared to microglia pre-treated with Aβ42 (Fig. 35C and D). 
However, treatment with CD200 after Aβ42 pre-treatment was able to partially restore 
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the percentage of phagocytic Aβ42Fitc+ microglia.  The Aβ42Fitc+ uptake by microglia, as 
determined by the mean fluorescent intensity of Aβ42Fitc+/CD11b+ microglia, was also 
increased by CD200 treatment, (Fig. 35E and F), demonstrating that CD200 not only 
increased the number of phagocytic CD11b+ microglia, but also increased the Aβ42Fitc 
uptake per cell.     
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Figure 35. CD200-treated microglia show increased phagocytosis of Aβ42 in vitro. 
Microglia were pre-treated with untagged Aβ42 prior to treatment with soluble CD200Fc 
ligand and then stimulated with Aβ42Fitc for phagocytosis. Smoothed histogram 
representations for percentage of CD11b+ microglia (A), percentage of CD11b+ microglia 
that phagocytosed Aβ42Fitc (C), and average fluorescent intensity of Fitc per cell (E) are 
quantified in (B), (D), and (F).  Histograms are normalized to % max.  In (B and D), * 
denotes p<0.05 compared to Control and # denotes p<0.05 compared to CD200-treated 
group as determined by one-way ANOVA and Bonferroni’s post-test.  In (F), *** 
denotes p<0.001 as determined by Student’s t-test.  N=3 per group. 
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3.3 TREM2-CLuc-TYROBP-NLuc construct induces luciferase activity in response to 
anti-TREM2 antibody  
 Our TREM2-CLuc-TYROBP-NLuc plasmid was transfected into HEK293 cells 
followed by stimulation with specific ligands.  Luciferase activity was measured over 30 
minutes (Fig. 36A, C, E, G), and area under the curve (Yasuda et al.) (Fig. 36B, D, F, H) 
was calculated.  Our TREM2 construct was successfully able to produce luciferase 
activity in response to TREM2 coupling to TYROBP as evidenced by the dose-dependent 
increase in luminescence induced by anti-TREM2 antibody stimulation (Fig. 36A and B).  
20 µg/ml of anti-TREM2 antibody induced significantly higher maximum luminescence 
compared to both untreated and TREM2-CLuc-TYROBP-NLuc-transfected unstimulated 
cells, as well as all concentrations of Aβ42 and anti-TYROBP antibody (Fig. 36E and F).  
The same effect was not seen with Aβ42 stimulation (Fig. 36C and D) or with anti-
Tryobp antibody (Fig. 36G and H), even at the highest concentrations.  We replicated 
these findings with an identical experiment.  These data demonstrate that our TREM2-
CLuc-TYROBP-NLuc construct is capable of being utilized to measure the protein-
protein interaction between TREM2 and TYROBP.    
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Figure 36. TREM2 antibody, but not Aβ or TYROBP antibody, induces dose-
dependent increase in the TREM2-TYROBP interaction in HEK293 cells. HEK293 
cells were transfected with internal control reporter pRL-TK or our TREM2-CLuc-
TYROBP-NLuc plasmid prior to stimulation with ligand.  Time-course data (A, C, E, G) 
was assessed for luminescence over time by area under the curve analysis (B, D, F, H) in 
relative light units (RLU) for n= 3 for each group. ααα denotes p<0.001 vs all other 
groups.  ** and *** denotes p<0.01 and p<0.001, respectively as determined by one-way 
ANOVA and Tukey post-test.   
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3.4 Anti-TREM2 antibody induces TREM2 coupling to TYROBP in HEK293 cells 
 To support our luciferase data, we demonstrate that stimulation of HEK293 cells 
transfected with our TREM2-CLuc-TYROBP-NLuc construct does induce an interaction 
between TREM2 and TYROBP using a “Sandwich” ELISA assay (Fig. 37). Transfected 
cells stimulated with anti-TREM2 antibody form TREM2-TYROBP complexes as 
indicated by a significant increase in chromogenic activity versus Untransfected cells, but 
crosslinking with DTBP significantly increases the amount of TREM2-TYROBP 
complexes formed in vitro.  
 
 
 
Figure 37. TREM2 antibody induces TREM2 coupling to TYROBP in HEK293 
cells. HEK293 cells were transfected with TREM2-CLuc-TYROBP-NLuc plasmid prior 
to stimulation with anti-TREM2 antibody (Ab) and protein crosslinking with DTBP.  
Average optical density (OD) by ELISA was quantified versus Untransfected cells (n= 4 
per group). Significant differences were determined by one-way ANOVA followed by 
Tukey’s post-test.  ✝✝ and ✝✝✝ denote p<0.01 and p<0.001, respectively, vs Untransfected 
cells.  ### denotes p<0.001 vs unstimulated cells transfected with TREM2-TYROBP.  ** 
and *** denote p<0.01 and p<0.001, respectively, vs those indicated.   
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3.5 T66M mutation in TREM2 induces enhanced basal luciferase activity and enhanced 
response to anti-TREM2 antibody  
 All TREM2 mutations, R47H, T66M, and S116C, induced dose-dependent 
increases in luciferase activity in response to 20 µg/ml of anti-TREM2 antibody, as 
assessed by time-course data (Fig. 38A, C, E) and AUC (Fig. 38B, D, F).  Interestingly, 
the T66M mutation elicited higher TREM2 coupling to TYROBP as indicated by 
significantly higher luciferase activity without stimulation and in response to anti-
TREM2 antibody compared to WT TREM2-transfected cells (Fig. 38C and D).  As 
expected, our TREM2-CLuc-TYROBP negative control construct elicited luciferase 
activity no higher than background compared to untreated cells that were not transfected. 
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Figure 38. The T66M mutation in TREM2 elicitis enhanced TREM2 coupling to 
TYROBP in HEK293 cells. HEK293 cells were transfected with internal control 
reporter pRL-TK, TREM2-CLuc-TYROBP-NLuc, or TREM2-CLuc-TYROBP plasmid 
prior to stimulation with ligand.  Time-course data (A, C, E) was assessed for area under 
the curve (Yasuda et al.) (B, D, F) in relative light units (RLU) for n= 3 for each group.  
Significant differences were determined by one-way ANOVA followed by Tukey’s post-
test.  ✝✝✝ denotes p<0.001 vs unstimulated R47H-, T66M-, or S116C-transfected cells.  *, 
**, and *** denotes p<0.05, p<0.01 and p<0.001, respectively.  
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3.6 TREM2 mutants show equal transfection efficiency compared to WT TREM2 in 
HEK293 cells 
 In order to establish that the differences induced by anti-TREM2 antibody and 
Aβ42 in our WT versus mutant TREM2 constructs were not due to differences in 
transfection efficiency, we transfected HEK293 cells with equal amounts of WT TREM2 
or R47H, T66M, or S116C mutants followed by analysis of intracellular TREM2 and 
TYROBP by flow cytometry.  Cells were gated based on unstained cells that were not 
permeabilized by Tween-20 treatment (Fig. 39A).  Most HEK293 cells showed 
endogenous expression of TYROBP (96.3% total of P2 population positive for Alexa 
fluor-647, or TYROBP) but no expression of TREM2 (0.52% total of P2 population 
positive for PE-conjugated TREM2) as determined by staining of permeabilized, 
untransfected cells (Fig. 39B).  TREM2-CLuc-TYROBP-NLuc (WT TREM2) (Fig. 
39C), R47H (Fig. 39E), T66M (Fig. 39F), and S116C (Fig. 39G) all had nearly equal 
percentages of TREM2+/TYROBP+ (around 19.5%), indicating equal transfection 
efficiency between groups.  TREM2-CLuc-TYROBP- (NC TREM2-) transfected cells 
showed a lower percentage of TREM2+ cells and slightly higher TYROBP+ cells (Fig. 
39D).  Fluorescent intensity of intracellular TREM2 (Fig. 39H) and TYROBP (Fig. 39I) 
was also assessed to determine if cells showed higher average TREM2 or TYROBP 
expression.  Data indicate that cells transfected with the S116C mutant had higher 
average intracellular TREM2 immunoreactivity compared to cells transfected with T66M 
(Fig. 39H).  WT TREM2 had equal intracellular TYROBP immunoreactivity compared 
to all other mutants, however, NC TREM2 was significantly higher than all other groups, 
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excluding untransfected cells (Fig. 39I).  Untransfected cells were significantly different 
from all other groups for both TREM2 and TYROBP immunoreactivity with significantly 
lower TREM2 and significantly higher TYROBP.  HEK293 cells do not have 
endogenous expression of TREM2, as reflected by our data.  The difference in TYROBP 
may be indicative of a reduction in endogenous TYROBP as a feedback reaction to 
increased TYROBP by transfection.   
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Figure 39. Flow cytometry analysis of WT or mutant TREM2 show equal 
transfection efficiency between groups. Cells were gated based on transfected cells that 
were left unstained (A).  Intracellular TREM2 and TYROBP expression was measured in 
untransfected (B), TREM2-CLuc-TYROBP-NLuc- (WT TREM2) (C), TREM2-CLuc-
TYROBP- (NC TREM2) (D), R47H- (E), T66M- (F), or S116C- (G) transfected cells.  
Average fluorescent intensity was measured for PE-conjugated TREM2 (H) and Alexa 
fluor-647-labeled TYROBP (i) for each group.  Significant differences were determined 
by one-way ANOVA followed by Bonferroni’s post-test.  t denotes p<0.05 vs all groups.  
** and *** denotes p<0.01 and 0.001, respectively. 
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3.7 T66M TREM2 mutant shows reduced cell surface expression of TREM2 and TYROBP 
 In addition to determining intracellular TREM2 and TYROBP expression in 
transfected cells, we also determined if there was a difference in cell surface expression 
compared to WT TREM2.  For this purpose, transfected HEK293 cells were not treated 
with Tween-20.  Cells were gated in the same manner as in Figure 40A from unstained 
cells.  HEK293 cells showed endogenous cell surface expression of TYROBP (13.37% 
total of P2 population positive for Alexa fluor-647, or TYROBP) but no expression of 
TREM2 (0.289% total of P2 population positive for PE-conjugated TREM2) as 
determined by untransfected cells (Fig. 40B).  Gating for positive staining was also done 
with TREM2-CLuc-TYROBP-NLuc- (WT TREM2-) transfected cells stained for either 
PE-conjugated TREM2 alone (Fig. 40C) or TYROBP tagged with Alexa fluor-647 alone 
(Fig. 40D).  Double-stained cells were then assessed for surface TREM2 and TYROBP 
in TREM2-CLuc-TYROBP-NLuc- (Fig. 40E), NC TREM2-CLuc-TYROBP- (Fig. 40F), 
R47H- (Fig. 40G), T66M- (Fig. 40H), and S116C- (Fig. 40I) transfected cells.  Both the 
percentage of cells positive for TREM2 as well as the fluorescent intensity of PE-TREM2 
(Fig. 40J) was lower in T66M-transfected cells, though not significantly.  One-way 
ANOVA analysis of results showed an overall significant difference with p= 0.0146, but 
post-test analyses revealed no significant differences between groups.  Cell surface 
expression of TYROBP based on fluorescent intensity of Alexa fluor-647, however, was 
significantly lower for T66M-transfected cells (Fig. 40K).  
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Figure 40. The T66M mutation results in a reduction of cell surface expression of 
TREM2 and TYROBP. Cells were gated based on transfected cells that were left 
unstained (A).  Cell surface TREM2 and TYROBP expression was measured in 
untransfected (B), PE-TREM2-stained (C), Alexa fluor-647-tagged Tryobp (D), TREM2-
CLuc-TYROBP-NLuc- (WT TREM2) (E), TREM2-CLuc-TYROBP- (NC TREM2) (F), 
R47H- (G), T66M- (H), or S116C- (I) transfected cells.  Average fluorescent intensity 
was measured for PE-conjugated TREM2 (J) and Alexa fluor-647-tagged TYROBP (K) 
for each group.  Significant differences were determined by one-way ANOVA followed 
by Bonferroni’s post-test.  t denotes p<0.05 vs all groups.  *** denotes p<0.001. 
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3.8 CD200 does not induce or enhance the TREM2-TYROBP interaction 
 We utilized our TREM2-CLuc-TYROBP-NLuc luciferase time-course assay to 
determine if CD200’s known interaction with the adaptor protein TYROBP via 
CD200R3 could induce or enhance the interaction between TREM2 and TYROBP 
(Figure 41).  From time-course data (Fig. 41A and C), we assessed area under the curve 
(Yasuda et al.) (Fig. 41B and D) of luciferase activity over time (30 minutes). As 
predicted, the control Goat IgG protein did not induce luciferase activity, which shows 
the specificity of our TREM2-CLuc-TYROBP-NLuc construct to stimulation by TREM2 
antibody. As in our preliminary studies testing our TREM2-CLuc-TYROBP-NLuc 
construct in transfected HEK293 cells, stimulation of transfected BV2 cells with anti-
TREM2 antibody significantly increased luciferase activity (Fig. 41D), indicating 
TREM2 coupling to TYROBP.  Unfortunately, the same effect was not seen in response 
to stimulation with CD200 ligand at any given concentration (Fig. 41D).  In fact, CD200 
actually showed a trend to reduce TREM2 coupling to TYROBP compared to transfected 
cells treated with PBS.  CD200 also did not enhance the TREM2-TYROBP interaction 
when in the presence of anti-TREM2 antibody or Aβ42 (Fig. 41D).  
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Figure 41. CD200 does not induce TREM2 coupling to TYROBP in BV2 cells in 
vitro. BV2 cells were transfected with our TREM2-CLuc-TYROBP-NLuc construct 
followed by stimulation with anti-TREM2 antibody, Aβ42, CD200, or control IgG. Time-
course data (A and C) was assessed for area under the curve (Yasuda et al.) (B and D) for 
n= 3 per group.  Significant differences were determined by one-way ANOVA followed 
by Tukey’s post-test.  * denotes p<0.05. ### denotes p<0.001 vs TREM2-transfected 
cells stimulated with PBS.  
 
 
IV. Discussion 
 In summary, we show that CD200 stimulation of primary microglia is able to 
enhance their phagocytosis of Aβ42 in vitro, suggesting a possible explanation for why 
we saw reduced amyloid deposition in the hippocampi of our APP mouse models in vivo. 
As shown in previous studies, pre-treatment of microglia with oligomerized Aβ42, but 
not fibrillar Aβ42, can reduce the ability of microglia to phagocytose Aβ42 (Pan et al., 
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2011), and we reflect the same pattern here, but with partial restoration of phagocytic 
capability by treatment with CD200.  This may partly explain why the aged brain and the 
AD brain, as well as our APP mouse brains, have high deposits of amyloid in the brain 
due to impaired microglial phagocytosis that is exacerbated by age-induced reductions in 
CD200 expression (Lyons et al., 2007b).    
 Interestingly, we also saw an increase in the number of CD11b+ microglia with 
our CD200 treatment that was reduced in cells treated with Aβ42.  CD11b is a component 
of the MAC-1 complex (CD11b/CD18) and is constitutively expressed on the surface of 
microglia (Akiyama and McGeer, 1990), but its expression can be altered after activation 
by specific stimulations (McGeer et al., 1993; McGeer and McGeer, 1995; Kalaria, 
1999).. Activation of CR3 induces phagocytosis, and it has been implicated in the 
phagocytosis of Aβ-opsonized yeasts (Choucair-Jaafar et al., 2011). M1 activation of 
microglia by pro-inflammatory cytokines or LPS, or Aβ in our case, reduces their ability 
to mount phagocytic responses via both CR3- and β1-integrin-dependent mechanisms, 
whereas anti-inflammatory microglial activation supports it (Koenigsknecht-Talboo and 
Landreth, 2005). We showed in a previous publication that incubation with high 
concentrations of Aβ42 reduces the number of surviving primary cultured mouse 
microglia	  (Kiyota et al., 2009a), suggesting the reduction in CD11b+ cells in our study is 
due to Aβ-induced cytotoxicity. Treatment of cells with CD200 may be protective of 
microglia against Aβ42-induced cytotoxicity.  
 We were able to successfully develop a split-luciferase construct to allow for real-
time analysis of TREM2 coupling to TYROBP utilizing a bioluminescence-based assay.  
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This construct shows a dose-dependent increase in luciferase activity indicative of 
TREM2-TYROBP signaling in response to TREM2 antibody stimulation in vitro.  We 
used this construct to study the effects of mutations in TREM2 associated with AD and 
FTD on TREM2-TYROBP coupling and saw a significant effect of the T66M mutation 
in both basal activity an in response to TREM2 antibody stimulation. Our examination of 
cell surface TREM2 expression replicate those found by Kleinberger et al, who show 
reduced cell surface expression of TREM2 in the presence of the T66M mutation 
(Kleinberger et al., 2014).  We also show reduced TYROBP surface expression.  
Dysfunctional processing of T66M TREM2 resulted in an accumulation of immature 
TREM2 and little production of mature membrane-bound or sTREM2 in cell media in 
vitro, which correlated with a reduced phagocytic capabilities (Kleinberger et al., 2014).  
The T66M mutation may result in hyperactive TREM2-TYROBP signaling that is 
detrimental to immune homeostasis and phagocytosis, thus increasing the risk for AD.  
Our split luciferase system is of great value to further examine the effects of TREM2 
polymorphisms in AD, as these have the greatest association with risk of AD after the 
well-known genetic risk factor, APOE.  The mutant constructs can also be used to 
examine the effects of TREM2 mutation on alterations in microglial activation, as WT 
TREM2 tends to skew microglia toward an M2a phenotype.      
 Unfortunately, we do not show CD200-induced enhancement of the TREM2-
TYROBP interaction.  It is important to note that comparison of this data with that of our 
TREM2-CLuc-TYROBP-NLuc test data should be done with some caution as those were 
done in HEK293 cells, whereas our CD200-TREM2 assay was done in BV2 cells. 
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Stimulation with CD200 actually reduced luciferase activity in this assay.  It is therefore 
plausible that, although CD200 can activate the CD200R3 to induce robust TYROBP 
expression in microglial cells, this does not mean that it can also indirectly activate 
TREM2.  It is also possible that CD200R3 competes with TREM2 for binding to 
TYROBP, and may have a stronger interaction with the adaptor protein as evidenced by 
the sustained reduction in luciferase acitivity over the total 30 minutes in the presence of 
CD200.  We therefore cannot conclude that CD200 enhances phagocytosis of Aβ42 
through activation of TREM2.  
 In conclusion, our data demonstrate that CD200 enhances phagocytosis of Aβ42, 
and we provide evidence that these actions are mediated through microglia.  
Enhancement of phagocytosis may not be mediated through activation of TREM2 and 
TYROBP, at least not in the time frame we examined.  It is possible that alterations in 
TREM2 activity with CD200 stimulation may take longer than the examined 30 minute 
window of time we examined.  It is therefore more likely that CD200 indirectly supports 
the survival of activated microglia that are more capable of phagocytosing Aβ42 in an 
alternatively activated environment.   
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Chapter 6: OVERALL SUMMARY AND FUTURE DIRECTIONS 
I. Summary  
 The objective of this project was to determine if CD200, an anti-inflammatory 
glycoprotein, could enhance neurogenesis and reduce amyloid deposition through 
reduction of neuroinflammation in the APP mouse brain.  We utilize the characterization 
of microglial activation phenotypes based off classifications of peripheral macrophage 
activation.  However, broad categorization of microglia into M1 or M2 phenotypes may 
be insufficient to characterize microglia in the brain.  The summary of our findings are 
illustrated in Figure 42.  Our data demonstrate that over-expression of CD200 is capable 
of restoring neurogenesis to WT levels and reducing levels of diffuse amyloid and Aβ42 
protein in the aged APP mouse brain, even at the early post-symptomatic disease phase.  
These reductions occur alongside a reduction in M1 microglial activation, as evidenced 
by a reduction in pro-inflammatory NOS2 and an increase in anti-inflammatory YM1.  
We demonstrate that CD200-treated microglia are capable of enhancing neuronal 
differentiation and complexity of NSCs through increase in expression of growth factors, 
such as GDNF, and likely through indirect support by skewing microglia toward an M2a 
activation phenotype.  Alternative activation of microglia has previously been shown to 
support neuronal differentiation and cell survival in vitro, even without the presence of 
inflammatory stimuli (Kiyota et al., 2011b).  Alternative microglial activation is also 
supportive of phagocytic activity (Koenigsknecht-Talboo and Landreth, 2005), which we 
demonstrate with the enhanced ability of primary microglia to phagocytose Aβ42 after 
CD200 stimulation.   
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 We saw little evidence for the involvement of TGF-β1 and TGF-βR1 as 
expression of both was reduced in the presence of CD200 in primary microglia. We show 
instead that CD200 stimulation of primary microglia resulted in a significant reduction in 
CD200R3 that was accompanied by an increase in TYROBP, which may be the 
mechanism by which CD200 induces microglia to phagocytose.  TYROBP is thought to 
be involved in TREM2 signaling to reduce NFκB production of pro-inflammatory 
cytokines through TLR4 activation, as well as induce phagocytosis because we see 
impairment in both functions in the presence of mutations in TREM2 or TYROBP 
(Kleinberger et al., 2014).  We did not see induction of TREM2-TYROBP coupling in 
the presence of CD200 with our TREM2-CLuc-TYROBP-NLuc construct in 
bioluminescence-based assays.  This may indicate that the CD200 induction of CD200R3 
coupling to TYROBP is enough to enhance the phagocytic capability of microglia. 
However, CD200 may be capable of restoring microglia toward an M2a phenotype in the 
presence of TREM2 polymorphisms, which may restore phagocytic capability in 
microglia in the AD brain.     
  The main question that arises from this study is whether or not CD200 is truly a 
candidate for the treatment of AD.  Our data suggest that CD200 mediates both anti-
inflammatory and phagocytic effects through transcriptional up-regulation of CD200R1 
and TYROBP.  If CD200 activation of CD200R3-TYROBP coupling can induce the same 
effects seen by TREM2-TYROBP coupling to reduce inflammation and enhance 
phagocytosis of Aβ42, then it may be a possible therapeutic approach for AD patients 
expressing TREM2 mutations. However, as evidenced by a lack of improvement in 
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reversal learning and memory in the later disease stages of our APP mice, CD200 therapy 
even at the early post-symptomatic disease stage may not be sufficient.  Earlier targeting 
of neuroinflammation in the pre-symptomatic disease stage may be more desirable to 
make CD200 a more effective therapeutic. 
 
II. Key Findings 
We report three novel findings with this research: 
1)  CD200 can act as a pro-neurogenic mediator in both the hippocampus in vivo and in 
microglia cultures in vitro.  This is similar to findings that showed that anti-
inflammatory mediatoris, such as IL-4 and IL-10 (Kiyota et al., 2010; Kiyota et al., 
2011b), could restore neurogenesis if expressed during the pre-symptomatic disease 
stage.  Unlike these studies, however, we show that CD200 expression is capable of 
having a similar effect even during the post-sympotatic disease stage, making it more 
clinically relevant in this context.   
2) Previous studies showed that treatment of microglia with M2a activators, such as IL-
4, is supportive of phagocytosis (Koenigsknecht-Talboo and Landreth, 2005). We 
show for the first time that CD200 is capable of enhancing the phagocytic functions 
of microglia, possibly through activation by CD11b.  This can be used to aid in 
clearance of Aβ prior to fibrillar plaque formation and before the onset of clinical 
symptoms if the optimal dosing is experimentally determined. 
3)  We present a novel tool that can be used to examine the TREM2-TYROBP 
interaction in vitro with our split-luciferase construct.  This TREM2-CLuc-TYROBP-
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NLuc construct can be used to discover ligands that can initiate TYROBP signaling 
after coupling with TREM2 as possible therapeutics.  For AD patients with 
polymorphisms in TREM2, we can use our mutant TREM2-CLuc-TYROBP-NLuc 
constructs to discover ligands that can bypass canonical TREM2 activation to induce 
TYROBP signaling, thus restoring TREM2 functions in patients at risk for AD.   
 
III. Future Directions 
 In this study, we established the possible therapeutic value of CD200 in our APP 
mouse models.  Despite the improvements seen in neurogenesis, inflammation, and 
amyloid pathology, we did not observe a behavioral improvement.  As dicussed in 
Chapter 2, the MWM test has limitations in detecting memory impairments, and other 
tests, such as the RAWM test, are more sensitive for detecting deficits in working 
memory in transgenic mice (Fine et al., 2015).  In order to address the possibility that our 
injection was too late in the disease phase, a similar study should be performed in which 
mice are injected at the pre-symptomatic disease stage and the effects of CD200 assessed 
at later timepoints.  As shown in our previous studies, injection of APP+PS1 mice at 
earlier timepoints with AAV2/1 expressing anti-inflammatory mediators results in 
improved behavioral outcomes (Kiyota et al., 2010; Kiyota et al., 2011a; Kiyota et al., 
2011b).  Additionally, these studies utilized RAWM testing rather than MWM to show 
cognitive improvements. 
 In Chapter 3, we characterized microglial activation by expression of 
inflammatory mediators and by phenotype in the hippocampus of our AAV2/1-injected 
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mice.  Aside from a significant increase in expression of YM1, we saw few differences in 
microglial activation phenotypes and survival in these regions in APP mice versus WT.  
However, in Chapters 4 and 5, we present evidence that microglia play a role in the 
enhancement of neurogenesis and phagocytosis of Aβ42 in vitro.  In order to determine if 
microglia play a major role in the function of CD200 in our in vivo studies, it is necessary 
to assess their involvement by further experimentation.  For this, we propose a study 
utilizing the microglia-depleting proprietary compound PLX3397 (Plexxikon, Inc, 
Berkeley, CA).  This compound, which can be fed to mice in the form of chow, can 
deplete microglia in four weeks	   (Coniglio et al., 2012).  Alternatively, mice could be 
injected with Clodronate liposomes directly into the hippocampi for site-specific 
depletion of microglia.  Clodronate liposomes (purchased from Clodronateliposome.org) 
contain dichloromethylene bisphonsphonate (Clodronate) within liposomes, which are 
ingested via phagocytosis by microglia	   (Delemarre et al., 1990; Van Rooijen and 
Sanders, 1994).  After breakdown of the liposome by the microglia, the Clodronate is 
released intracellularly and disrupts the metabolism of ATP, thus killing the microglia	  
(Delemarre et al., 1990; Van Rooijen and Sanders, 1994).  WT and APP mice will be fed 
PLX3397 chow for four weeks or injected with Clodronate liposomes prior to injection 
with our AAV2/1-CD200 or –GFP viruses before assessing the hippocampi for changes 
in neurogenesis and amyloid deposition compared to our previous findings as a result of 
microglial depletion.  In this way, we can determine if microglia are essential for the 
effects of AAV2/1-CD200 in vivo.    
 Lastly, we intend to utilize our TREM2-CLuc-TYROBP-NLuc construct for 
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further study of the role of TREM2 in the development of AD.  For this, we propose 
utilizing our WT and mutant constructs to determine how specific mutations alter the 
phagocytic capability of microglia for Aβ42, zymosan, or apoptotic bodies, and how this 
alters TREM2 coupling to TYROBP.  We also intend to conduct a drug screening study 
to identify complex molecules that act as ligands to induce TREM2 coupling to 
TYROBP.  This requires the creation of a stable cell line expressing our TREM2-CLuc-
TYROBP-NLuc construct in HEK293 cells, which has already been initiated. Ligands 
that successfully reconstitute luciferase activity in our bioluminescence-based assays will 
be screened for their ability to initiate phagocytosis of Aβ42 in BV2 microglial cells.  
Compounds can also be screened for their ability to suppress pro-inflammatory activation 
induced by Aβ42 and establish an anti-inflammatory microglial milieu in vitro.   
 
IV. Conclusions 
 In summary, our data support the hypothesis that CD200 gene delivery can 
enhance neurogenesis and reduce amyloid deposition in APP mice.  We present a novel 
function of CD200 to promote phagocytosis of Aβ42 and induce a neurogenic microglial 
environment that is skewed toward M2a.  This study was meant to be a proof-of-concept 
study by artificial over-expression of the CD200 gene.  Overall, these findings support 
the further exploration of CD200 as a novel therapeutic for the treatment of AD, though it 
requires more testing to utilize it to its full potential. 
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Figure 42. Over-expression of CD200 in APP mouse neurons restores neurogenesis 
and enhances amyloid phagocytosis by microglia.  Our data demonstrate an increase in 
NOS2 expression associated with reduced neurogenesis and elevated levels of Aβ42 in 
the APP mouse brain.  Upon over-expression of CD200, we demonstrate restored 
neurogenesis and reduced amyloid deposition associated with increased levels of YM1 in 
microglia-like cells.  Our data suggest that these changes are due to CD200R1- and 
CD200R3-induced inhibition of NFκB signaling as well as an increase in GDNF and 
CD11b that aide in supporting neuronal differentiation and enhancing phagocytosis by 
microglia. 
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